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Synopsis 
 
Rpb1, the largest subunit of eukaryotic RNA Polymerase II (Pol II), contains a highly 
flexible structure at its C-terminus. This carboxyl-terminal domain (CTD) of Rpb1 is 
unique to eukaryotic organisms and consists of multiple tandemly repeated 
heptapeptides with the consensus sequence Y1S2P3T4S5P6S7. Interestingly, the 
number of repeats differs from organism to organism and seems to correspond to 
genomic complexity, from 26 repeats in the yeast Saccharomyces cerevisiae to 52 
repeats in the mammalian CTD (Chapman et al., 2008; Liu et al., 2010). 
Remarkably, five out of seven residues within the consensus sequence of the CTD 
can be potentially phosphorylated. In line with this, the production of monoclonal 
antibodies in our laboratory, against all different phosphosites within the heptad 
repeat confirmed the phosphorylation of Y1, S2, T4, S5 and S7 in vivo. Additionally to 
phosphorylation, other posttranslational modifications, such as cis-trans 
isomerisation of the two proline residues can also take place (Egloff et al., 2008).  
The potential of the CTD to be modified at each residue can create a wide range of 
distinct combinations which could carry information that is essential at different steps 
of the transcription cycle, where the modifications can be recognized as a readable 
code, the so-called ‘CTD code’. In this respect, the CTD might serve as a dynamic 
platform constantly signalling between the transcription machinery and factors that 
interact with Pol II (Buratowski et al., 2003; Corden et al., 2007).  
In this work, in order to gain new insights into the CTD code, CTD mutants were 
established to make the whole sequence accessible to mass spec (MS) analysis and 
to map phosphosites within the CTD in vivo. MS results showed that the CTD can be 
phosphorylated within all 52 repeats revealing the existence of the full repertoire of 
possible phosphosites within the CTD in vivo. Moreover, individual CTD peptides 
displayed many different phosphorylation patterns reflecting the great diversity of 
phosphorylation signatures existing in parallel within the same CTD. Data produced 
in this thesis showed that mono-phosphorylated CTD repeats represent the 
prevailing phosphorylation form in vivo. Additionally, dominant phosphorylation 
signatures in di-phosphorylated (2P) CTD repeats could be mapped along the CTD 
by MS analysis. Tri- and tetra-phosphorylated (3P and 4P) CTD peptides were 
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detected as well, but only in very low amounts. By analysing 2P-signatures in more 
detail it was demonstrated that different 2P-combinations predominated within 
distinct repeats along the CTD, suggesting that CTD phosphorylation is location 
dependent. Finally, known CTD-protein binding motifs could be mapped and linked 
to specific CTD repeats. 
In conclusion, this work has established an approach for identifying high numbers of 
CTD-phosphosites, as well as high abundant CTD signatures along the whole CTD 
molecule, that contribute towards a better understanding of the ‘CTD code’ and open 
ways to yet undiscovered specific CTD-binding protein interactions. 
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1. Introduction 
 
 
Three nuclear structurally related DNA-dependent RNA polymerases are responsible 
for transcribing DNA into RNA in eukaryotes (Cramer et al., 2008). RNA Polymerase 
I (Pol I) synthesizes most of the ribosomal RNAs (rRNAs), while RNA Polymerase III 
(Pol III) produces tRNAs, 5S rRNA, and other small RNAs, comprising 75% and 15% 
of transcripts in the cell, respectively (Grummt et al., 2003; Russell et al., 2005; Dieci 
et al., 2007; Werner et al., 2009). 
The best studied polymerase is RNA Polymerase II (Pol II), which transcribes not 
only all protein-coding genes, but also a variety of small non-coding RNAs, including 
small nuclear and nucleolar (sn/sno) RNAs, cryptic unstable transcripts (CUTs), 
stable unannoted transcripts (SUTs) and XRN1-dependent unstable transcripts 
(XUTs) (Neil et al., 2009; Tisseur et al., 2011). 
Five out of the twelve Pol II subunits are common in all three polymerases and the 
specific functions attributed to each polymerase are probably based on the combined 
action of the remaining non-identical subunits and other co-/factors (Young et al., 
1991; Woychik et al., 1994; Shpakovski et al., 1995). In this respect, only the largest 
subunit of Pol II, Rpb1, contains a unique long and flexible carboxy-terminal domain 
(CTD). The CTD can be divided into three parts: (1) a flexible linker region, (2) a 
region consisting of tandem repeats of the consensus sequence tyrosine-serine-
proline-threonine-serine-proline-serine (Y1S2P3T4S5P6S7), and (3) a divergent C-
terminal part. This unique structure is conserved from fungi to humans, although 
there is a variation in the number of repeats (15 repeats in amoeba; 26 repeats in 
budding yeast; 29 repeats in fission yeast; 52 repeats in human) as well as their 
deviation from the consensus sequence, reflecting to a large degree the complexity 
of the organism (Corden et al., 1985 and 1990; Chapman et al. 2008; Liu et al. 2010) 
(Figure 1). The ability of this repetitive sequence to interact with a wide range of 
nuclear factors is related to the dynamic plasticity of its structure and the diversity of 
binding surfaces generated by the multitude of posttranslational modifications it can 
accommodate. The association of specific posttranslational modifications of the CTD 
with particular events of the transcription cycle gave rise to the concept of the CTD 
code (Buratowksi et al., 2003). Tyrosine, threonine, and serine can all be 
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phosphorylated, threonine and serine can be glycosylated, and proline can undergo 
isomerisation (Egloff et al., 2008; Zeidan et al. 2010; Fuchs et al. 2009). In 
mammals, non-consensus repeats of the CTD predominantly involve substitution of 
S7 of the heptad-motif by arginine or lysine, which are, therefore, excluding a 
phosphorylation on this position, while introducing the possibility for a broad array of 
additional modifications; lysine can be mono-, di-, or trimethylated, acetylated, 
ubiquitinylated and sumoylated, while arginine can be mono- or dimethylated 
(dimethylation can be asymmetric or symmetric). Sims and co-workers detected 
asymmetric dimethylation of arginine1810 within the CTD of Pol II in mammalian 
cells (Sims et al., 2011), while six out of seven lysines of the Mus musculus CTD 
were shown to be ubiquitinylated (Li et al., 2007). The combinatorial nature of these 
modifications, which is reminiscent of the histone code, is the key element of the 
CTD code that is generated by CTD-modifying enzymes and ‘read’ by CTD-
associated protein factors (Buratowksi et al., 2003; Jenuwein et al., 2001).  
 
 
 
 
 
 
 
The timely and precise combination of these factors leads to spatially and temporally 
controlled events that mediate transcription and RNA processing. A detailed 
Figure 1 Comparison of CTD sequences in budding yeast, fission yeast and 
human. All-consensus YSPTSPS heptad repeats are shown in red, human residues that 
deviate from the consensus sequence are in blue, and the numbers next to the parentheses 
indicate the repeat number (Hsin and Manley, (2012), The RNA polymerase II CTD 
coordinates transcription and RNA processing; Genes & Development 26:2119-2137). 
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introduction to various aspects of the CTD and its interactions, CTD-modification 
patterns, genetic studies, as well as its role during transcription follows below. 
 
 
 
1.1  The role of Pol II CTD in transcription and  
    RNA processing 
 
 
1.1.1  The role of CTD in transcription initiation 
 
Initiation of transcription starts with the recruitment of gene-specific transcription 
factors (TFs), general transcription factors (GTFs), the Mediator complex, and Pol II. 
These factors form the pre-initiation complex (PIC) at the promoters of Pol II 
transcribed genes (Buratowski et al., 2009; Nechaev et al., 2010). The Mediator 
complex plays a predominant role by linking the PIC to assemblies of transcription 
factors bound at the upstream regulatory (activating/repressing) sequences 
(UAS/URS) (Svejstrup et al., 1997; Myers et al., 2000; Kornberg et al., 2005; Malik et 
al., 2005). The Mediator complex binds the unphosphorylated form of Pol II CTD, but 
when incorporated into the PIC, it strongly stimulates the CTD kinase (Kin28 in 
yeast, CDK7 in metazoans) of the basal transcription factor TFIIH. It has been 
shown, that Kin28/CDK7 and the Mediator complex subunit Srb10/CDK8 
phosphorylate S5 in vivo with Kin28/CDK7 being the predominant kinase (Phatnani 
et al., 2006; Hengartner et al., 1998; Dahmus et al., 1996; Bensaude et al., 1999; 
Palancade et al., 2003; Feaver et al., 1994; Rickert et al., 1999; Gebara et al., 1997).  
In turn, the serine-5 phosphorylation (S5P) is a prerequisite for coordinating the 
placement of several key posttranslational modifications on chromatin like 
trimethylation of histone H3 at lysine 4 (H3K4me3) by Set1 and subsequent 
trimethylation of histone H3 at lysine 79 (H3K79me3) by Dot1 (Venters et al., 2009; 
Ng et al., 2003; Nakanishi et al., 2008; Wood et al., 2003). Set1 establishes two 
distinct chromatin zones on genes, H3K4me3 found at promoter regions and 
H3K4me2 located further downstream in the body of the gene (Kim and Buratowski 
2009). Eventually, H3K4me2 and CTD S5P trigger the recruitment of the histone 
deacetylase complexes Set3 and Rpd3C(S), leading to reduced histone acetylation 
levels at the 5’ ends of genes, which promotes the association of Pol II and inhibits 
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CUT initiation at promoters (Kim and Buratowski 2009; Govind et al., 2010; Drouin et 
al., 2010). 
The key role of S5P, however, is the binding of the capping enzyme complex and 
therefore promoting transition of transcription to elongation. The CTD repeats 
proximal to the core Pol II are ideally located near the RNA exit tunnel to facilitate the 
capping reaction (Cramer et al., 2001; Ghosh et al., 2011). Although capping 
enzyme recognition by CTD is structurally different in mammalian and yeast (see 
also part 1.2.3), both organisms require S5P for binding (Fabrega et al., 2003; Ghosh 
et al., 2011). In this context, specific inhibition of Kin28 has little effect on 
transcription of protein-coding genes, but causes a striking reduction of capping (Liu 
et al., 2004; Kanin et al., 2007). Interestingly, Kin28/CDK7 is also the primary kinase 
for CTD serine-7 phosphorylation (S7P) (Akhtar et al., 2009; Glover-Cutter et al., 
2009; Kim et al., 2009) (Figure 2). S7P seems to be Mediator complex-dependent, 
but the role of this phosphorylation at promoters remains elusive and will be 
discussed further below (Boeing et al., 2010).  
 
 
1.1.2   The role of CTD in Pol II pausing and transcription   
           elongation 
 
Following promoter release, transcription initiation factors are exchanged by 
elongation factors, playing an important role in RNA processing by moving through 
chromatin, and suppressing cryptic transcripts. In mammalian cells, the positive 
elongation factor P-TEFb kinase subunit, CDK9, phosphorylates both CTD S2 and 
the DRB-sensitivity-inducing factor (DSIF), thus allowing Pol II to overcome the 
promoter-proximal pausing induced by the negative elongation factor (NELF) 
complex (Sims et al., 2004; Peterlin et al., 2006). Interestingly, about one-third of 
genes in both fly and human cells appear to contain a paused Pol II downstream of 
the transcription start site (Core et al., 2008; Nechaev et al., 2010). Pausing seems 
to allow rapid and coordinated transcription during development, or in response to 
external stimuli (Muse et al., 2007). It is unclear if promoter-proximal pausing exists 
in yeast, but it is known that Bur 1, the yeast homolog of CDK9, promotes elongation 
through phosphorylation of Spt5, the yeast homologue of DSIF (Zhou et al., 2009). 
Additionally, Bur1 also phosphorylates CTD S2 downstream of the promoter and 
triggers the ubiquitylation of histone H2B lysine 123 (H2BK123ub) by the ubiquitin 
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conjugating enzyme Rad6 and Bre1 (Wood, 2003 and 2005). H2BK123ub promotes 
subsequent Set1 trimethylation of histone H3K4 and subsequent trimethylation of 
H3K79, both of which represent important marks of transcription activation (Venters 
et al., 2009; Ng et al., 2003; Nakanishi et al., 2008; Wood et al., 2003).   
The S5P mark is a prerequisite for the recruitment of Bur1 to the transcription 
complex at the promoter. It then phosphorylates S2, priming the CTD for the 
recruitment of Ctk1, the major S2 kinase which then phosphorylates S2 further 
downstream in the coding region (Keogh et al., 2003; Qiu et al., 2009). Recent 
studies in Drosophila and human cells have shown that CDK12 can phosphorylate 
the CTD on S2 and proposed, based on phylogenetic relationships, that the ortholog 
of Bur1 is CDK9, whereas CDK12 is the counterpart of Ctk1 (Guo and Stiller 2004; 
Bartkowiak et al., 2010) (Figure 3a). Indeed, CDK12 is required for most S2 
phosphorylation in vivo and is associated with elongating Pol II. Interestingly, Bur1 
has been identified as an ‘internal’ S7 kinase ‘travelling’ with Pol II and 
phosphorylating S7 in later phases of the transcription cycle. Although the exact role 
of this modification is unclear, it is likely to be a mark that promotes elongation as 
genes with uniformly high levels of S7P are transcribed at significantly higher levels 
(Tietjen et al., 2010).  
The newly characterized CTD phosphatase Rtr1 associates with Pol II and removes 
S5P marks immediately after promoter clearance (Figure 2; Figure 3a). The S2P 
phosphatase Fcp1 is also recruited during elongation, but S2P levels remain high 
across the transcript due to the opposing action of the S2P kinase Ctk1 (Mosley et 
al., 2009; Kobor et al., 1999; Cho et al., 2001). Increasing levels of S2P, in 
combination with the residual S5P, lead to the recruitment of the Set2 
methyltransferase, which di- and trimethylates H3K36, followed by the removal of 
acetylation from histones H3 and H4 by the histone deacetylase complex Rpd3C(S) 
and thus, preventing cryptic transcription initiation within open reading frames in 
yeast (Kizer et al., 2005; Vojnic et al., 2006; Krogan et al., 2003; Li et al., 2002; 
Govind et al., 2010; Carrozza et al., 2005; Keogh et al., 2005). Similarly, the splicing 
factor Prp40 and U2AF65 recognize the S2P-S5P double mark followed by the 
recruitment of Prp19 to activate splicing (Egloff et al., 2008; Phatnani et al., 2004; 
David et al., 2011). Splicing in turn triggers the binding of the yeast export factor, 
Yra1, to S2P-S5P CTD repeats (MacKellar et al., 2011). S2P is also bound by the 
serine/arginine rich protein Npl3, which functions in elongation, 3’-end processing, 
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hnRNP formation, and mRNA export (Gilbert et al., 2001; Bucheli and Buratowski 
2005; Bucheli et al., 2007). Additionally, the RNA binding factor, Ssd1, the mitotic 
kinase, Hrr25, and RecQ5 genome stability helicase also bind to S2P-S5P CTD 
repeats (Kanagaraj et al., 2010; Phatnani et al., 2004). However, the precise role 
that Ssd1 and Hrr25 play during transcription cycle remains unclear. 
 
 
1.1.3   The role of CTD in 3’ RNA processing and transcription  
   termination 
 
The CTD also plays an important role in 3’ end processing of Pol II-produced 
transcripts and it has been shown that several 3’ processing factors like CPSF, CstF 
and Pcf11 interact with the CTD (Shi et al., 2009; McCracken et al., 1997). Pcf11, for 
instance, contains an N-terminal CTD interaction domain (CID) and binds the CTD in 
a S2P-dependent manner (Barilla et al., 2001; Licatalosi et al., 2002; Meinhart and 
Cramer 2004) (see also part 1.2.3). Indeed, S2P is critical to the 3’ end processing, 
as genome-wide chromatin immunoprecipitation (ChIP) experiments showed that 
peaks of 3’ processing factors coincide with S2P peaks, suggesting that both poly(A) 
sites and S2P are a prerequisite for subsequent recruitment/assembly of the 
polyadenylation complex in the newly processed RNA (Kim et al., 2010; Mayer et al., 
2010, 2012).  
Importantly, the 3’ ends of several types of Pol II transcribed RNAs, comprising 
snRNA and histone mRNA, are not polyadenylated, but here tight regulation of CTD 
phosphorylation/dephosphorylation is important to the cleavage complex recruitment. 
Proper snRNA 3’ end formation needs the promoter and 3’ box, located just 
downstream from the snRNA-encoding region. A multi-subunit RNA 3’ end 
processing complex, the Integrator, is associated to the 3’ box of snRNA genes. 
Interestingly, the RPAP2 phosphatase is recruited to snRNA genes via S7P, close to 
the promoter region where S7P is most frequent. The combined action of 
dephosphorylation of S5 by RPAP2 and phosphorylation of S2 by P-TEFb, as 
transcription progresses, creates a double mark consisting of S7P on one repeat and 
S2P on the following repeat which is then specifically bound by Int11, the catalytic 
cleavage subunit of the Integrator (Baillat et al., 2005; Egloff et al., 2010). These 
results support the idea that S5P dephosphorylation is a prerequisite for 3’ end 
formation in both, snRNA and mRNA genes (Xiang et al., 2010). In this context, 
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RPAP2 is also recruited to protein-coding genes but in a S7P independent way. Two 
proteins, RPRD1A and RPRD1B, which interact both with RPAP2 and the CTD, 
could help recruit the S5 phosphatase to mRNA genes in the absence of S7P (Ni et 
al., 2011). 
 
 
 
 
 
 
 
A number of 3’ cleavage factors have been shown to be critical for Pol II termination, 
while a functional polyadenylation signal is required for subsequent termination 
(Proudfoot et al., 1989; Birse et al., 1998; Dichtl et al., 2002; Ganem et al., 2003; 
Nedea et al., 2003; Kim et al., 2010; Zhang et al., 2012). In this line, one CTD-
binding cleavage factor, Pcf11, seems to play a key role; mutated yeast Pcf11 that 
retains 3‘ cleavage activity, but is defective in CTD binding, was found to be 
defective in terminating Pol II mediated transcription (Sadowski et al., 2003). Two 
models have been suggested for Pol II termination, but most probably a combination 
Figure 2 Transcription cycle of RNA polymerase II in yeast. Recruitment of 
primary RNA processing factors concomitant with dynamic modifications within both, the 
Pol II CTD and chromatin, along the transcription cycle are shown (Zhang and Ansari, 
(2011) Emerging Views on the CTD Code; Genetics Research International; Volume 
2012, Article ID 347214). 
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of the two models could best explain the mechanism. In the first model, termed the 
‘allosteric’ model, after transcribing the poly-(A) site, Pol II undergoes conformational 
changes that lead to an exchange of elongation factors for termination factors. In 
support to this proposition, Pcf11 has been shown to directly bind the CTD of Pol II 
causing breakdown of the whole transcription complex (Zhang and Gilmour, 2006; 
Mayer et al., 2010; Kim et al., 2004).  
In the second model, called the ‘torpedo’ model, it is proposed that cleavage of the 
transcript at the cleavage and polyadenylation site (CPS) creates an entry site for the 
5’-3’ exonuclease Rat1 (Xrn2 in mammals), which degrades the 3’ RNA and triggers 
Pol II release by ‘chasing’ the complex (Kim et al., 2004; Connelly and Manley 1988; 
West et al., 2004). Importantly, recruitment of Rat1 seems to be indirect, probably via 
its partner Rtt103 which has been shown to bind S2P CTD in a cooperative manner 
with Pcf11 (Lunde et al., 2010), an essential component of the cleavage factor IA 
(CFIA) complex that also promotes Pol II release (Zhang et al., 2005). ChIP 
experiments revealed that Pcf11 is located at both protein-coding and non-coding 
genes and Pcf11 mutations lead to transcript read-through due to inefficient 
cleavage, indicating that it probably plays a key role in termination, as well as 
processing of coding and non-coding genes (Figure 3b) (Meinhart and Cramer 2004; 
Licatalosi et al., 2002; Zhang et al., 2005; Sadowski et al. 2003; Kim et al., 2006; Kim 
et al., 2010).  
In yeast, Pol II transcript processing is exerted through two different gene class-
specific pathways (Figure 3b). The majority of small mRNAs (<550 bp), CUTs, 
snRNA, and snoRNAs are processed through the Nrd1-Nab3 pathway, while longer 
mRNAs are processed in a polyadenylation-dependent process (Lykke-Andersen et 
al., 2007; Arigo et al., 2006; Thiebaut et al., 2006; Egloff et al., 2008; Richard and 
Manley 2009; Buratowski et al., 2005; Kim et al., 2006; Birse et al., 1998; Gudipati et 
al., 2008; Steinmetz et al., 2001). The pathway selection is dependent on the CTD 
phosphorylation state, with Nrd1 preferentially binding to S5P and its recruitment is 
additionally enhanced through histone H3me3K4 (Vasiljeva et al., 2008; Terzi et al., 
2011). The helicase Sen1 (senataxin in humans), which exists in a complex with 
Nrd1 and Nab3, associates with the exosome complex, linking transcription 
termination to 3’ exonuclease activity that can ‘trim’ snoRNA ends, or completely 
degrade cryptic transcripts. Remaining in yeast, interestingly, while transcription 
proceeds, phosphorylation of S2P CTD blocks the use of the Sen1/Nrd1/Nab3 
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termination pathway, providing a mechanism by which S2 phosphorylation could 
enhance downstream elongation (Gudipati et al., 2008). Senataxin, the Sen1 
homolog in higher eukaryatoes, has not been implicated to date in termination and it 
therefore still remains to be proven whether a similar early termination pathway 
exists in higher animals too. No functional homologs of Nrd1 and Nab3 have been 
identified yet, and there is no evidence for the existence of a Nrd1-like complex in 
human cells. SCAF8, which shares sequence similarity with Nrd1, specifically binds 
to CTD via its CID domain, however, its function is unknown and does not appear to 
involve termination (see also part 1.2.3) (Yuryev et al., 1996; Patturajan et al., 1998; 
Becker et al., 2008). 
The second pathway, responsible for the processing of most mRNA transcripts, 
includes the cleavage and polyadenylation factor (CPF) complex, cleavage factor IA 
and IB (CFIA and CFIB) complexes, and the exosome (Richard and Manley 2009; 
Kim et al., 2006; Birse et al., 1998) (Figure 3b). Importantly, the majority of 
termination and 3’ processing factors involved in this pathway tend to preferentially 
bind to S2P or S2P/S5P enriched CTD including: Npl3, Rtt103, Rna14, Rna15, Ydh1, 
Yhh1, Pta1, and Pcf11. Binding of Rna15 to nascent RNA triggers endonucleolytic 
cleavage followed by polyadenylation by the polyadenylate polymerase (Pap1). 
Subsequently, polyadenylation–binding proteins (PAB) protect the mature transcript 
from exonucleolytic degradation (Birse et al., 1998; Minvielle-Sebastia et al., 1994).  
In both pathways, the CTD is hypophosphorylated by the combined action of two 
essential phosphatases at the end of transcription, Ssu72 and Fcp1. Ssu72 which is 
primarily localized at the 3’ end of genes, is the main S5P phosphatase and its 
activity is enhanced by the prolyl isomerase Ess1 (Pin1 in humans) and by 
interacting with Pta1 (Figure 2, Figure 3a) (Nedea et al., 2003; Krishnamurthy 2004 
and 2009; Ghazy et al., 2009; Singh et al., 2009). In contrast to Ssu72, Fcp1 is found 
across the entire transcribed region and mainly dephosphorylates S2P CTD (Kobor 
et al., 1999; Cho et al., 2001; Archambault et al., 1997; Kong et al., 2005; Hausmann 
et al., 2004; Ghosh et al., 2008). Recent data showed that Ssu72 may be the 
phosphatase that removes S7P at both 5’ and 3’ ends of genes (Zhang et al., 2012). 
Global dephosphorylation of the CTD promotes the release of Pol II from DNA, which 
can then bind to promoters for a new round of transcription (Steinmetz and Brow 
2003; Cho et al., 1999; Dichtl et al., 2002). Interestingly, it has been suggested that 
transcription termination and subsequent dephosphorylation of the CTD is coupled to 
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transcription re-initiation via gene looping, during which the promoter and terminator 
regions come in close proximity, allowing Pol II to form a new PIC more rapidly 
(O’Sullivan et al., 2004; Singh et al., 2009). In line with this, Ssu72 and TFIIB have 
been shown to be essential in gene looping (Ansari and Hampsey 2005; Singh et al., 
2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
In summary, the phosphorylation and dephosphorylation of the CTD is a complex 
and highly controlled mechanism, which is clearly involved in every stage of 
transcription, from initiation, to elongation, to termination, and possibly re-initiation. 
Phosphorylated residues may be individually conceived as marks, but in a broader 
sense, waves of phosphorylation and simultaneous waves of dephosphorylation of 
Figure 3 
a) Dynamic modifications of the CTD during transcription cycle in mammals. 
Dynamic phosphorylation pattern of CTD due to the recruitment of CTD kinases, CTD 
phosphatases, prolyl isomerase Pin1 at different stages (initiation, elongation and 
termination) within the transcription cycle is shown.  
b) Different pathways for transcription termination for protein-coding and 
noncoding genes. Left: poly(A)-dependent termination: RNA is cleaved by 3’ end 
processing factors at the polyadenylation site. The CTD with S2P is involved in recruiting 
factors like Pcf11, Rtt103, p54/PSF, and Sen1, to facilitate termination of long 
polyadenylated transcripts. Right: Nrd1-dependent termination: The Nrd1 complex (Nrd1-
Nab3-Sen1) interacts via Nrd1 with S5P CTD which is present at the 3’ ends of short genes, 
such as snoRNAs and CUTs (Hsin and Manley, (2012), The RNA polymerase II CTD 
coordinates transcription and RNA processing; Genes & Development 26:2119-2137).  
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specific residues create combinatorial platforms that highly coordinate every step of 
the transcription cycle. 
 
 
1.2 CTD- a closer look 
 
 
The largest subunit of eukaryotic RNA Polymerase II, Rpb1, consists of a unique 
structure at its C-terminal domain, the CTD, with tandem repeats of the heptapeptide 
sequence Y1-S2-P3-T4-S5-P6-S7 (Allison et al., 1985; Corden et al., 1985). The length 
of the domain is a direct link to the genetic complexity of the organism where it is 
encountered. The CTD is dispensable for Pol II activity in vitro, (West and Corden 
1995; Bartolomei et al., 1988), however, deletion of the entire CTD in mice, 
drosophila and yeast is lethal (Egloff et al., 2008). Moreover, it is well proven that the 
CTD plays a direct and major role in coupling transcription with co-transcriptional 
nuclear processes, such as chromatin modification and RNA processing (see also 
part 1.1) (Egloff et al., 2008). The CTD has been also implicated in a variety of 
transcription-extrinsic processes like mRNA export and stress response. The 
process of mRNP export is controlled by the protein Sus1. This key player in mRNA 
export directly interacts with S5P and S2P/S5P CTD, Ub8 subunit of the SAGA 
complex, Yra1 subunit of the TREX1 complex, and Sac3 subunit of the TREX2 
complex at the nuclear pore (Stewart et al., 2010; Pascual-Garcia et al., 2008; Jani 
et al., 2009). Interestingly, in response to DNA damage, the ubiquitin ligase Rsp5 
binds the CTD and ubiquitylates Pol II (Huibregtse et al., 1997; Beaudenon et al., 
1999). Similarly, UV-induced DNA damage in mammalian fibroblasts leads to 
hyperphosphorylation of the CTD by P-TEFb, which then promotes Pol II 
ubiquitylation and subsequent degradation (Heine et al., 2008). Additionally, S5P 
CTD can also recruit the Asr1 ubiquitin ligase, promoting ejection of the Rpb4/7 
heterodimer from the core polymerase that may provide a mechanism for stopping 
polymerases engaged in abortive or cryptic transcription (Daulny et al., 2008). 
Recent studies have identified new posttranslational modifications of the CTD 
repeats, new CTD-binding factors and there are new insights into the relation 
between the different sites within the CTD based on genetic studies and ChIP data 
mainly performed in yeast. Some of these new exciting data linked to Pol II CTD will 
be discussed below. 
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1.2.1   Posttranslational modifications within the CTD of Pol II 
 
 
Serine-5 and Serine-2 phosphorylation: As discussed above, dynamic 
phosphorylations of the three serine residues are the best-characterized CTD 
modifications and in particular the exchange between S2P and S5P patterns play a 
pivotal role in the mediation of transcription and RNA processing. In ChIP 
experiments it has been shown that S5P marks are highly abundant at TSSs 
(transcription start sites) and strongly decline in the body of active genes (Kim et al., 
2010; Mayer et al., 2010; Tietjen et al., 2010; Bataille et al., 2012; Koch et al., 2011; 
Brookes et al., 2012) (Figure 4). The two main functions of this mark described to 
date are the recruitment of the capping machinery during transcription initiation and 
the interaction with Nrd1 that plays an important role in the 3’ end formation and 
early termination of non-polyadenylated transcripts (Cho et al., 1997; McCracken et 
al., 1997; Gudipati et al., 2008; Vasiljeva et al., 2008). In contrast to S5P, S2P is 
absent at TSS, progressively increases within the body of active genes while its peak 
is found in proximity to the poly(A) site (Kim et al., 2010; Mayer et al., 2010; Tietjen 
et al., 2010; Bataille et al., 2012; Koch et al., 2010; Brookes et al., 2012) (Figure 4). 
Interestingly, in S.cerevisiae, S2 phosphorylation is controlled by two different 
kinases, Bur1, which directly binds to S5P CTD, and Ctk1. Most S2P sites on 
elongating Pol II seem to be catalyzed by Ctk1 (Buratowski et al., 2009; Qiu et al., 
2009). Similarly, S. pombe has two S2 kinases equivalent to Ctk1 and Bur1, CDK9 
and Lsk1 (Viladevall et al., 2009). In metazoans, CDK9, the kinase subunit of P-
TEFb, phosphorylates both elongation factor Spt5 and CTD S2 (Bres et al., 2008). 
Due to the dual functionality of CDK9, it was thought that P-TEFb combines the 
activities of both yeast Bur1/CDK9 and Ctk1/Lsk1 homologues, respectively. 
However, recent studies in Drosophila and human cells have discovered two 
additional S2 CTD kinases, CDK12 and CDK13 (Blazek et al., 2011; Bartkowiak et 
al., 2010; Bartkowiak and Greenleaf 2011). ChIP data showed that CDK12 
contributes the majority of S2P sites on elongating Pol II and that its abundance at 
the 5’ end of genes is rather low (Bartkowiak et al., 2010; Bartkowiak and Greenleaf 
2011). In addition, CDK12 can promote the expression of a subset of human genes, 
including the DNA damage response genes. The function of CDK13 during the 
transcription cycle remains elusive (Kohoutek et al., 2012). A recent study has 
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revealed the existence of yet another S2 kinase, bromodomain protein Brd4, which is 
an atypical CTD S2 kinase that can phosphorylate S2 in vitro and in vivo (Devaiah et 
al., 2012). Brd4 is able to recruit P-TEFb but can also activate transcription of a 
subset of genes independent of P-TEFb (Devaiah et al., 2012; Rahman et al., 2011). 
The identification of these new metazoan S2 kinases emphasizes that the 
maintenance of distinct homologues in yeast species between Bur1- and Ctk1-type 
kinases has also been preserved in higher organisms. Apart from their role in gene 
transcription, CTD S2 and S5 phosphorylation has been implicated in other 
processes. For instance, S2P has been shown to be essential for additional cellular 
pathways, like sexual differentiation in S.pombe (Coudreuse et al., 2010), whereas 
the mitotic phosphatase Cdc14 has been shown to remove S2P and S5P and thereby 
repressing transcription during mitosis (Clemente-Blanco et al., 2011) (see also part 
1.2.2.2 and Table 2). 
 
Serine-7 phosphorylation: Next to S2P and S5P, other CTD posttranslational 
modifications, such as S7P, have been discovered more recently and fulfil gene 
class-specific tasks. The requirement for S7 phosphorylation was the first example of 
a specifically modified form of Pol II involved in expressing a particular type of gene 
and therefore strengthening the idea of a gene-specific CTD code (Chapman et al., 
2007; Egloff et al., 2007). S7P is required for expression of snRNA genes in 
mammalian cells and mutations of this residue leads to a marked defect in 
transcription of human snRNA genes and 3’ processing of the transcripts (Egloff et 
al., 2007). S7P specifically recruits the RPAP2 S5P phosphatase and the RNA 3’ 
processing integrator complex to snRNA genes, ensuring proper transcription and 
processing of transcripts (Egloff et al., 2012). Surprisingly, CDK7/Kin28, the kinase 
responsible for S5 phosphorylation turned out to be critical for S7 phosphorylation in 
yeast and humans (Boeing et al., 2010; Akhtar et al., 2009; Glover-Cutter et al., 
2009; Kim et al., 2009). Consequently, S7P ChIP-profiles at the beginning of snRNA 
and protein-coding genes generally resemble those of S5P, and knockdown of CDK7 
dramatically decreases both S5 and S7 phosphorylation (Akhtar et al., 2009). 
However, a very important finding is that, in contrast to S5P, the S7P levels remain 
high toward the 3’ end of coding and non-coding genes, suggesting that CDK7 is not 
the only S7- specific kinase. Indeed, it has been shown that the inactivation of Bur1 
kinase reduces the levels of S7P within coding regions and CDK9, the Bur1 homolog 
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in humans, is capable of phosphorylating S7 in vitro (Tietjen et al., 2010; Glover-
Cutter et al., 2009). Interestingly, Ssu72 has recently been shown to also remove 
phosphates from S7P (Zhang et al., 2012) underlying the close connection between 
the S5P and S7P marks that share a common kinase, as well as a phosphatase. 
 
Modulation of residue-specific serine phosphorylation pattern during 
transcription 
Distinct patterns of CTD phosphorylation are detected between non-coding and 
protein-coding genes. S5P marks the initiation site and is also detected on paused 
genes. High levels of S7P along transcribed regions suggest an important function of 
this mark in transcription elongation (Figure 4). Indeed, high levels of S7P are 
present on highly transcribed genes (Kim et al., 2010; Tietjen et al., 2010). S2P 
levels are lower on non-coding genes whereas S7P is equivalent to, or higher, on 
non-coding genes than on protein-coding genes (Kim et al., 2010; Tietjen et al., 
2010). The reason for this could be the short length of non-coding genes, since S2P 
generally occurs later in the transcription cycle. Accordingly, S2P is important for 
elongation and in activating splicing and 3’ end processing in protein-coding genes. 
Because snRNA genes are intronless, the requirement for a high level of S2P might 
be bypassed. S7P specifically recruits the RPAP2 S5P phosphatase and the RNA 3’ 
end processing integrator complex to snRNA genes for accurate transcription and 
processing of transcripts (Egloff et al., 2012).  
In yeast, short genes also exhibit a lower level of S2P for non-coding snoRNAs, 
compared to protein-coding genes. In respect of this, termination factors are 
recruited to protein-coding genes at S2P sites, whereas in snoRNAs the termination 
factor Nrd1 specifically binds to S5P CTD. Additionally, S7P levels can be found at 
high levels on non-coding genes (Kim et al., 2010; Tietjen et al., 2010; Vasiljeva et 
al., 2008). In yeast, it is not known, whether this could also be a positive signal for 
the recruitment of gene-specific factors to non-coding genes. In summary, a low level 
of S2P and an abundance of S7P at non-coding genes could stand for a CTD gene-
type specific signal. 
 
Threonine-4 phosphorylation: T4P was the fourth identified posttranslational 
modification in the CTD heptad repeat (Hsin et al., 2011; Hintermair et al., 2012). In 
ChIP analysis, T4P signals are very weak or absent at the TSS, remain low in the 
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gene body, but strongly rise downstream of the poly(A) site (Hintermair et al., 2012) 
(Figure 4). Interestingly, in mammalian cells, T4P peaks at about 300 bp downstream 
of S2P, suggesting that the increase of S2P might be a prerequisite for the 
subsequent phosphorylation of T4 (Hintermair et al., 2012). Likewise, T4P is tightly 
associated with S2P in co-IP experiments and no T4P can be detected in a serine-
2/alanine (S2/A) mutant. Moreover, the S2/A mutant promotes a global defect in RNA 
elongation, while few genes become activated, and show an enrichment of Pol II 
within the gene body (Hintermair et al., 2012). Additionally, the elongation defect was 
concomitant with a local accumulation of polymerases immediately downstream of 
the initiation site in mutant cells (Hintermair et al., 2012). In contrast, no enrichment 
of T4P at 3’ regions of genes can be detected in yeast, which correlates with the 
finding that T4P would block the binding of the termination factor Pcf11 (Mayer et al., 
2012; Meinhart et al., 2004). In a recent study in chicken cells, it has been shown 
that T4P is crucial for processing, but not transcription, of the intron-less replication-
activated histone genes, whereas expression of other protein-coding genes or non-
coding RNA genes remains unaffected by T4 mutation (Hsin et al., 2011). This 
observation reflects another example of a gene-specific role of the Pol II CTD. In 
human cells, Plk3 can phosphorylate T4 CTD under physiological conditions, as well 
as under stress conditions, leading to the contribution of a new class of CTD-specific 
kinases (Hintermair et al., 2012). Accordingly, inhibition of CDK9, the known S2P 
kinase, by DRB and flavopiridol also leads to diminished T4P levels, suggesting that 
T4 phosphorylation is also CDK9-dependent (Hsin et al., 2011). However, this could 
be an inhibitory effect caused by the lack of S2P, which has been shown to be a 
prerequisite for priming T4 phosphorylation. Finally, to date, no specific T4 CTD 
kinase has been identified in yeast and no T4 CTD phosphatase has been described 
in any species. 
 
Tyrosine-1 phosphorylation: Recently, the CTD code has been expanded by 
another CTD posttranslational modification, tyrosine-1 phosphorylation (Y1P), which 
plays an important role in the regulation of transcription termination (Baskaran et al., 
1993; Mayer et al., 2012). Y1 is phosphorylated in yeast and ChIP data showed that 
this modification can be found at all active genes. Importantly, Y1P levels drop before 
reaching the poly(A) site, whereas S2P levels still remain high (Figure 4). This led to 
the discovery that Y1P has a key function in suppressing termination during 
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elongation by blocking the recruitment of Rtt103 and Pcf11 (Mayer et al., 2012). Y1P 
blocks CTD binding to the conserved CTD-interacting domain (CID) of termination 
factors in vitro, whereas within the gene body, the CTD binding of elongation factor 
Spt6 through its CTD-binding domain is maintained and accompanied by high Y1P 
levels. 
This fundamental role of Y1P in gene expression might also explain the lethal 
phenotype of the tyrosine-1/phenylalanine (Y1/F) mutant in yeast and human. 
Nevertheless, an in vivo kinase screen including the CTD kinases Kin28, Srb10, 
Bur1 and Ctk1 has not led to the discovery of the responsible Y1P kinase in yeast, 
suggesting that Y1 phosphorylation of the yeast CTD depends on a kinase other than 
the known CTD kinases (Mayer et al., 2012). Concurrently, Y1 phosphorylation in 
human is performed by c-Abl, a kinase that lacks a yeast homolog (Baskaran et al. 
1999). 
 
 
 
 
 
 
 
 
 
Phosphospecific CTD antibodies: Hallmarks and considerations  
Monoclonal antibodies against CTD Y1P, S2P, T4P, S5P and S7P have also been 
established successfully in our lab and are a powerful tool for the study and 
identification of new phosphoresidues in ChIP experiments, as well as in vivo cell 
Figure 4 Average profile of CTD phosphorylation profiles along genes from 
ChIP experiments. Schematic graph of genome-wide distribution for all CTD 
phosphorylation marks (Heidemann et al., (2012), Dynamic phosphorylation patterns of 
RNA Polymerase II CTD during transcription; Biochim Biophys Acta. 2013 Jan; 
1829(1):55-62). 
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studies. However, it is very important to be aware of limitations in the epitope 
recognition capacities of these antibodies, due to epitope masking. Furthermore, the 
epitope specificity of antibodies is also an issue, as it can change at high antigen, as 
well as high antibody concentration. Additionally, the signal strength of antibodies in 
western blotting or ChIP analysis reflects the number of accessible CTD-marks and 
not the overall number of existing modifications, which are physically present in the 
CTD under investigation. Accordingly, the absence of a signal can be explained 
either with its physical absence or with the masking of the targeted epitope by other 
modifications. Consequently, in order to get a more detailed insight into how other 
adjacent modifications can influence or inhibit epitope recognition, our CTD 
antibodies were tested in enzyme-linked immunosorbent assays (ELISA) using a 
panel of di-heptad CTD peptides with various combinations of modifications. With 
this analysis we obtained a comprehensive overview of inhibitory modifications that 
interfere with binding of specific antibodies to the CTD (Figure 5). 
The results of this investigation demonstrate that all CTD-specific antibodies underlie 
specific restrictions in recognition of their respective epitope (Hintermair et al., 2012; 
Heidemann et al., 2012). For example, Y1P in the same repeat together with S2P 
influences the recognition by the S2P specific antibody 3E10 (Figure 5). In another 
case, phosphorylation of S2 or S5 next to T4P inhibits the epitope recognition of the 
T4P specific antibody 6D7 (Hintermair et al., 2012; Heidemann et al., 2012). 
Consequently, the T4P specific antibody cannot distinguish between de-novo 
phosphorylation of a T4 residue and the unmasking of pre-existing T4P marks, which 
leaves us for the interpretation of the strong increase of T4P in the 3’ region of genes 
either or both options (Figure 4) (Hintermair et al., 2012). Nevertheless, T4P-linked 
structural changes occur in the CTD downstream of the poly(A) site. Additionally, the 
CTD-specific antibodies were used to purify and define different fractions of the 
hyperphosphorylated form of Pol II (IIO form) biochemically. IP-experiments showed 
that three different populations of Pol IIO regarding their CTD marks exist. A 
population associated preferentially with (i) S5P marks, (ii) S5P and S2P marks, and 
(iii) S2P and T4P marks. The S7P mark can be found in all three populations 
(Hintermair et al., 2012). These data indicate that T4P is strictly associated with the 
S2P mark and that S5P/S7P and S2P marks are associated with different populations 
of Pol IIO in human cells. Importantly, recent ChIP studies in yeast revealed that the 
phosphoserine marks are placed and removed as a function of the distance from 
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transcription start site (TSS) and termination site, respectively, with no significant 
detectable difference between genes (Mayer et al., 2010; Bataille et al., 2012). In 
other words, the CTD cycle is very similar at all genes including the fact that short 
genes will have higher levels of S5P and lower levels of S2P than long genes when 
they reach the termination site. In line with this, short genes, such as snoRNAs and 
genes coding for small proteins tend to use an alternative mechanism for termination 
compared to most class II genes (Kim et al., 2006; Lykke-Andersen and Jensen, 
2007) (Figure 3b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Arginine methylation: Interestingly, in addition to 21 consensus repeats, the 
mammalian CTD consists of 31 non-consensus repeats that are mainly found in the 
distal part of Pol II CTD. Recently, for the first time, a specific role in CTD function 
within non-consensus repeats has been discovered. In human cells, the CTD of Pol 
II is methylated at arginine1810 (R1810) of CTD repeat 31 by the methyltransferase 
CARM1 in vitro and in vivo (Sims et al., 2011). This specific modification is linked to 
the regulation of snRNA and snoRNA expression since substitution of R1810 to 
alanine, as well as genetic knockout of CARM1, lead to a specific up-regulation of 
these classes of RNA species (Sims et al., 2011). Contrary to the inhibitory effect on 
snRNA gene expression of the S7 mutation, expression of snRNA and snoRNA were 
up-regulated when R1810 was mutated to alanine, indicating a repressive rather 
 
αTyr1-P (3D12)   T4S5P6S7Y1S2P3T4S5 
 
        
αSer2-P (3E10)   S5P6S7Y1S2P3T4S5 
 
                
αThr4-P (6D7)   Y1S2P3T4S5P6S7Y1 
 
        
αSer5-P (3E8)   Y1S2P3T4S5P6S7Y1 
 
        
αSer7-P (4E12)   P3T4S5P6S7Y1S2P3 
 
Figure 5 Overview of the characteristics in epitope recognition of 
monoclonal phospho-specific-CTD antibodies established in our lab. Blue 
circle indicates phospho-specific epitope of each antibody. Red amino acid residues 
reveal full or partial inhibition of antibody binding. 
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than activating function of this mark (Egloff et al., 2007; Sims et al., 2011). Thus, 
methylation of R1810 by CARM1 controls the expression of a subclass of RNAs, 
further expanding the gene-specific functions associated with the CTD. Interestingly, 
R1810 methylation is inhibited by S5P and S2P marks in vitro, suggesting that the 
methylation is placed before early initiation. However, this novel CTD mark can be 
detected within the actively transcribed Pol IIO form in vivo showing that arginine 
methylation is maintained within Pol II CTD during transcription (Sims et al., 2011). 
Additionally, the Tudor domain of TDRD 3 specifically binds to dimethylated R1810 
(Sims et al., 2011). However no specific role of this novel interaction has been yet 
found. Although the mechanism of how this new CTD mark of R1810 interferes with 
the expression of short transcripts is unknown, this and maybe other modifications 
within the non-consensus repeats of the distal part of mammalian CTD may play a 
key role in recruiting the transcription machinery to certain gene loci or keep it away. 
In addition to R1810, eight lysines are located within the distal part of the CTD and 
are potential residues for acetylation, methylation, sumoylation and ubiquitylation. 
Mass spectrometry might be a powerful tool for mapping new additional 
posttranslational modifications within non-consensus repeats of the distal part of Pol 
II CTD. 
 
Proline isomerisation: Proline-3 (P3) and proline-6 (P6) are totally conserved in all 
52 repeats of mammalian CTD and are surrounded by phosphorylation sites on each 
side. Prolines can be in either cis or trans orientation, resulting in four possible 
configurations of each repeat further expanding the complexity of the CTD code 
(Egloff et al., 2008). The peptidyl proline isomerase Ess1 in yeast and Pin1 in 
mammals can isomerize the prolines at position 3 and 6 of each CTD repeat (Egloff 
et al., 2008). CTD-protein binding studies revealed that the 
polyadenylation/termination factor Pcf11 binds exclusively to repeats with S2P and 
prolines in the trans configuration whereas the Ssu72 S5P phosphatase recognizes 
repeats with S5P and the downstream proline in the cis configuration (Noble et al., 
2005; Werner-Allen et al., 2011) (see also part 1.2.3). These findings show that the 
isomerisation status of prolines interferes with the CTD phosphorylation pattern 
directly and vice versa suggesting a further regulatory mechanism in regulating 
recruitment and binding of CTD-interacting factors. Furthermore, Ess1 and Pin1 can 
activate Ssu72 to promote S5P dephosphorylation (Noble et al., 2005; Werner-Allen 
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et al., 2011; Xiang et al., 2010). In addition, Pin1 is also involved in the 
hyperphosphorylation of the CTD during the mitotic (M) phase performed by 
Cdc2/cyclin B (Xu et al., 2003). 
 
Serine and threonine glycosylation: Serine and threonine residues within the CTD 
can be glycosylated by the addition of a monosaccharide N-acetylglucosamine (O-
GlcNAc) to their hydroxyl groups (Kelly et al., 1993). Importantly, phosphorylation 
and O-GlcNAcylation of single CTD residues are mutually exclusive proposing a role 
for CTD glycosylation in inhibiting CTD phosphorylation (Comer et al., 2001). In line 
with this, a recent study showed that dynamic glycosylation of CTD S5 and S7 
mediated through O-GlcNAc transferase (OGT) and O-GlcNAc aminidase (OGA) 
exists during the assembly of the pre-initiation complex. A reduction in the 
transcription and Pol II occupancy at several B-cell promoters could be observed by 
the knockdown of OGT (Ranuncolo et al., 2012). These data suggest that the 
glycosylated form of Pol II is recruited to the promoter and that OGA acts at this 
stage to selectively remove the O-GlcNAc group before phosphorylation occurs. 
However, so far, no clear evidence has been demonstrated that glycosylation within 
the CTD plays an important role in gene expression. 
 
 
 
1.2.2   Genetic analysis of the CTD of Pol II 
 
The CTD is dispensable for polymerase activity in vitro, but deletion of the entire 
CTD in mice or yeast is lethal. In mammals, CTD with only 31 repeats interferes with 
cell viability (Meininghaus et al., 2000) whereas mice homozygous for a CTD 
containing 39 repeats show a high degree of neolethality (Litingtung et al., 1999). In 
yeast, but not in mammals, cells expressing Rpb1 with CTDs consisting of only ~ 
50% of the original numbers of heptads are viable. In line with this, the CTD of 
budding yeast contains 26 repeats, but only eight heptads are required for cell 
viability and 13 are needed for wild-type-like growth (West and Corden, 1995). 
Genetic studies in mammalian cells revealed that a CTD composed of 55 consensus 
repeats can fulfil all essential functions for proliferation (Chapman et al., 2005). 
Moreover, a mutant consisting of only non-consensus repeats showed a severe 
growth defect compared to mutants of similar length, containing consensus repeats 
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(Chapman et al., 2005). Interestingly, these repeats differ from the consensus 
sequence mainly at S7 suggesting an important role for this position within the CTD. 
These data also imply that the highly conserved composition of the mammalian CTD 
consensus and non-consensus repeats is probably not entirely essential for life but 
rather ‘optimized’ for efficient function or other, as yet unknown, purposes that could 
come along with a survival advantage e.g. in response to cellular stress. In addition, 
non-consensus repeats may play an important role in the expression of specific 
genes as shown for R1810 in regulating the expression of snRNA and snoRNA 
genes (Sims et al., 2011). Furthermore, it has been shown that the effect on cell 
viability and growth appears to be dependent on the number of repeats. In other 
words, the greater the number of consensus repeats, the greater the rate of 
proliferation and cell survival (Litingtung et al., 1999: Meininghaus et al., 2000: 
Chapman et al., 2005). The number of repeats that comprise the Pol II CTD in 
different organisms may reflect the requirement for complex pre-mRNA processing 
events and transcriptional control. In this line, by both increasing the number of 
repeats and diverging their sequence, a greater number and diversity of factors can 
bind the CTD. Chapman et al. could show that both the last repeat 52 that contains a 
unique site for the binding of the CTD tyrosine kinases Abl1 and Abl2 as well as 
repeats 1-3 serve to regulate the stability of Pol II by preventing its degradation to 
the CTD-less RNA Pol II form (IIb form). Interestingly, all other repeats could be 
deleted without inducing degradation (Chapman et al., 2004 and 2005). In more 
detail, mutagenesis of CTD repeat 52 showed a requirement for acidic amino acids 
at its C-terminus independent of their specific sequence. In addition, repeats 1-3 can 
not be replaced by consensus repeats suggesting that these repeats may serve as a 
spacer between the Linker region and the CTD rather than being a binding site for a 
specific factor (Chapman et al., 2004 and 2005). 
A CTD-less RNA polymerase II can stimulate capping but the presence of the CTD 
increases the efficiency of this reaction fourfold (Mortillaro et al., 1996). However, a 
CTD-less RNA polymerase II is not able to initiate on the endogenous chromatin 
template (West and Corden, 1995; Bartolomei et al., 1988; Meininghaus et al., 
2000). In a different study it has been demonstrated that the CTD independently 
stimulates each of the three major pre-mRNA processing events in vivo (Fong and 
Bentley, 2001). Interestingly, there is a difference between the amino- and carboxy-
terminal halves of the CTD in the ability to stimulate different processing steps. While 
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the proximal part of the CTD can support capping without efficient splicing or 3’ 
processing, the distal part of the CTD supports all of the three pre-mRNA processing 
steps (Fong and Bentley, 2001). Moreover, the CTD carboxyl-terminus (repeat 27-
52) was sufficient for 3’ processing and splicing concluding that although the CTD is 
a highly repetitive structure, there seems to be functional specialization of different 
segments within it (Fong and Bentley, 2001). In different studies, mutants where the 
positions S2, T4, S5 or S7 of the CTD had been replaced by alanine were transfected 
into mammalian cells and the viability of these Pol II CTD mutants was measured 
over a period of 4 days. As a result, mutants containing replacements of S2/A, T4/A, 
and S5/A in 48 out of 52 CTD repeats revealed a strong growth defect with a 
dramatically reduced cell count after 4 days. Additionally, the T4/S and S7/A mutants 
showed an attenuated phenotype with almost constant cell numbers (Chapman et 
al., 2007; Hintermair et al., 2012). 
Most genetic studies of CTD have been performed in yeast and the next chapter will 
focus on different aspects of yeast CTD mainly focussing on deciphering the CTD 
code in both budding yeast and fission yeast. 
 
 
1.2.2.1 Genetic analysis of the budding yeast CTD  
 
In a recent genome-wide ChIP study in budding yeast new insights in the complex 
interplay between the CTD-modifying enzymes have been gained. In a kin28 mutant 
strain the levels of both S5P and S7P are strongly reduced at the 5’ end of genes as 
expected, however, a dramatic increase of these phospho marks could be detected 
throughout the ORF compared to wild-type cells (Bataille et al., 2012). Consequently, 
the distribution but not the overall level of S5P and S7P is affected in the absence of 
Kin28. This result can be explained by the fact that Bur1 is a potent S5 and S7 kinase 
but its activity is repressed in the presence of a functional Kin28 complex. Another 
interesting finding is that Kin28 and Bur1 seem to have opposing roles during early 
transcription as the accumulation of Pol II at the 5’ end of genes in a kin28 mutant 
can be rescued by simultaneous knockout of Bur1. Bataille et al. also showed that 
the depletion of CTD phosphatase Ssu72 led to a similar pattern in both S5P and S7P 
marks extending further to the end of the gene, implying that Ssu72 
dephosphorylates S5 and S7 prior to termination. In line with this, new data also 
revealed that the Ess1 isomerase can specifically stimulate the dephosphorylation of 
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both S5 and S7 at the 3’ end of genes. Ess1 catalyzes the cis/trans inter-conversion 
of the peptidyl-proline bond between S5-P6 and the cis-isomer form is known to be 
the preferred substrate of Ssu72. Therefore Ess1 plays a crucial role in CTD 
dephosphorylation by Ssu72 (Bataille et al., 2012). 
Bataille et al. also suggests that distinct variants of the same phosphoserine can be 
found within the CTD. They observed that S5P is removed in two waves, first by Rtr1 
and later by Ssu72. The same is true for S2P by removing one part of it prior to 
termination whereas the rest is dephosphorylated after termination. These different 
subclasses of the same phosphoserine may arise because of trans versus cis 
conformations of the S-P bonds or due to differential phosphorylation of 
neighbouring residues. Another explanation would be that the degenerate repeats 
located within the distal part of the CTD might be functionally distinct from consensus 
repeats located mainly in the proximal part of the CTD with respect to targeting by 
the different CTD modifying enzymes. 
Genetic studies in budding yeast have shown that Y1, S2, and S5 are essential for 
CTD function (West and Corden, 1995; Pei et al., 2001) and that A-insertions 
between adjacent repeats are lethal whereas individual residues inserted between 
pairs of heptapeptides are well tolerated (Liu, 2010; Stiller et al., 2004). These 
findings propose that the minimal function unit of CTD lies within a di-heptad. Based 
on this, Stiller and colleagues discovered the irreducible unit of CTD function in 
budding yeast performing genetic analyses of CTD mutants (Table 1). The two 
essential sequence motifs defining the functional unit are paired tyrosines placed 7 
amino acids apart (Y1-Y8) as well as three potential phosphoserines in a 2-5-9 
orientation with respect to the Y8 residue to a given di-heptapeptide (Liu, 2008 and 
2010). Since these two essential elements are somewhat independent the final 
functional unit consists of the sequence Y1-S2-P3-X4-S5-P6-X7-Y8 that is either linked 
to a proximal S2-P3-X-S5-P6-X or to a distal S2-P3. In this line, yeast mutants are 
viable with repeats containing only a minimal sequence of these two essential 
elements (Y1-S2-P3-T4-S5-P6-S7-Y1-S2-P3-T4) or by replacing the right-hand S5-P6-S7 
residues by alanines (mutant ‘252’ and ‘AR’; Table 1). Additionally, 9 or more tandem 
copies of this 11-mer sequence unit were sufficient for wild-type growth (Liu, 2008 
and 2010). Since this mutant contains a row of non-overlapping individual minimal 
functional units it seems like that the overall sequence required for most or all CTD 
functions is not based on tandemly repeated heptads but is rather defined within 
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repeated units of three consecutive S-P pairs interspersed with Y residues that are 
spaced at a heptad interval. In a different approach it has been shown that additional 
distance between essential units results in a progressive decline in CTD efficiency. A 
very slow growth phenotype could be detected in mutants with five A insertions 
between every diheptad and complete lethality was obtained when units were 
separated by seven A residues (mutant ‘5A’ and ‘7A’; Table 1) (Liu et al., 2010). 
Importantly, the lethal phenotype could be rescued by replacing alanine with proline 
in position 3 and 6 suggesting that the quality of the inserted sequence rather than 
the physical distance between functional units is important for CTD function (mutant 
‘AP’; Table 1). The long stretch of alanine residues tends to form stably secondary 
structure like α-helices and by replacing alanine with proline disrupts this structure 
leading to a more structurally unordered sequence around each given functional unit. 
In this line, a CTD mutant where seven alanine insertions are placed between every 
tri-heptad instead of every di-heptad grows vigorously explained by the fact that the 
amount of normal, structurally unordered sequence around the essential sequences 
has been increased (mutant ‘A7’; Table 1) (Liu et al., 2010). This leads to the 
conclusion that placing ordered structures directly next to essential CTD units 
negatively influences the interactions between these units and binding partners. In 
this respect, CTDs with only two heptads between each 7 alanine stretch are not 
recognized as substrate for any tested CTD kinase (human Cdk7 and Cdk9, yeast 
Ctk1), whereas CTDs with three heptads between each 7 alanine stretch showed 
efficient substrate specificity for all three tested kinases. In an experiment focussing 
on the question what is most important for optimal CTD function: the total overall 
length of the CTD, the absolute number of essential units present, or the spacing of 
the essential elements along the CTD? It turned out that independent of the 
sequence repeated, the length variant in each strain set revealing the highest growth 
rate always contained the CTD with closest to normal length, rather than the CTD 
with a WT-equivalent number of essential functional units. These genetic studies in 
budding yeast show that on the one hand CTD repeats are functionally redundant 
but on the other hand overall length of the CTD is most important and also strongly 
conserved within species. One idea based on this observed CTD characteristics is 
that a certain length is required to establish an optimal ‘loading platform’ for CTD- 
and phospho CTD-associating proteins (PCAPs) (Liu, 2008 and 2010). In more 
detail, binding of protein factors needed for key functions determines the minimum 
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number of repeats and is responsible for the strong purifying selection on CTD 
towards overlapping tandem functional units. Next, length beyond the minimum 
gains extra space to bind proteins involved in additional or accessory functions and 
finally non-consensus repeats provide landing platforms for proteins that play a role 
in more taxon-specific functions. In conclusion, the need for maintenance of a 
dynamic microenvironment around each functional CTD unit in combination with an 
optimized macroenvironment for overall binding across the full CTD length probably 
led to the highly conserved evolution of CTD across many species (Liu et al., 2010).  
 
 
 
 
 
 
 
 
 
1.2.2.2 Genetic analysis of the fission yeast CTD  
 
In Shuman’s lab, recent genetic studies in fission yeast shed light into the key rules 
that govern the CTD code in this organism by manipulating the composition and 
structure of the Rpb1 CTD. The fission yeast is an ideal model system for CTD 
studies as the native heptad repeat array is relatively homogeneous consisting of 29 
repeats of which 24 follow the consensus sequence (Figure 1). First they 
investigated the importance of all individual amino acids within the canonical repeat 
by introducing alanine in lieu of Y1, S2, P3, T4, S5, P6, and S7 of every heptad of the 
The ‘+’ marks for each viable CTD mutant indicate the relative vigor of the yeast cells 
bearing the mutants, compared to WT cells (WT is labeled as five pluses). Adapted from: 
(Liu and Greenleaf, (2010), Genetic Organization, Length Conservation, and Evolution of 
RNA Polymerase II Carboxyl-Terminal Domain; Mol. Biol. Evol. 27(11):2628-2641. 2010). 
Table 1 Overview of CTD mutants used in genetic studies in budding yeast. 
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Rpb1 CTD array (Table 2). The key results from this approach were that Y1, P3, S5, 
and P6 are essential for viability whereas S2, T4, and S7 are not (Table 2) (Schwer 
and Shuman, 2011). Interestingly, the S2/A mutant grew well at 30°C revealing that 
S2 phosphorylation is not essential and this observation contrasts clearly with the 
situation in budding yeast, where the same mutant was lethal (Table 2). In line with 
this, a similar result was obtained by studying a different mutant where Y1 was 
replaced by phenylalanine along the whole CTD. This Y1/F mutant was viable, 
though cold sensitive in fission yeast, whereas the analogous mutant in budding 
yeast is lethal. The Y1/F phenotype in fission yeast suggests that the Y1 hydroxyl 
group and therefore any tyrosine phosphorylation are not essential for the growth 
but, instead, the phenyl ring of Y1 is indispensable at this position within the CTD. 
The lethal phenotype of both, the S5/A mutant and the S5/E mutant occurs in both 
yeast strains and the negative outcome of replacing S5 with glutamate indicates that 
a state simulating constitutive S5 phosphorylation is detrimental across species 
(Table 2) (Schwer and Shuman, 2011). Additionally, the finding that replacing S5 with 
threonine is lethal, too, might be explained by the fact that the extra methyl group of 
threonine is directly deleterious due to steric hindrance with CTD binding proteins in 
fission yeast. The dominant role of S5 as the sole serine phosphorylation source for 
the Pol II CTD code regarding vegetative growth was underlined by the viability of 
the double mutant S2/A-S7/A at 30°C in fission yeast (Table 2). Another interesting 
finding of the Shuman group was the requirement of S2 for transcription during 
sexual differentiation and that this specific function of this CTD residue could be 
bypassed by subtracting S7. They found out that the S7P signal was higher in the 
S2/A mutant compared to wildtype even though the total Rpb1 signal was higher in 
WT than in the S2/A background. Based on this, Shuman and co-workers proposed 
that an imbalance in the CTD phosphorylation array and not the absence of a 
particular phospho-CTD residue reflects a CTD-associated pathology in this specific 
case and thereby adding a new aspect in how to read a CTD code (Schwer and 
Shuman, 2011).  
On top of this, Shuman’s lab could show in a very exciting experiment that the 
lethality of S5/A is rescued by the fusion of the Mce1 capping protein in-frame to the 
mutant S5/A cassette. The key finding of this experiment is that the essentiality of the 
S5P mark reflects its singular requirement for capping enzyme recruitment, which 
can be bypassed by fusing the capping enzyme to the S5/A CTD. In a similar 
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approach the Mce1 coding region was fused to mutant Y1/A, P3/A, P6/A, and S2/A-
S5/A CTD cassettes showing that the need for P6 as an essential letter is withdrawed 
when the capping enzyme is directly tethered to the CTD. Additionally, S2 does not 
turn into an essential factor regarding viability in the absence of S5. Finally, the 
requirement for Y1 and P3 could not be bypassed by Mce1 fusion suggesting that Y1 
and P3 might be used as recognition sites for CTD binding factors other than the 
capping enzymes (Schwer and Shuman, 2011). 
Following the pioneer work performed in the labs of Stiller and Greenleaf focussing 
on the discovery of the minimal essential CTD unit in budding yeast Shuman’s lab 
set up similar approaches for getting first insights in the grammar and punctuation of 
the CTD code in fission yeast. First, they confirmed that the essential CTD 
information lies within a di-heptad repeat in fission yeast, too. In genetic studies 
using CTD mutants where blocks of alanine insertions replaced the native amino 
acid residues at the distal end of each di-heptad unit they found out that the essential 
S5-P6 dipeptide need not to be located in consecutive heptad repeats. Additionally, 
the deca-peptide unit Y1-S2-P3-T4-S5-P6-S7-Y1-S2-P3 is the minimal coding unit of the 
CTD and the spacing between adjacent units is flexible (Schwer and Shuman, 2012). 
Moreover, Y1 must be present in consecutive heptads and proper spacing between 
consecutive tyrosines is important for CTD function, a common feature of Y1 in both, 
budding yeast and fission yeast. Interestingly, knockout of Ssu72 in fission yeast is 
not lethal, in contrast to its essentiality in budding yeast suggesting that a 
phosphatase other than Ssu72 is mainly responsible for dephosphorylating S5P and 
S7P in fission yeast.  
Shuman’s lab investigated the effect of CTD mutations on CTD phosphorylation in 
vivo. One result of this study is that independent pathways exist for S2 and S5 
phosphorylation in fission yeast. Furthermore, S2P and S5P marks can be placed in 
T4/A and S7/A cells as well as in Y1/F cells implying that neither S2 nor S5 
phosphorylation requires concomitant phosphorylations of Y1, T4, or S7. On the 
contrary, the P6/G mutant directly influences the Rpb1 S5P mark strengthening the 
idea that P6 plays a specific role in the recognition of S5 residues by cyclin–
dependent kinases in vivo (Schwer and Shuman, 2012). 
In summary, genetic studies of the Rpb1 CTD in both, budding yeast and fission 
yeast share important common features defining the minimal functional unit in 
respect of the need of an adjacent pair of tyrosines spaced 7 amino acids apart and 
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the essentiality of three consecutive serine residues in a 2-5-2 configuration. These 
results correlate with  findings based on crystal structures of proteins complexed with 
the CTD showing e.g. that paired tyrosines anchor binding of the CTD to several 
associated protein partners (see  also part 1.2.3). In addition, CTD-protein binding 
studies emphasize the importance of contiguous and properly spaced 
phosphoserines and that specific protein-CTD contacts although highly variable, tend 
to occur over relatively short stretches within the CTD (see  also part 1.2.3). The last 
chapter of the introduction part will discuss the structural features of the CTD and will 
summarize the basic rules that govern the CTD-specific recognition of several CTD 
binding proteins. 
 
 
 
 
 
 
 
 
 
   
 
1.2.3   Structural view of the CTD of Pol II 
 
The CTD of yeast spans up to 650 Å in an extended conformation and is located 
near the RNA exit channel of Rpb1. Consequently, both the location and the flexible 
nature of the CTD support the binding of many protein factors in close proximity of 
Table 2 Overview of CTD mutants used in genetic studies in fission yeast. 
A summary of the mutational effects on growth and mating in fission yeast is shown. The 
alleles are named according to the amino acid substitutions introduced into all 14 
consensus heptads appended to the ‘rump’ that connects the CTD to the body of Pol II 
(Schwer and Shuman, (2011), Deciphering the RNA Polymerase II CTD Code in Fission 
Yeast; Molecular Cell 43, 311-318, July 22, 2011). 
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the nascent transcript (Phatnani et al., 2006; Munoz et al., 2010). Multiple 
phosphorylations of the CTD create not only new recognition sites, but also lead to 
an overall structural change of the CTD. The CTD structure becomes more extended 
upon phosphorylation due to charge repulsion between phosphate groups (Zhang 
and Corden 1991: Cagas and Corden 1995; Cramer et al., 2001; Noble et al., 2005). 
In line with this, phosphorylations and other modifications not only change the 
chemical structure of the CTD but also increase or restrict the conformational 
variability on the domain and effect recognition by other factors. For example, the 
phosphate group of phosphoserine contains a double negative charge and can form 
multiple hydrogen bonds and salt bridges. In contrast, a methyl group, linked to 
arginine or lysine, deletes the possibility for the formation of H-bonds but promotes 
hydrophobic interactions instead. Importantly, phosphorylation and glycosylation 
occurs on the same hydroxyl groups of serine and threonine residues, causing the 
modifications to be mutually exclusive. Glycosylation inserts a relatively large sugar 
rest to the peptide chain serving as a steric block to prevent aberrant 
phosphorylation (Kelly et al., 1993; Comer et al., 2001). In the same line, 
ubiquitination and sumoylation would lead to even more drastic changes to the CTD 
structure. The addition of carbohydrate, ubiquitin, and SUMO likely inhibit access to 
the neighbouring amino acids and might prevent or control the dynamic exchange of 
other posttranslational modifications and binding factors. However, no detailed 
information about the functional relevance of these modifications within the CTD is 
available yet. Another important feature of the CTD code is the cis/trans 
isomerisation of the S2-P3 and S5-P6 peptide bonds (Lu et al., 2007; Shaw 2002 and 
2007). The majority of peptide bonds in the cis conformation appears in surface-
accessible bend, coil, or turn motifs (Lu et al., 2007). Switches between the cis and 
trans isomers induce large structural changes, leading to sharp turns into the 
backbone that destroys previous interactions and also creates new epitopes for 
recognition. Due to its flexibility, the CTD has not been detected in the crystal 
structures of Pol II. Nuclear magnetic resonance (NMR) spectroscopy data, however, 
imply that the free CTD is largely flexible, although it also contains some residual 
structure and shows a tendency to form ß-turns at two SPXX motifs (S2-P3-T4-S5 and 
S5-P6-S7-Y1) (Suzuki et al., 1989).  Importantly, available structures of bound CTD 
peptides demonstrate how complex and diverse the recognition of basically the 
same peptide sequence may be implying that no simple rules of the CTD code exist. 
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In other words, the specificity of binding depends on different modification isoforms, 
modification patterns, length of bound CTD peptides, and cis or trans conformations 
of the phosphoserine-proline peptidyl-prolyl bonds. A combination of steric 
constrains, intramolecular and intermolecular hydrogen bonds, van der Waals forces, 
and electrostatic and stacking interactions contribute to the specific recognition and 
binding of protein factors to the CTD. Based on this, each CTD-binding protein has 
its own minimal requirement for the functional unit of a CTD peptide, which can be as 
long as three repeats (Cgt1; Figure 6c), or as short as four residues, similar to Scp1 
(Figure 6b) (Fabrega et al., 2003; Zhang et al., 2006). 
 
CIDs (CTD-interacting domains) are the best studied family of the CTD binding 
domains and can be found in Rtt103, SCAF8, Pcf11, and Nrd1 (Figure 6a) (Meinhart 
and Cramer 2004; Becker et al., 2008; Lunde et al., 2010; Kim et al., 2004; 
Patturajan et al., 1998; Barilla et al., 2001; Sadowski et al., 2003; Steinmetz et al., 
1998; Vasiljeva et al., 2008). This domain contains eight α-helices and binds from 8 
to 11 residues of the CTD. The CTD forms a classical ß-turn conformation which is 
positioned in the binding groove of the CID. The ß-turn consists of S2b-P3b-T4b-S5b 
and is always stabilized by three intramolecular H-bonds independent from the 
phosphorylation pattern (Figure 6a) (Becker et al., 2008). Contacts of the CTD-CID 
interaction are made by H-bonds between the CID and P6a,b, S7a, Y1b, and S5b. In 
addition, the side chain hydroxyl group of Y1b forms an H-bond with a conserved 
aspartate of CID (Figure 6a). Interestingly, both the Rtt103 and SCAF8 CID binds the 
S2P CTD with a higher affinity than the Pcf11 CID due to the presence of a 
conserved arginine that creates a salt bridge interaction with the phosphate group of 
S2P (Lunde et al., 2010; Noble et al., 2005). In all CTD-CID complexes the S-P 
peptidyl-prolyl bonds are in trans conformation with the exception of Nrd1 that binds 
to S5P CTD favouring a cis conformation of the S5aP-P6a peptidyl-prolyl bond (Figure 
6a) (Kubicek et al., 2012). A common feature shared by all CTD-CID interactions 
involves the Y1 residue. Its hydroxyl group forms an H-bond with a conserved 
aspartate of the CID and its aromatic ring is tightly placed in the hydrophobic pocket 
of the CID. In line with this, recently it has been demonstrated that the 
phosphorylation of Y1 impairs the binding to all three yeast CID-containing proteins, 
Nrd1, Pcf11, and Rtt103 (Mayer et al., 2012). 
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Both, fission yeast CTD phosphatase Fcp1 and human small CTD phosphatase 
Scp1 belong to the family of Mg2+ dependent S-P/T-P-specific phosphatases (Zhang 
et al., 2006; Ghosh et al., 2008). Scp1 contains a FCPH (FCP homology) domain 
and binds the CTD in a CID-CTD similar way. In more detail, the peptide forms a ß-
turn-like structure spanning residues S2b-P3b-T4b-S5bP and one intramolecular H-
bond is formed between the hydroxyl groups of S2b and T4b (Figure 6b). Additionally, 
P3b is placed in a hydrophobic pocket while the S2b and T4b backbone carbonyls 
develop H-bonds with arginine178 (Figure 6b) (Zhang et al., 2006). 
Fcp1 instead needs the minimal CTD peptide stretch of S5a-P6a-S7a-Y1b-S2bP-P3b-T4b 
for binding and in contrast with Scp1, Y1b and P3b residues flanking S2bP are 
important for the phosphatase activity (Ghosh et al., 2008; Hausmann et al., 2004). 
These differences in positioning the CTD peptide within the structure of Scp1 and 
Fcp1 respectively, might explain that Scp1 preferentially dephosphorylates S5, 
whereas Fcp1 favours S2P residues as a substrate (Hausmann et al., 2002; Yeo et 
al., 2003).  
Interestingly, mouse capping enzyme Mce1, and Candida albicans 
guanyltransferase Cgt1 use distinct CTD binding interfaces to read the same pattern 
of modification (Fabrega et al., 2003; Ghosh et al., 2011). Both enzymes bind the 
CTD peptides that contain S5P in an extended ß-like conformation. However, the 
structure of Cgt1 covers almost three CTD heptads with S5P in each whereas Mce1 
interacts with a short doubly phosphorylated S5aP-P6a-S7a-Y1b-S2bP-P3b peptide 
(compare Figure 6c and 6d) (Fabrega et al., 2003; Ghosh et al., 2011). In the Cgt1-
CTD interaction, the two terminal phosphoserines are anchored in two positively 
charged pockets whereas the central S5bP is not recognized. In more detail, 
interactions take place with Y1b,c, P3b, P6a, and the terminal S5a,cP side chains 
whereas the middle heptad forms an exposed loop and may serves as a binding 
platform for other CTD-protein interactions (Figure 6c). In other words, the Cgt1 
protein is associated with two distinct functional units, with the intervening CTD 
segment looped out suggesting that efficient CTD-Cgt1 interaction requires contact 
with more than one minimum CTD unit and enough flexibility between them to 
support cooperative binding. Similar to the Cgt1 structure, the most important 
residues that are involved in Mce1-CTD binding are Y1b and S5aP. While S5P is 
placed in a positively charged pocket and forms several H-bonds, Y1b is located in a 
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hydrophobic pocket forming an H-bond via its side chain hydroxyl group (Figure 6d) 
(Fabrega et al., 2003; Ghosh et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The human peptidyl-prolyl cis-trans isomerase PIN1 binds the CTD via its WW 
domain forming a compact triple-stranded anti parallel ß-sheet (Verdecia et al., 
2000). Its WW domain belongs to the class IV group that specifically recognizes 
compact S-P motifs within peptide sequences. The binding interface includes one 
canonical heptad repeat of the CTD, which is phosphorylated at positions S2aP and 
S5aP. Main contacts in the Pin1-CTD complex originate from P3a, S5aP, and P6a and 
Figure 6 Overview of crystal structures between CTD-interacting proteins 
and CTD peptides.  
a) Nrd1 CID-CTD complex; b) Scp1-CTD complex; c) Cgt1-CTD complex; d) 
Mce1-CTD complex; e) Pin1 WW-CTD complex; f) Ssu72-CTD complex; The 
CTD residues forming the ß-turn conformation are highlighted in orange, the phosphate 
group of serine is shown in magenta, the serine-proline peptide bonds are highlighted in 
blue, and the dashed lines indicate H-bonds. CTD peptide sequence below: blue boxes 
indicate residues involved in the intermolecular H-bonds, dashes lines indicate residues 
forming the intramolecular H-bonds, green asterisks indicate a direct recognition of the 
phosphorylated serine, red circles indicate other types of electrostatic interactions 
contributing to the binding. Alphabetical subscripts indicate the sequential number of the 
heptads. (Jasnovidova and Stefl, (2012), The CTD code of RNA Polymerase II: a 
structural view; WIREs RNA 2013, 4:1-16. Doi: 10.1002). 
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the specificity towards S5P recognition can be explained by the generation of several 
H-bonds between the phosphate group and aginine17 and serine16 of the WW 
domain (Figure 6e) (Verdecia et al., 2000). 
Recent crystal structures of human and fruit fly Ssu72 revealed that this CTD-
phosphatase requires the cis conformation of the S5P-P6 for placing the S5P residue 
into the catalytic side of Ssu72 (Werner-Allen et al., 2011; Xiang et al., 2010). Upon 
cis-configuration, the phosphate group is attached to the active side via multiple H-
bonds and additional interactions include intramolecular H-bonds between T4a and 
P6a, H-bonds of S5aP and S7a backbone amides and Ssu72 residues. Additionally, 
van der Waals forces, electrostatic and stacking interactions take part in the binding 
of P3a, T4a, P6a and Y1b residues (Figure 6f) (Werner-Allen et al., 2011; Xiang et al., 
2010).  
In summary, extensive structural studies have shown an enormous diversity of 
interactions within CTD-protein complexes, however, contacts to CTD Y1 and 
phosphorylated S5 side chains predominate in most of these complexes which is 
consistent with the fact that these two positions within the CTD heptad array are the 
least degenerate in Nature. In the future, it will be important to combine the structural 
and dynamic data of the CTD interactions which may then lead to the deciphering of 
how the CTD code is written, read, and erased. 
  
 
Aim of present study: 
 
Mammalian RNA polymerase II (Pol II) largest subunit Rpb1 contains a unique and 
highly repetitive domain at the carboxy-terminus (CTD) with the consensus heptad 
Y1-S2-P3-T4-S5-P6-S7. As discussed earlier (see Introduction) each single residue of 
the consensus sequence can potentially be modified. Whereas phosphorylation of 
serine-2, serine-5 and serine-7 have already been extensively characterised, the role 
of tyrosine-1 and threonine-4 phosphorylation are poorly understood. Several CTD 
modification specific antibodies have been raised in our laboratory, providing 
valuable information while mapping these modifications in vivo by ChIP analyses. 
However, in spite of the availability of all these CTD-specific antibodies, many 
questions about the modification pattern of the CTD in vivo still remain elusive and a 
number of questions remain unanswered. For example, how extensively are 
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individual repeats modified? Are there distinct phosphorylation marks excluding each 
other? Are there distinct ’signatures’ marking the proximal or the distal part of the 
CTD? Do these ‘signatures’ form platforms for specific recruitment of CTD-binding 
proteins?  And finally, is there a difference in the degree of phosphorylation among 
the different CTD heptad repeats? 
So far, several CTD-phosphosites have already been published (e.g. 
http://www.phosphosite.org) and accordingly, the first part of this work was to set up 
a protocol for mapping phosphosites in order to confirm existing patterns. Of note 
here, is that the distal part of the wild-type (WT) CTD of Pol II is accessible to mass 
spectrometry analysis (MS) due to lysine (K) and arginine (R) residues at the 
seventh position of the non-consensus heptad repeats. However, the main part of 
WT CTD-sequence is inaccessible. The main reason for this is that the mass 
spectrometer is most efficient at obtaining sequence information from peptides that 
are up to 30 residues long, rather than from longer peptides or whole proteins. 
Therefore, in a second step, CTD mutants were established to make the whole 
sequence accessible to MS and to map phosphosites within the entire CTD in vivo. 
MS analysis of four CTD mutants showed that it was difficult to ‘read’ longer peptides 
with more than 28 amino acids in length and thus, the sequence coverage of the 
proximal part of the CTD was still incomplete. Consequently, a second round of CTD 
mutants was created, where the proximal part of the CTD can be fragmented into 
only di- and tri-heptads that are readily assessable by MS.  
This work has established a workflow for identifying abundant CTD signatures that 
define a so-called ‘CTD-code’ and can finally be linked to specific CTD-binding 
protein interactions. 
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2. Results 
 
 
The establishment of a reliable protocol for mapping phosphosites within the CTD of 
Pol II using tandem mass spectrometry (MS/MS) was attained in this work. 
Additionally, development of a standardized procedure summarized in the workflow 
scheme in Table 3 was attempted and the initial results appear very promising in 
opening new ways to the evaluation of phosphorylation patterns within the CTD of 
Pol II in vivo. 
  
 
 
2.1  Mapping phosphosites of WT CTD peptides of Raji  
       cells 
 
 
In order to map posttranslational modifications of proteins via MS the protein of 
interest has to be digested into peptides using a sequence-specific protease, such 
as trypsin. The aim of producing optimally up to 30 amino acid long peptidic 
Table 3 The principle of my workflow. 
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fragments is imposed by the detection limit of the mass spectrometer, which can 
provide sequence information up to this size. Here, trypsin is used for the digestion 
of Rpb1 proteins into peptides. Trypsin is an aggressive and stable protease, which 
very specifically cleaves proteins on the carboxy-terminal side of R and K residues. 
For the case of the Rpb1, this creates peptides both in the preferred mass range for 
sequencing and with a basic residue at the carboxyl terminus of the peptide. Such 
peptides are ‘information-rich’ and provide easily interpretable peptide-fragmentation 
spectra. 
 
2.1.1  Closer look to the mammalian WT CTD sequence 
 
Mammalian WT CTD of Rpb1 of Pol II consists of a long stretch of consensus heptad 
repeats with the sequence YSPTSPS in its proximal part, whereas the last 26 
repeats contain only three consensus repeats (see Figure 7). Among the non-
canonical repeats, position 7 is the most variant residue. Importantly, eight lysines 
and one arginine can be found at this position which makes the distal part of 
mammalian CTD accessible to MS analysis.  
 
1  YSPTSPA
2  YEPRSPGG
3  YTPQSPS
4  YSPTSPS
5  YSPTSPS
6  YSPTSPN
7  YSPTSPS
8  YSPTSPS
9  YSPTSPS
10 YSPTSPS
11 YSPTSPS
12 YSPTSPS
13 YSPTSPS
14 YSPTSPS
15 YSPTSPS
16 YSPTSPS
17 YSPTSPS
18 YSPTSPS
19 YSPTSPS
20 YSPTSPS
21 YSPTSPS
22 YSPTSPN
23 YSPTSPN
24 YTPTSPS
25 YSPTSPS
26 YSPTSPN
27 YTPTSPN
28 YSPTSPS
29 YSPTSPS
30 YSPTSPS
31 YSPSSPR
32 YTPQSPT
33 YTPSSPS
34 YSPSSPS
35 YSPTSPK
36 YTPTSPS
37 YSPSSPE
38 YTPTSPK
39 YSPTSPK
40 YSPTSPK
41 YSPTSPT
42 YSPTTPK
43 YSPTSPT
44 YSPTSPV
45 YTPTSPK
46 YSPTSPT
47 YSPTSPK
48 YSPTSPT
49 YSPTSPKGST
50 YSPTSPG
51 YSPTSPT
52 YSLTSPAISPDDSDEEN
32-35 YTPQSPTYTPSSPSYSPSSPSYSPTSPK
36-38 YTPTSPSYSPSSPEYTPTSPK
39    YSPTSPK
40    YSPTSPK
41-42 YSPTSPTYSPTTPK
43-45 YSPTSPTYSPTSPVYTPTSPK
46-47 YSPTSPTYSPTSPK
48-49 YSPTSPTYSPTSPK
50-52 GSTYSPTSPGYSPTSPTYSLTSPAISPDDSDEEN
Trypsin
 
 
 
 
 
 
The first step was to set up a protocol that allows the efficient mapping of 
phosphosites within the distal part of the WT CTD. The analysis of the WT CTD 
served as an original ‘internal control’ of this protocol, by comparing and confirming 
Figure 7 Human CTD sequence. Left: Scheme of the 52 repeats of human CTD. 
Amino acids that diverge from the consensus sequence are marked in blue. Repeat 
number is shown in front of each corresponding sequence. Right: Predicted fragmented 
CTD peptides after trypsin digestion. Repeats 39 and 40 as well as repeats 46-47 and 48-
49 can not be separated in the MS analysis due to identical masses.  
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the outcome of the spectra with published data of phosphorylated CTD peptides 
originating from whole phosphoproteomic approaches. 
 
2.1.2  Purification of the WT Rpb1 protein  
 
A key point for the purification of the Rpb1 protein was to use phospho-CTD specific 
antibodies that purify the hyperphosphorylated Pol IIO form very efficiently. 
Importantly, our lab has established monoclonal antibodies against all different 
phosphorylated epitopes within the consensus sequence of CTD-heptad repeats.  
These antibodies were all tested individually as well as in all different combinations 
to find the CTD-antibodies with the highest IP-efficiency. The combination of CTD α-
S2-P/α-S5-P (view also Figure 5, Introduction) in a 1:1 ratio turned out to be the best 
choice resulting in the purification of approximately 80-90% of the Pol IIO form using 
whole Raji cell lysates (Figure 8). Whole cell lysate extracts of Raji cells growing 
under normal cell culture conditions were used for the IP reaction and the western 
blot analysis using a specific Rpb1 antibody (Pol3.3) for detection was performed via 
the ECL-detection system applying two different exposure time points (view also 
4.4.5.3 in Material and Methods).  
 
 
 
 
 
 
 
 
 
On the membrane with the longer exposure duration (30 seconds) saturation of the 
signal of the Rpb1 antibody is obtained and about 10% of the Pol IIO form can be 
found left in the supernatant fraction of the IP reaction. Interestingly, although the IP 
Figure 8 ECL-Western blot analysis of WT Raji Rpb1 purification. Left: Exposure 
time of membrane for 10 seconds. Right: Exposure time of membrane for 30 seconds. 
Rpb1 (IIO and IIA form) was purified with α-S2P/ αS5P in a 1:1 ratio and detected on the 
ECL blot via α-Rpb1. SN=Supernatant fraction of IP. 
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antibodies used (α-S2-P/α-S5-P) are specifically recognising the Pol IIO form they 
also purify a large amount of the hypophosphorylated Pol IIA form when using high 
amounts of cells in the IP-reaction (Figure 8). 
Next step was to isolate enough Rpb1 protein for subsequent MS analysis. The 
detection of the protein of interest after Coomassie gel staining served as a 
quantitative assessment of the amount of isolated protein. Consequently, 80 Mio 
cells were needed to visualize both the Pol IIO and Pol IIA form on the Coomassie 
geI (~ 50 ng of protein) following IP and SDS-PAGE (Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Both Rpb1 forms (IIO+IIA) were analysed via MS/MS analysis and the results are 
summarized in Figure 10. When using 80 Mio cells as starting material the MS 
output was rather low, detecting only five phosphorylated CTD peptides. Due to this 
weak outcome the protein amount was increased using 300 Mio cells, instead of 80 
Mio cells, for every MS run. An additional phosphopeptide purification step using 
TiO2 beads was included. The TiO2 enrichment strategy is based on the general 
affinity of phosphorylated peptides towards metal oxides and reduces the 
underrepresentation of phosphorylated peptides in a high ‘background’ of non-
phosphorylated peptides. These improvements led to a 10-fold increase in the MS 
outcome and not yet described to date, new phosphorylated CTD peptides, that 
could be found in several positions within the WT CTD of Pol II (Figure 10). 
 
Figure 9 Coomassie gel after WT Raji Rpb1 purification. 80 Mio cells were used for 
the IP and Rpb1 (IIO and IIA form) was purified with α-S2P/ αS5P in a 1:1 ratio and detected 
on the SDS-PAGE gel after Coomassie staining. Both forms of Rpb1 (IIO and IIA) can be 
detected in the IP lane (Lane 3). SN=supernatant fraction of IP. 
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41-42 (1)
YSPTSPTYSPTTPK
43-45 (1)
YSPTSPTYSPTSPVYTPTSPK
46-47, 48-49 (6)
YSPTSPTYSPTSPK(2)
YSPTSPTYSPTSPK(3)
YSPTSPTYSPTSPK
36-38 (17)
YTPTSPSYSPSSPEYTPTSPK
YTPTSPSYSPSSPEYTPTSPK
YTPTSPSYSPSSPEYTPTSPK
YTPTSPSYSPSSPEYTPTSPK(2)
YTPTSPSYSPSSPEYTPTSPK
YTPTSPSYSPSSPEYTPTSPK
YTPTSPSYSPSSPEYTPTSPK
YTPTSPSYSPSSPEYTPTSPK(6)
YTPTSPSYSPSSPEYTPTSPK
YTPTSPSYSPSSPEYTPTSPK(2)
40-42 (5)
YSPTSPKYSPTSPTYSPTTPK
YSPTSPKYSPTSPTYSPTTPK
YSPTSPKYSPTSPTYSPTTPK(2)
YSPTSPKYSPTSPTYSPTTPK
41-42 (10)
YSPTSPTYSPTTPK(2)
YSPTSPTYSPTTPK
YSPTSPTYSPTTPK
YSPTSPTYSPTTPK(2)
YSPTSPTYSPTTPK
YSPTSPTYSPTTPK(3)
43-45 (26)
YSPTSPTYSPTSPVYTPTSPK
YSPTSPTYSPTSPVYTPTSPK
YSPTSPTYSPTSPVYTPTSPK(2)
YSPTSPTYSPTSPVYTPTSPK(4)
YSPTSPTYSPTSPVYTPTSPK
YSPTSPTYSPTSPVYTPTSPK
YSPTSPTYSPTSPVYTPTSPK
YSPTSPTYSPTSPVYTPTSPK
YSPTSPTYSPTSPVYTPTSPK
YSPTSPTYSPTSPVYTPTSPK
YSPTSPTYSPTSPVYTPTSPK(2)
YSPTSPTYSPTSPVYTPTSPK
YSPTSPTYSPTSPVYTPTSPK(2)
YSPTSPTYSPTSPVYTPTSPK
YSPTSPTYSPTSPVYTPTSPK(2)
YSPTSPTYSPTSPVYTPTSPK(4)
46-47, 48-49 (10)
YSPTSPTYSPTSPK
YSPTSPTYSPTSPK
YSPTSPTYSPTSPK
YSPTSPTYSPTSPK(4)
YSPTSPTYSPTSPK
YSPTSPTYSPTSPK(2)
40 Mio cells: 300 Mio cells:
 
 
 
 
 
 
 
 
  
Preliminary results of the MS analysis of WT CTD showed that 101 phosphosites 
could be mapped within 184 heptad repeats, which is a rather low average 
phosphorylation frequency of 0.55 phosphosites / CTD-heptad. Most abundant 
phosphorylated residues within the CTD were T4 and S5 with 26 and 32 
phosphorylation counts, respectively. As depicted in figure 10, most frequent 
phosphorylated CTD peptides contained three phosphorylation sites and the 
preferred distribution of these triple-phosphosites was one phosphosite per heptad 
repeat. 
  
 
2.2  Mapping phosphosites of mutated CTDs of Pol II  
 
 
To get insights into phosphorylation patterns of the entire CTD of Pol II in vivo, CTD 
mutants were established for optimal mapping of phosphosites via MS. Mutated CTD 
sequences were synthesized by Geneart in Regensburg, subcloned into a final Rpb1 
Figure 10 MS analysis of WT CTD of Pol II. Left: Detected phospho-CTD peptides 
using 80 Mio cells in one run. Right: Detected phospho-CTD peptides using 300 Mio cells 
and including a phosphopeptide purification step. Repeat numbers and detection counts 
are indicated for corresponding phospho-CTD peptide (shown in brackets). Amino 
residues diverging from the consensus sequence are marked in blue and amino acid 
residues that are found to be phosphorylated are marked in red. 
80 Mio cells:  io cells + Phospopeptide purification:
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expression vector and transfected into Raji cells. Recombinant Rpb1 was then 
purified with CTD-specific antibodies and phosphosites of mutated CTD sequences 
were finally mapped in a MS/MS approach. 
  
 
2.2.1  Designing CTD mutants to obtain  complete sequence  
          coverage for  subsequent MS analysis 
 
In order to obtain MS data including the complete CTD, K and R residues were 
introduced at position 7 of heptad repeats mainly within the proximal part of the CTD. 
K and R residues are a prerequisite for subsequent peptide fragmentation using 
trypsin for protein digestion. To receive full sequence coverage, it is essential that all 
fragmented peptides have different masses based on their length and amino acid 
composition. Consequently, additional amino acid residues next to K and R were 
strategically inserted into the CTD sequence. All in all, 9 different CTD mutants have 
been designed according to different numbers and lengths of fragmented peptides 
and different numbers of CTD mutations. The length of the different CTD peptides 
ranged from mono-heptads (7 residues) to hexa-heptads (42 residues). 
Subsequently, CTD mutants that comprise longer CTD peptides are less mutated 
and vica versa. Figure 11 shows one example of how the CTD can be mutated for 
achieving CTD peptides comprising the whole CTD sequence that can be then 
analysed MS. In this CTD mutant (M-8K4R), eight lysines and four arginines were 
inserted at the seventh position of CTD heptad repeats via amino acid substitutions 
leading to the fragmentation of 20 CTD peptides each containing a unique mass. In 
the M-8K4R, the longer CTD peptides cover four heptad repeats (28 residues) with 
the longest peptide covering 34 residues (repeat 50-52), whereas the shortest CTD 
peptides can be found with repeat 39 and 40 including only 7 residues. The majority 
of mutations were introduced into the CTD via amino acid substitutions, however, in 
CTD peptide 19-21 an alanine was placed into the CTD in an additive manner 
expanding the overall CTD length. Importantly, while most mutations were placed in 
the proximal part of the CTD, two lysines were replaced by arginine at position seven 
of repeat 40 and repeat 47 in the distal part of the CTD in order to avoid peptides 
with identical sequences and, therefore, to obtain different masses for CTD peptide 
39 and 40, as well as for CTD peptides 46-47 and 48-49. For the same reason, 
further amino acid substitutions (alanine in peptide 13-15; serine in peptide 16-18; 
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leucine in repeat 19-21), next to arginine and lysine, were created by using aliphatic 
non-polar amino acids (Figure 11). 
1  YSPTSPA
2  YEPRSPGG
3  YTPQSPS
4  YSPTSPK
5  YSPTSPS
6  YSPTSPN
7  YSPTSPK
8  YSPTSPS
9  YSPTSPK
10 YSPTSPS
11 YSPTSPS
12 YSPTSPK
13 YSPTSPS
14 YSPTSPS
15 YSPASPK
16 YSPTSPS
17 YSPTSPS
18  YSPSSPK
19 AYSPTSPS
20  YSPTSPS
21  YSPLSPR
22  YSPTSPN
23  YSPTSPN
24  YTPTSPK
25  YSPTSPS
26  YSPTSPN
27  YTPTSPN
28  YSPTSPK
29  YSPTSPS
30  YSPTSPS
31  YSPSSPR
32  YTPQSPT
33  YTPSSPS
34  YSPSSPS
35 YSPTSPK
36 YTPTSPS
37 YSPSSPE
38 YTPASPR
39 YSPTSPK
40 YSPTSPR
41 YSPTSPT
42 YSPTTPK
43 YSPTSPT
44 YSPTSPV
45 YTPTSPK
46 YSPTSPT
47 YSPTSPR
48 YSPTSPT
49 YSPTSPKGST
50 YSPTSPG
51 YSPTSPT
52 YSLTSPAISPDDSDEEN
1-2    YSPTSPAYEPR
2-4 SPGGYTPQSPSYSPTSPK
5-7 YSPTSPSYSPTSPNYSPTSPK
8-9 YSPTSPSYSPTSPK
10-12 YSPTSPSYSPTSPSYSPTSPK
13-15 YSPTSPSYSPTSPSYSPASPK
16-18 YSPTSPSYSPTSPSYSPSSPK
19-21 AYSPTSPSYSPTSPSYSPLSPR
22-24 YSPTSPNYSPTSPNYTPTSPK
25-28 YSPTSPSYSPTSPNYTPTSPNYSPTSPK
29-31 YSPTSPSYSPTSPSYSPSSPR
32-35  YTPQSPTYTPSSPSYSPSSPSYSPTSPK
36-38  YTPTSPSYSPSSPEYTPASPR
39     YSPTSPK
40     YSPTSPR
41-42  YSPTSPTYSPTTPK
43-45  YSPTSPTYSPTSPVYTPTSPK
46-47  YSPTSPTYSPTSPR
48-49  YSPTSPTYSPTSPK
50-52  GSTYSPTSPGYSPTSPTYSLTSPAISPDDSDEEN
Trypsin
 
 
 
 
 
 
 
 
2.2.2  Establishing cell lines expressing Pol II CTD mutants 
 
All 9 CTD mutants were successfully cloned into the final expression vector RX4-267 
(Meininghaus et al., 2000). This vector contains the full length, haemagglutinin-(HA)-
tagged, mouse Rpb1 gene comprising 28 exons (Figure 12). The CTD is encoded by 
exon 28 and can be exchanged for any given CTD sequence using flanking 
restriction sites on both ends (AgeI and NotI) as insertion points. The Rpb1 gene 
contains a point mutation (N793D) conferring α-amanitin resistance (Bartolomei and 
Corden, 1987). Consequently, in the presence of α-amanitin, the endogenous  Pol II 
is effectively, chemically ‘knocked-out’, thereby allowing the properties of the mutant 
RNA polymerases to be examined in vivo. Since the Rpb1-expression vector uses 
the replication origin of the Epstein-Barr virus (EBV-oriP), it is episomally maintained 
instead of being integrated into the genome, when using human cells expressing the 
EBV-nuclear antigen 1 (EBNA1). Episomes replicate like extra chromosomes 
thereby offering a great advantage of avoiding position effects within the genome, as 
well as allowing cell lines to be produced as a ‘batch-culture’.  
Figure 11 CTD sequence and predicted CTD peptides after trypsin digestion of 
CTD mutant M-8K4R. Left: Scheme of the 52 repeats of CTD mutant M-8K4R. Amino 
acids that diverge from the consensus sequence are marked in blue and mutated residues 
are marked in red. Repeat number is shown in front of each corresponding sequence. Right: 
Predicted CTD peptides after trypsin digestion. CTD peptides cover whole CTD sequence 
(all repeats) and contain unique masses.  
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Rpb1-expression     
vector
(pRX4-267/25837bp)
 
 
 
 
 
The Rpb1-expression vector containing the mutated CTD was transfected into Raji 
cells via electroporation and was positively selected due to its neomycin resistance. 
After 2-4 weeks under neomycin selection, cell viability of 80-90% was obtained and 
α-amanitin was added thereby knocking out the endogenous Pol II within the next 24 
hours.  
 
 
 
 
 
 
 
 
 
Viability of WT Raji cells dramatically decreases after 5-7 days under α-amanitin 
Figure 12 Scheme of the final Rpb1 expression vector. This vector encodes the 
whole mouse Rpb1 gene containing 28 exons. CTD is encoded by the last exon and can be 
easily exchanged using the restriction sites AgeI and NotI on both ends, respectively. For 
more detailed informations view text above. 
Figure 13 Western blot analysis showing stable expression of all 9 CTD 
mutants. Cell lysates of CTD mutants were produced after 2 weeks under α-amanitin 
treatment and stably expressed recombinant Rpb1 containing hyperphosphorylated and 
hypophosphorylated mutated CTDs, respectively. IIO- and IIA-forms were detected via α-
HA. WT Raji lysate (second lane) was used as a negative control obtaining no signal with α-
HA. 
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selection. All 9 CTD mutants showed full viability and stable expression of their 
recombinant polymerases over months under treatment with α-amanitin using normal 
cell culture conditions and therefore all CTD mutants were included in the final MS 
analysis (Figure 13). 
 
2.2.3  Purification of Rpb1 CTD mutants 
 
Compared to WT Rpb1 immunoprecipitation from Raji cells and subsequent band 
isolation, for the recombinant Rpb1 proteins there was an additional option, due to 
an HA-tag inserted in their sequence. Therefore, in this case, both purification 
schemes were adopted, either with the combination of the α-S2P/α-S5P-IP, or with an 
α-HA antibody (3F10) and their efficiencies were compared by western blot analysis 
(Figure 14).   
 
 
 
 
 
As it can be seen in Figure 14, in both α-S2P/α-S5P and α-HA immunoprecipitates 
recovery of the hyperphosphorylated Pol IIO, as well as the hypophosphorylated Pol 
IIA form can be observed. The α-S2P/α-S5P IP appears to enrich CTD mutant M-
3K5R as efficiently as it has been shown for WT cells (see Figure 8), purifying 80-
90% of the hyperphosphorylated Pol IIO form and the results were consistent for all 
9 CTD mutants. The α-HA IP seems to be less efficient in the recovery of the 
hyperphosphorylated form, apparently due to the fact that the amounts of the 
overexpressed unmodified recombinant protein are more abundant in the cell and in 
this case there is no phospho-selection of the precipitates. 
For subsequent MS analysis, 450 Mio cells were used for one experimental round for 
Figure 14 Odyssey-Western blot analysis of CTD mutant M-3K5R purification. 
Left: IP purification of IIO and IIA form using α-S2P/α-S5P. Detection antibody: α-HA; Right: 
IP purification of IIO and IIA form using α-HA. Detection antibody: α-Rpb1; SN=Supernatant 
fraction of corresponding IP. 
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each CTD mutant comprising IP purification either with α-S2P/α-S5P or α-HA and 
subsequent band isolation after SDS-PAGE and Coomassie staining (Figure 15). 
Interestingly, after Coomassie staining, a third RNA Pol II form, termed IIO low, 
located between the IIO and IIA form could be detected in the α-HA 
immunoprecipitates. The reason why this intermediate Rpb1-form was not observed 
in the western blot analysis might be due to several causes, such as the different 
amount of cells used in western blot and coomassie stained gel as well as the 
arbitrary resolution of the gel bands in each case. For western blot analysis lower 
cell amounts are preferred in order to avoid saturated signals in the antibody 
detection reaction, whereas in the final purification destined for subsequent MS 
analysis more material is used to obtain a more informative MS data outcome. These 
results concerning the differences between the two IP procedures and what they 
recover will be discussed in more detail later (see Discussion).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Following Coomassie staining, the IIO form and IIA form purified from the α-S2P/α-
S5P-IP as well as the IIO form, IIO low form and the IIA form purified from the α-HA-
IP were excised from the gels and further processed as described before (see 
Material and Methods) for final MS analysis. Massive MS data from the 9 different 
CTD mutants were collected, performing multiple replicate rounds of each mutant 
and the final results were implemented into bioinformatics evaluations. 
 
Figure 15 Coomassie gel after purification of recombinant Rpb1 of M-9K4R 
and M-12K2R. Left: Coomassie staining of IP-purified IIO and IIA form of M-9K4R and M-
12K2R using α-S2P/α-S5P. Right: Coomassie staining of IP-purified IIO, IIO low and IIA 
form of M-9K4R and M-12K2R using α-HA. Purified recombinant Rpb1 extracted from 450 
Mio cells were loaded in each well. 
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2.3  Mass spec results of Pol II CTD mutants 
 
All data obtained for the same CTD mutant independent from the origin of the probe 
(IP-approach; different Pol II forms) were collected as one data set for the 
corresponding mutant. The raw MS data were further processed using the computer 
software Sequest. Sequest is a MS/MS database search program originally 
developed in 1993 in the Yates lab at the University of Washington. It correlates 
MS/MS spectra of peptides against peptide sequences from a sequence database. 
Classical Sequest applies a two-stage scoring method for each search. The first 
stage applies the preliminary score to filter through all candidate peptides in the 
sequence database. The best scoring candidate peptides are then re-scored using 
the cross correlation algorithm. The sensitivity of the cross correlation algorithm is 
enhanced by the correction factor that is applied in its calculation (copied from: 
http://proteomicsresource.washington.edu/sequest.php). 
Sequest data files of each CTD mutant were then used for further more detailed 
bioinformatics analysis addressing the degree and patterns of modifications in 
specific heptad repeats of each individual mutant. 
 
2.3.1 CTD sequence coverage by MS/MS analysis 
 
The MS outcome clearly showed that CTD peptides consisting of di- or tri-heptads 
exhibited by far the highest total count numbers in the MS detection. A massive drop 
in data acquisition could be observed when analysing very short CTD peptides (i.e., 
one heptad repeat). Similar weak results were obtained when increasing the length 
of CTD peptides beyond three heptad repeats. Consequently, 100% CTD sequence 
coverage could be obtained in three CTD mutants (M-13K2R, M-9K4R and M-
12K2R), for which protein digestion led to the fragmentation of only di- and tri-
heptads. Furthermore, in these three mutants, all potential phosphosites within the 
CTD were found to be phosphorylated (Figure 16). Interestingly, all CTD repeats 
were also found in the unphosphorylated state except repeat 52. 
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The CTD phosphosite graph of M-12K2R shows that next to the well described 
phosphorylation residues S2P and S5P, also the remaining three Y1, T4 and S7 are 
frequently highly phosphorylated. In more detail, a tendency towards equal 
distribution of phosphorylation counts among phosphosites could be observed in 
Figure 16 CTD sequence coverage and CTD phosphosites of M-12K2R All 52 
repeats of M-12K2R are shown with repeat number in front of corresponding repeat. Each 
box represents a residue with corresponding position within the repeat written at the 
bottom. Repeat 2 lies on two different peptides due to an arginine at position 4. Left: Blue 
color code refers to total coverage count of each repeat. Right: Red color code refers to 
total phosphorylation counts of each phospho-residue within the CTD.  
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most of the CTD repeats. In addition, phosphorylated residues in heptad repeats 
diverging from the consensus CTD sequence and mainly located in the distal part of 
the CTD were found to be strongly phosphorylated as well.  
 
2.3.2 Different phosphorylation patterns in adjacent heptad repeats 
 
Analysing adjacent CTD repeats one interesting observation was that in some cases 
neighbouring repeats were phosphorylated on the same residue reflecting 
synchronised phospho-heptad repeats (Figure 17A+D). However, the majority of 
adjacent heptad repeats displayed different phosphorylation patterns (Figure 
17B+C). 
 
 
 
 
 
 
 
 
Figure 17 Comparison of phosphorylation patterns detected within the adjacent 
repeats 8-10 of M-9K4R. Each row corresponds to one specific amino acid annotated at the 
bottom, whereas red boxes indicate phosphosites. Blue squares divide the detected CTD 
peptide in the three adjacent heptad repeats 8-10. A+D: Identical phosphorylation patterns can 
be found between adjacent repeats. B+C: Different phosphorylation patterns can be found 
between adjacent repeats. C: Central CTD heptad (repeat 9) is in the unphosphorylated state, 
while the flanking heptad repeat on each side is phosphorylated. 364 = all possible 3P-
combinations of repeat 8-10; 43 = detected 3P-combinations of repeat 8-10; 53 = total counts 
of detected 3P-peptides comprising repeats 8-10. Dark red: 3P-combinations found three 
times; red: 3P-combinations found twice; light red: 3P-combinations found once. 
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Additionally, the MS analysis detected unphosphorylated CTD heptads flanked by 
phosphorylated neighbour CTD repeats at both ends as well (Figure 17C). All 14 
potential phosphorylation-sites participated in the formation of specific patterns. 
 
 
2.3.3 Phosphorylation frequencies within mono-, di- and tri- 
heptads 
 
Interestingly, the highest phosphorylation frequency found within CTD peptides 
detected in the mass spectra, were four phosphosites (4P) in parallel and this 
appeared to be independent from the length of the peptide.  
 
 
 
 
 
 
 
 
Figure 18 Phosphorylation frequencies within mono-, di- and tri-heptads 
shown for adjacent CTD repeats 5-7 of M-12K2R. Each row corresponds to one 
specific amino acid annotated at the bottom, whereas red boxes indicate phosphosites. Blue 
squares divide the detected CTD peptide in the three adjacent heptad repeats 5-7. A+B: 
Four phosphosites in parallel can be found within di-heptads. C+D: Four phosphosites in 
parallel can be found within mono-heptads. Majority of detected 4P-combinations are found 
within tri-heptads (16 out of 20). 715 = all possible 4P-combinations of repeat 5-7; 20 = 
detected 4P-combinations of repeat 5-7; 30 = total counts of detected 4P-peptides 
comprising repeats 5-7. Dark red: 4P-combinations found three times; red: 4P-combinations 
found twice; light red: 4P-combinations found once. 
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In other words, mono-heptad repeats (Figure 18C+D) showed the same highest 
degree of phosphorylation as that observed for di- and tri- heptad repeats, although 
the longer CTD peptides tended to carry more 4P-combinations than shorter ones. 
More specifically, to date, 4P-combinations have been detected either in mono-, or in 
di- or in tri-heptads in 4 out of 9 CTD mutants. All 13 potential phosphorylation-sites 
contributed to the formation of specific 4P-signatures (Figure 18). 
However, the average counts of detected 3P- and 4P-peptides were rather low in the 
MS analysis. A much better outcome was achieved when analysing mono- and 
double-phosphorylated (2P/3P) di- and -tri-heptads. In more detail, in the CTD 
mutants, M-13K2R, M-9K4R and M-12K2R, from which CTD peptides were detected 
that covered their whole CTD sequence, on average, 80% of possible 2P-
combinations have been found within di-heptads and 63% of possible 2P-signatures 
within tri-heptads. Moreover, all possible mono-phosphorylated-forms of all CTD 
peptides originating from these three mutants were found except for the last CTD 
repeat. 
 
2.3.4 Phosphorylation patterns within the consensus heptad 
sequence 
 
A profound and to date unclarified question in the field of CTD research addresses 
the actual phospho-combinations occuring within the highly conserved CTD-
consensus sequence consisting of the residues Y1S2P3T4S5P6S7 in vivo. Importantly, 
the total count numbers (absolute abundance) of consensus heptads containing only 
one phosphosite (1P) are dominant compared to the higher P-levels (2P, 3P and 
4P), with total counts ranging between 3000 and 5000, taking into account the data 
obtained with all 9 CTD mutants. 2P-heptad consensus repeats were found between 
100 and 500 times, whereas detection counts of 3P- and 4P-levels were very low 
(Figure 19A).  
In these analyses, at the mono-phospho level (1P) all 5 potential phosphosites were 
found to be phosphorylated in rather equal amounts comparing the relative 
abundance (ranging from 15-20%) among all 1P-signatures (Figure 19B). 
Furthermore, all possible 2P-combinations (10 out of 10) were mapped within the 
CTD-consensus sequence. Among the 2P-combinations, the two most abundant 
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ones were S2-P/S7-P (more than 20%) and Y1-P/S7-P (13%) whereas the 
combination Y1-P/S2-P displayed the lowest relative abundance (3%) among all ten 
possible 2P-signatures (Figure 19B). Additionally, all possible 3P-combinations (10 
out of 10)  with their relative abundance ranging from 5-17%  could also be identified, 
with the two most relative abundant 3P-combinations being S2-P/S5-P/S7-P (17%) 
and Y1-P/S2-P/S7-P (17%). On the contrary, at the 4P-level of consensus heptads, 
only 2 out of 5 possible combinations could be observed in very low equal counts 
with S2-P/T4-P/S5-P/S7-P and Y1-P/T4-P/S5-P/S7-P (relative abundance 50% each). 
In this analysis all consensus heptad repeats of all mutants were included 
independent from their location within the CTD, as well as from variations in 
sequence of adjacent repeats (Figure19). 
 
 
 
 
 
2.3.5 Phosphorylation patterns within di-consensus heptad repeats 
 
Next to mono-consensus repeats, di-consensus repeats were also scanned for 
phosphorylation patterns extracting data form all 9 CTD mutants (Figure 20). Similar 
Figure 19 Phosphorylation patterns of the CTD consensus sequence. A: 
Absolute abundance (total counts form 0-4000 counts) of all detected 1P- , 2P-, 3P- or 4P-
combinations found within consensus heptads. B: Relative abundance (0-50%) among all 
detected 1P- (5 out of 5/red), 2P-(10 out of 10/blue), 3P-(10 out of 10/green) or 4P- (2 out of 
5/violet) signatures within consensus heptads. Each row corresponds to one specific amino 
acid annotated at the bottom, whereas black boxes indicate phosphosites. 
Results 
 
 
 
51
to mono-heptad repeats, in di-heptad consensus repeats all possible 1P- (10/10) and 
2P-combinations (45/45) could be detected. However, in contrast to 100% saturation 
of 3P-combinations within mono heptad repeats, in di-heptad consensus sequences 
only 83 out of 120 3P-combinations could be found (69%). Additionally, 16 different 
4P-di-consensus heptads were mapped in this approach (16 out of 210, 7,6%). 
Interestingly, when performing the same analysis deleting position 14 (S7 in second 
repeat) of the di-consensus heptad mapping phosphosites within the sequence 
YSPTSPSYSPTSP, higher percentages of different combinations of detected 3P- 
and 4P-levels were obtained (3P: 81 out of 84, 96%; 4P: 40 out of 126, 31%) (Figure 
20).  
 
 
 
 
 
 
Figure 20 Phosphorylation patterns of the CTD consensus sequence containing 
14 (left) and 13 residues (right). Left: Relative abundance (0-6%) among all detected 2P- 
(45 out of 45/blue) and 3P- signatures (83 out of 120/green) within CTD di-consensus heptad 
sequences. Right: Relative abundance (0-7%) among all detected 2P- (36 out of 36/blue) and 
3P- signatures (81 out of 84/green) within CTD di-consensus heptad sequences missing 
residue 14. Each row corresponds to one specific amino acid annotated at the bottom, 
whereas black boxes indicate phosphosites. Numbers of detected 1P- and 4P-combinations 
for both sequences are additionally indicated in a text box. 
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The reason for higher 3P-and 4P-levels in the consensus sequence, comprising 13 
residues instead of 14 residues, might be explained by the fact that all CTD peptides 
with consensus sequences containing a lysine or arginine in position 14 were 
included in this second analysis. 
Consequently, higher data input led to higher percentages of 3P-and 4P-
combinations in the 13 consensus sequence stretch compared to the di-consensus 
heptads. In line with this, more dominant 3P-patterns could be observed within the 
YSPTSPSYSPTSP sequence. The three most abundant 3P-combinations included 
S2a-P/S7a-P/S5b-P, S2a-P/S7a-P/T4b-P and S2a-P/Y1b-P/S5b-P (Figure 20). 
 
2.3.6 Mapping phosphosites within the minimal functional unit of 
CTD  
 
It has been shown that in yeast the minimal functional unit of CTD requires three 
consecutive serine residues in a row in the configuration 2-5-2, as well as paired 
tyrosines spaced 7 amino acids apart (Y1-Y8). These requirements lead to two 
possible sequences comprising the minimal functional unit of CTD, either 
YSPTSPSYSP or SPTSPSYSPTSPSY. These two newly defined CTD consensus 
sequences were analysed in order to obtain data on highly abundant phospho-
patterns within these sequences in mammalian cells (Liu et al., 2008 and 2010: 
Schwer et al., 2012; see also chapter 1.2.2 of Introduction) (Figure 21). 
The three most abundant 2P-combinations found within the short functional unit of 
CTD (YSPTSPSYSP) were S5a-P/S2b-P, T4a-P/S2b-P and S2a-P/S2b-P. Within the long 
version of the minimal functional unit of CTD (SPTSPSYSPTSPSY) 5 predominant 
2P-combinations could be observed with S5a-P/S5b-P, T4a-P/S5b-P, T4a-P/T4b-P, S2a-
P/S5b-P and S2a-P/T4b-P. Interestingly, although the same three residues (S2, T4 and 
S5) were found in all of these high abundant 2P-combinations there was no overlap 
of these combinations between the two differently defined functional units. 
Accordingly, no interference between the most abundant 3P-combinations of the 
short functional unit (S2a-P/Y1b-P/S2b-P, S2a-P/S7a-P/S2b-P, S2a-P/S5a-P/S2b-P and 
Y1a-P/S7a-P/S2b-P) and the long functional unit (S7a-P/S2b-P/S5b-P, S5a-P/S2b-P/Y1c-P 
and T4a-P/S2b-P/Y1c-P) could also be found (Figure 21). 
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However, most of the 3P-combinations contained two CTD residues, Y1 and S7, 
which were absent in all dominant 2P-combinations within the two functional units. 
Interestingly, in the short functional unit, two out of three of the most dominant 2P-
combinations could  be again detected within some of the corresponding most 
abundant 3P-combinations (S2a-P/S2b-P integrated in S2a-P/Y1b-P/S2b-P, S2a-P/S7a-
P/S2b-P, S2a-P/S5a-P/S2b-P and S5a-P/S2b-P integrated in S2a-P/S5a-P/S2b-P), 
whereas in the long functional unit, none of the most frequent 2P-combinations were 
recovered in any of the related most abundant 3P-combinations (Figure 21).  
 
S5a/S2b 
T4a/S2b 
S2a/S2b 
S2a/Y1b/S2b 
S2a/S7a/S2b 
S2a/S5a/S2b 
Y1a/S7a/S2b 
S5a/S5b 
T4a/S5b 
T4a/T4b 
S2a/S5b 
S2a/T4b 
S7a/S2b/S5b 
S5a/S2b/Y1c 
T4a/S2b/Y1c 
Figure 21  2P- and 3P- combinations of defined functional units within CTD. 
Left: Total counts (0-700) of all 2P- and 3P- combinations within the defined sequence 
YSPTSPSYSP. Right: Total counts (0-80) of all 2P- and 3P- combinations within the defined 
sequence SPTSPSYSPTSPSY. Most abundant phospho-signatures within 2P- and 3P-levels 
are indicated. Green letters within 3P-combinations mark phospho-residues absent in the 
dominant 2P-combinations. Each row corresponds to one specific amino acid annotated at 
the bottom, whereas black boxes indicate phosphosites. 
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2.3.7 Dominant phosphorylation signatures in non-consensus 
repeats within the distal part of CTD. 
 
Since the distal part of the CTD was less mutated compared to the proximal part 
containing most of the consensus sequences, many WT-repeats can be found in the 
last 26 repeats of all 9 CTD mutants. These non-consensus repeats consisting of 
WT-sequences were scanned for dominant phosphorylation signatures within 2P-
and 3P-combinations.  
 
 
 
 
 
 
 
 
S5a/T4b 
T4a/S2b 
S2a/S2b 
S2a/T7a/S2b 
S2a/S5a/S2b 
S5a/S2b 
T4a/T4b 
S2a/T7a/S5b 
S2a/T7a/T4b 
Figure 22  2P- and 3P- combinations of non-consensus repeats 41-42 and 48-
49. Left: Relative abundance (0-8%) among all detected 2P- (34 out of 36/blue) and 3P- 
signatures (44 out of 84/green) of repeat 41-42 (YSPTSPTYSPTTPK) is shown. Right: 
Relative abundance (0-7%) among all detected 2P- (36 out of 36/blue) and 3P- signatures 
(57 out of 84/green) of repeat 48-49 (YSPTSPTYSPTSPK) is shown. Most abundant 
phospho-signatures within 2P- and 3P-levels are indicated. Each row corresponds to one 
specific amino acid annotated at the bottom, whereas black boxes indicate phosphosites. 
Portions of detected 1P-, 2P-, 3P- and 4P-combinations are shown as text. 
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In Figure 22 two different di-heptad repeats with defined location within the CTD 
(repeat 41-42 and repeat 48-49) are shown displaying all mapped 2P- and 3P-
combinations found within these sequences.  
In repeat 41-42 (YSPTSPTYSPTTPK) the three most abundant 2P-combinations 
were S5a-P/T4b-P, T4a-P/S2b-P and S2a-P/S2b-P whereas two predominant signatures 
regarding 2P-levels could be detected in repeat 48-49 (YSPSPTYSPTSPK) including 
S5a-P/S2b-P and T4a-P/T4b-P. Although these two sequences only differ in one 
position, residue number 12, and their most frequent 2P-combinations shared the 
same residues including S2, T4 and S5, no overlap among the most dominant 2P-
levels of repeat 41-42 and repeat 48-49 could be found. The two most abundant 3P-
signatures of repeat 41-42 and repeat 48-49 were S2a-P/T7a-P/S2b-P, S2a-P/S5a-
P/S2b-P and S2a-P/T7a-P/S5b-P, S2a-P/T7a-P/T4b-P, respectively. When comparing the 
most abundant 2P-and 3P-signatures, only one phospho-combination could be 
detected within both forms (S2a-P/S2b-P integrated in S2a-P/T7a-P/S2b-P and S2a-
P/S5a-P/S2b-P of repeat 41-42). Although no crossover between the most frequent 
3P-signatures of  repeat 41-42 and repeat 48-49 could be observed as well, the non-
consensus residue T7 (instead of S7) was found in three out of the 4 most abundant 
3P-combinations (S2a-P/T7a-P/S2b-P in repeat 41-42; S2a-P/T7a-P/S5b-P and S2a-
P/T7a-P/T4b-P in repeat 48-49). 
 
 
2.3.8 Phosphorylation patterns within the CTD are location 
dependent 
 
In a further approach, comparison of phosphorylation patterns of an identical 
sequence located within different repeats along the CTD was addressed. In more 
detail, the consensus sequence YSPTSPS was analysed regarding detectable 2P- 
and 3P-combinations facing different repeat numbers. In Figure 23, consensus 
heptad repeats 11 and 13 show very similar phosphorylation patterns. Both repeats 
are predominantly phosphorylated at S2/S7 and Y1/S7 concerning 2P-levels. 
However, repeat 9 and repeat 25 of the same sequence showed different dominant 
2P-signatures, indicating that phosphorylation of CTD is location dependent.   
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Figure 23  Total counts of 2P- and 3P- combinations of consensus heptad 
repeats 9, 11, 13 and 25. Repeat number and corresponding total counts (n) are shown 
on top of each graph. The two most abundant 2P-signatures of each repeat are indicated. 
Each row corresponds to one specific amino acid annotated at the bottom, whereas black 
boxes indicate phosphosites. All found 2P-and 3P-combinations are counted.  
Figure 24  Total counts of 2P- and 3P- combinations of consensus heptad 
repeats 5 and 16. Repeat number and corresponding total counts (n) are shown on top 
of each graph. Each row corresponds to one specific amino acid annotated at the bottom, 
whereas black boxes indicate phosphosites. All found 2P-and 3P-combinations are 
counted. Blue square marks 3P-combination part of the graph of both repeats. 
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Although repeat 25 revealed the same most abundant 2P-combination (S2-P/S7-P) 
compared to repeat 11 and 13 other high frequent 2P-signatures like Y1-P/S5-P could 
be observed in this repeat that was only detectable at very low abundance within the 
other three repeats.  Moreover, in repeat 9, other most abundant 2P-signatures were 
mapped comprising T4-P/S5-P and S2-P/S5-P, which seem to play only a minor role 
in the repeats 11, 13 and 25. 
Comparing consensus repeat 5 and 16 reflected another example of location 
dependency of phosphorylation patterns within the CTD (Figure 24). While the 
frequency of detected 2P-signatures was rather similar among these two repeats, big 
differences could be observed at the 3P-levels between these two locations. No 3P-
combinations could be found in repeat 5, whereas several 3P-signatures were 
mapped in repeat 16. 
 
 
 
 
 
 
 
 
Figure 25 Total counts of 2P- and 3P- combinations of neighbouring 
consensus heptad repeats 28, 29 and 30. Repeat number and corresponding total 
counts (n) are shown on top of each graph. Each row corresponds to one specific amino 
acid annotated at the bottom, whereas black boxes indicate phosphosites. All found 2P-
and 3P-combinations are counted. Blue arrows indicate the right order of repeat 28, 29 
and 30. 
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Additionally, differences in phosphorylation patterns could also be found within 
neighbouring consensus heptad repeats within the CTD. By comparing adjacent 
repeats 28, 29 and 30, it became apparent that repeat 28 and 30 shared a very 
common pattern at the 2P-levels, comprising all possible 2P-combinations, whereas 
repeat 29, located in between the two, displayed a very unique pattern including only 
two 2P-combinations in total (Figure 25). 
 
 
 
2.3.9 Scanning for known CTD-binding motifs of CTD-interacting 
proteins 
 
 
Ghosh et al. revealed the crystal structure capturing the interaction of the human 
capping enzyme Mce1 with the CTD. It has been shown that both the N-terminal 
nucleotidyl transferase domains (NTD) of the two Mce1 protomers interact with a 6 
amino acid long CTD segment that is connected via T4 and phosphorylated at 
residues S5 and S2. The CTD binding motif for this interaction is, therefore, S5a-
PP6aS7aY1bS2b-PP3bT4bS5b-PP6bS7bY1cS2c-PP3c., where a, b, c correspond to the 
residues originating from the three consecutive heptad repeats (Ghosh et al., 2011). 
Our MS data confirmed the existence of the Mce1 binding motif in vivo (Figure 26). 
All in all, 30 out of 126 possible 4P-combinations could be detected within the 
defined sequence SPSYSPTSPSYSP among which the 4P-combination S7a-P/S2b-
P/S5b-P/S2c-P showed the highest frequency (8%). Additionally, the Mce1 CTD-
binding motif could be mapped to repeat 9 (repeat number refers to the central 
heptad repeat), whereas all other repeats containing the defined sequence lack the 
specific 4P–combination essential for binding of Mce1 to the CTD (Figure 26). 
Interestingly, when comparing different repeats within the CTD comprising the Mce1-
CTD binding sequence SPSYSPTSPSYSP a tendency towards lower frequent 
phosphorylated repeats within the distal part of the CTD could be observed. In more 
detail, several 4P-combinations could be mapped within the repeats 12 and 14, 
whereas repeats 25 and 30, located more distal within the CTD, did not carry any 
4P-signatures. The comparative study of phosphorylation patterns within the Mce1-
binding sequence of different repeats along the CTD revealed again that CTD 
phosphorylation signatures tend to be location dependent (Figure 27). 
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The most common CTD-binding domain is the CTD interacting domain (CID) and 
crystal structures of CTD peptides and the CID-domains of Rtt103, Pcf11 (both 
yeast), SCAF8 and SCP1 (both human) have been obtained (Lunde et al., 2010; 
Meinhart and Cramer, 2004; Becker et al., 2008; Zhang et al., 2006). The CTD-
binding motif of the CID domain comprises 8 residues of the sequence 
PSYSPTSPS. Rtt103 and Pcf11 bind the S5-P form, whereas SCAF8 is recruited to 
the S2-P form of PSYSPTSPS. In contrast, SCP1 binds the double-phosphorylated 
PSYS2-PPTS5-PPS CTD sequence. The CTD binding motifs of all four proteins could 
be found in the MS analysis (Figure 28). 
Figure 26  Mapping of the Mce1 CTD-binding motif within the CTD. Left: 
Relative abundance (0-12%) among all detected 4P-combinations (30 out of 126/purple) of 
the defined Mce1 sequence binding motif SPSYSPTSPSYSP is shown. Right: Total counts 
of all detected 2P-, 3P- and 4P-combinations of the defined Mce1 sequence binding motif 
SPSYSPTSPSYSP in repeat 9 (repeat number refers to central heptad repeat) are shown. 
Each row corresponds to one specific amino acid annotated at the bottom, whereas black 
boxes indicate phosphosites. Blue squares in both graphs mark the detected specific 4P-
CTD binding motif of human capping enzyme Mce1. 
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In general, all possible 1P- and 2P-combinations were mapped within the CTD 
sequence PSYSPTSPS. Additionally, 11 out of 20 possible 3P-combinations could 
be detected as well. Furthermore, the S2-P binding motif of Rtt103 and Pcf11, as well 
as the S5-P binding motif of SCAF8 could be mapped in all repeats containing the 
defined sequence motif PSYSPTSPS. In contrast, the 2P-binding motif S2-P/S5-P of 
SCP1 was found in only 8 out of 15 possible CTD repeats indicating that CTD-SCP1 
binding might be restricted to specific CTD repeats (examples are shown in Figure 
28). 
Figure 27  Total counts of 2P-, 3P- and 4P-combinations of  CTD repeats 12, 
14, 25 and 30 containing the Mce1-binding sequence. Repeat number (refers to 
central heptad repeat) and corresponding total counts (n) are shown on top of each graph. 
Each row corresponds to one specific amino acid annotated at the bottom, whereas black 
boxes indicate phosphosites. All found 2P-, 3P- and 4P-combinations are counted. Blue 
square marks 4P-combination part of repeat 12 and 14. 
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Figure 28  Mapping of the CID CTD binding motifs of Rtt103, Pcf11, SCAF8 
and SCP1. Left: Relative abundance (0-20%) among all detected 1P- (6 out of 6/red), 
2P- (15 out of 15/blue) and 3P- signatures (11 out of 20/green) of the defined CID 
sequence binding motif PSYSPTSPS is shown. Specific binding motifs of Rtt103, Pcf11, 
SCAF8 and SCP1 are indicated. Blue square marks SCP1 binding motif. Right: Repeat 
number (refers to the consensus heptad repeat) and corresponding total counts (n) are 
shown on top of each graph. Each row corresponds to one specific amino acid annotated 
at the bottom, whereas black boxes indicate phosphosites. All found 1P-, 2P- and 3P-
combinations are counted. Blue squares mark SCP1-binding motif found in repeat 10 and 
11. 
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3. Discussion 
 
 
3.1  Phosphopeptide analysis by mass spectrometry (MS) 
 
In order to obtain a successful phosphopeptide detection and phosphosite 
localization by MS one has to overcome several barriers. The primary goal is to 
detect the phosphopeptide of interest in a typically enormous pool of non-modified 
peptides. Generally, phosphopeptides are present at sub-stoichiometric amounts 
when compared to the unmodified peptides of the protein of interest. Additionally, the 
ionization efficiency of phosphopeptides in positive ion mode MS is lower than in 
unphosphorylated peptides due to the negative phosphate group (Boersema et al., 
2009). Consequently, to overcome the underrepresentation of phosphorylated 
targets in a high background of non-phosphorylated species, several enrichment 
strategies have been established. Enrichment is based on two main features that 
distinguish phosphorylated from non-phosphorylated peptides: the negative charge 
of the phosphate group due it its low pKa in combination with its steric structure. In 
this work, metal oxide affinity chromatography, in particular titanium dioxide (TiO2), 
was used for phosphopeptide purification taking in advantage the strong affinity of 
negatively charged phosphate groups towards metal ions (Larsen et al., 2005). 
However, enrichment of phosphopeptides using TiO2 can be influenced by the 
presence of acidic and basic residues and is known to preferentially purify low 
phosphorylated peptides. In contrast, immobilized metal affinity chromatography 
(IMAC) enriches multiphosphorylated peptides better than TiO2 (Thingholm et al., 
2009; Bodenmiller et al., 2007).  Consequently, the combined and consecutive use of 
IMAC and TiO2 should lead to the separation of mono-phosphorylated (TiO2) from 
multi-phosphorylated peptides (IMAC), thereby decreasing sample complexity 
(Thingholm et al., 2008). In more detail, acidic buffers mainly elute mono-
phosphorylated peptides from IMAC material, whereas subsequent basic elution 
recovers multiply phosphorylated peptides that are normally hard to detect. Thus, 
this two step purification procedure should enable separation of non-, mono- and 
multi-phosphorylated peptides in distinct fractions. However, in this work, a single 
purification step using only TiO2 turned out to be the most efficient method in yielding 
both low and high phosphorylated CTD peptides. Nevertheless, mono-
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phosphorylated peptides were the dominant detected form as shown by the MS data 
and synthetic peptides carrying different numbers of phosphate groups will be tested 
in the near future in order to exclude a technical bias towards low phosphorylated 
CTD peptides leading to falsified MS results. Additionally, other phosphopeptide 
purification methods will also be tested or optimized, like the capacity and binding 
efficiency of TiO2 beads, e.g. by repeated incubation of the same sample with fresh 
TiO2 beads have rarely been investigated yet. An interesting approach comes from 
Mamone and co-workers who have recently developed an efficient method for the 
separation of mono- and multi-phosphorylated peptides called hydroxyapatite (HAP) 
affinity chromatography (Mamone et al., 2010).  A strong interaction of HAP with 
phosphate and calcium ions takes place and due to the higher affinity of multi-
phosphorylated peptides to the HAP surfaces, stepwise elution with a phosphate 
buffer gradient allows the selective isolation of mono- and multi-phosphorylated 
peptides. Thus, optimization of the phosphopeptide purification step might lead to 
higher detectable numbers of mutliphosphoylated CTD-peptides in the near future. 
In this approach, collision-induced dissociation (CID) technique was used for gas 
phase fragmentation of the peptides and the identification of phosphorylated 
peptides and subsequent phosphosite localization has been achieved by tandem MS 
(MS/MS) linked to MS3 and multistage activation (MSA).  
Trypsin generally produces double positive charged (2+) peptides (Steen et al., 
2004). In CID, protonated peptides are accelerated by an electric potential in the 
vaccum of the MS and then forced to collide with an inert neutral gas (helium in this 
approach). Due to the collisions, the kinetic energy of the peptide ion is partially 
converted into internal energy that is spread over the molecule, breaking bonds and 
causing the peptide ion to fragments (Roepstorff et al., 1984; Biemann et al., 1988). 
Importantly, the phosphate group of a phosphopeptide is relatively labile providing a 
low-energy pathway like CID that competes with backbone fragmentation. 
Consequently, a CID spectrum of a phosphopeptide typically shows an intense 
neutral loss peak that locates at 98 Da or 80 Da lower than the precursor mass, 
reflecting the loss of H3PO4 and HPO3, respectively (Boersema et al., 2009). 
Generally, peptides are fragmented at the amid bonds along the backbone which 
results in the appearance of amino acid sequence-informative b- and y-ions with the 
charge retained at the N- or C-terminal end, respectively. Therefore, if a population 
of precursor peptide ions dissociate to produce a series of consecutive b- and y-ions, 
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the amino acid sequence of the peptide can be determined from the difference 
between these consecutive ions, including the mapping of the phosphorylation site. 
Since the residue masses of phosphorylated serine (167 Da), phosphorylated 
threonine (181 Da), and phosphorylated tyrosine (243 Da) are unique, the sequence 
ions of phosphorylated peptides are directly indicative of the existence of 
phosphopeptides and the location of the phosphorylation sites within the peptide 
(Palumbo et al., 2010). Figure 29 shows how phosphosites are mapped using b- and 
y-ions.  For phosphorylation site localization, fragmentation spectra of the non-
phosphorylated peptide and its phosphorylated analogue are compared (compare 
Figure 29A and 29B). Fragment ions that contain the same masses in both spectra 
indicate that these peptide fragments are not phosphorylated, thereby excluding Y3, 
S4, T6 and S7 as phosphosites (b3 to b9 in Figure 29A and 29B). Analysing the C-
terminal fragment ions, y3-y6 have masses corresponding to the fragment ions that 
are unmodified implying that these peptide fragments are not phosphorylated as 
well.  
Consequently, the determination of the backbone fragment ion series leaves T10 as 
the only option for containing the detected phosphorylation group within the 
phosphorylated peptide. Additionally, the site-determining ions b10 and y7 show 
shifted mass peaks compared to the corresponding fragment ions in the unmodified 
peptide either due to the  carriage of the phosphate group (+ 80 Da) or due to the 
loss of the phosphate group (- 18 Da) confirming the phosphorylation site to be T10. 
Figure 29C gives an example where no clear phosphosite determination can be 
achieved. In more detail, fragment ions y6-y9 reflect unphosphorylated peptide 
fragments restricting the phosphorylation site to S6, S7 or S8. With the additional 
dissection of the ion b-series b2-b6 residues Y1, S3, S4 and S6 can be excluded as 
potential phosphosites. However two residues, S7 and S8 remain as potential carriers 
of the phosphate group, since no complete b-and y-ion series are obtained and no 
site-determining ions with an intact phosphate group for direct validation are found 
for this phosphopeptide (Figure 29C). 
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In this work, to minimize incorrect phosphosite mapping within CTD-peptides, at 
least six replicates for each mutant were analysed leading to large MS data 
outcome.  Moreover, to gain more complete b- and y-ion series of corresponding 
CTD-peptides, MS3 and multistage activation were performed. The initial CID-
MS/MS 98 Da neutral loss product ion was automatically subjected to either 
multistage CID-MS/MS (i.e. MS3) or ‘pseudo-MS3’ in ion trap mass spectrometers in 
Figure 29 Phosphorylation site localization. A) CID spectrum of a non-
phosphorylated peptide compared to the CID spectrum of its phosphorylated counterpart. 
B) Indicated on the peptide sequence are the fragment ions that were found, including ions 
that lost 98 Da or were 80 Da heavier than in the non-phosphorylated peptide. Highlighted 
in red are the site-determining ions and the corresponding peaks in the spectrum. In blue 
are indicated fragment ions that confirm the site localization. C) A CID spectrum of a 
phosphopeptide for which a precise phosphorylation site could not unambiguously be 
determined. Highlighted in blue are fragment ions that indicate that the phosphorylation is 
on either S7 or S8 (copied from Boersema et al., (2009), Phosphopeptide fragmentation and 
analysis by mass spectrometry; J. Mass. Spectrom. 2009, 44, 861-878). 
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a data dependent mode of operation. Accordingly, CID-MS3 involved isolation and 
further fragmentation of the neutral loss species, whereas pseudo MS3 provided 
simultaneous activation of the precursor ion and the resultant 98 Da neutral loss 
product ion during a single CID-MS/MS event. In more detail, the stepwise MS 
procedure in this work included that the three most intense peptide ions with charge 
state higher than 1 were sequentially isolated to a target value of 10,000, fragmented 
in the linear ion trap by collision induced dissociation (CID). The pseudoMS3 (pdMS3) 
or multistage activation (MSA) was selected to automatically select and further 
fragment the fragment ion originating from the loss of one or two phosphate groups 
from the parent ion (see also Material and Methods).  
 
 
3.2  Different Pol II forms 
 
The human genome comprises approximately of 25000 genes which are transcribed 
by only a small fraction out of about 300000 Pol II molecules found in one single cell 
(Kimura et al., 1999). Theoretically, every single active or inactive Pol II molecule 
could feature a diverse phosphorylation profile along its CTD. However, Pol II 
accumulates in only two main forms as shown in SDS-PAGE electrophoresis, 
suggesting that the majority of Pol II within a cell is divided into only a few sub-
populations carrying similar modifications patterns. In this work, however, many 
different phosphorylation patterns have been identified within every single CTD 
peptide, implying a great diversity of possible phosphorylation signatures along every 
single CTD of Pol II in vivo.  The two main Pol II forms are Pol IIA form containing a 
hypophosphorylated CTD and Pol II0 form consisting of a hyperphosphorylated CTD, 
respectively. It has been suggested that the mammalian Pol II0 form carries on 
average one phosphate per repeat (Payne and Dahmus, 1993) although the number 
of phosphosites of the CTD at a certain stage during the transcription cycle remains 
elusive.  
Pol IIA preferentially associates with the preinitiation complex at the promoter site 
and, therefore, any phosphorylation of the CTD before this site would potentially 
block the recruitment of Pol II and subsequent transcription initiation. It has been 
proposed that the hyperphosphorylation of CTD triggers the massive shift from IIA to 
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IIO (Palancade and Bensaude, 2003). However, the appearance of only a few Pol II 
subpopulations in the SDS-PAGE suggests that CTD-phosphorylation rather 
contributes to the shift of IIA to IIO in an indirect way by influencing the cis-/trans-
isomerization of P3 and P6 within each single heptad repeat. Accordingly, different 
phosphorylation patterns might either stabilise a certain conformation of the proline 
residues or serve as binding motifs for corresponding proline isomerases. 
In this work both IIO and IIA forms were analysed via MS and surprisingly many 
phosphorylated CTD peptides were found in the hypophosphorylated IIA form. 
Moreover frequently, highly phosphorylated CTD repeats carrying three or even four 
phosphosites at the same time were detected within the IIA form, as well. However, 
our MS data cannot decipher if the overall phosphorylation frequency along the 
whole CTD is different between IIO and IIA forms, as only small CTD fragments, 
mainly 14 or 21 amino acids long, originating from the same CTD could be analysed. 
Since many phosphorylated CTD peptides were found in both forms all data were 
collected and implemented in the subsequent bioinformatic analysis as one big data 
set. However, it will be interesting to investigate the phosphorylation signatures 
obtained from both forms in more detail in order to find out if possible variations in 
phosphorylation patterns between these two forms might explain the separation into 
these two main Pol II forms in the SDS-PAGE. Nevertheless, one reason for 
detecting similar highly phosphorylated CTD peptides in both forms could be that no 
complete separation of both forms had taken place in the SDS-PAGE. Instead, both 
forms might accumulate in both bands due to the high amount of material used in 
this approach. Therefore, next to the comparison of distinct phosphorylation 
signatures among both forms the total amount of detected peptides within the 
different phosphorylation levels (1P, 2P, 3P and 4P) of both forms should be 
analysed as well. 
Interestingly, in the SDS-PAGE of the α-HA-IP a third Pol II form arose, IIO low, 
which was located between IIO and IIA (see also Figure 15 in results part). Since the 
α-HA recognizes Rpb1 outside of the CTD this antibody had no preference towards 
IIO or IIA during the purification step. This enrichment is most probably attributed to 
the fact that a greater amount of the IIA form was purified with this antibody, as the 
IIA form consists the inactive Pol II pool that was over-expressed in the CTD 
mutants. Both, IIO and IIO low gave weaker signals than the IIO form purified with 
the α-S2/S5 (see also Figure 15 in results part). Less amount of purified material of 
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the hyperphosporylated Pol II form might explain the further separation into two 
subpopulations both carrying a hyperphosphorylated CTD. Another reason of the 
occurrence of two different IIO forms could be that the CTD was more accessible to 
CTD-phosphatases as the α-HA binds outside the CTD. Consequently, the IIO low 
form might carry a slightly lower phosphorylated CTD form due to dephosphorylation 
by CTD phosphatases. Data obtained from the IIO low form revealed that the same 
phosphorylation frequencies within CTD peptides could be found in this form. 
A more detailed analysis of phosphorylation signatures and overall phosphorylation 
counts of the IIO low form might uncover differences in phosphorylation patterns 
compared to the other two Pol II forms obtained in this work. 
 
 
3.3  The most distal CTD repeat (repeat 52) exhibits unique 
       features 
 
In this work, MS analysis of recombinant CTDs that were mutated, in order to obtain 
information of phosphosites along the whole CTD sequence, revealed the existence 
of the full repertoire of possible phosphosites in the CTD in vivo. In more detail, MS 
data obtained from three different mutants that displayed 100% sequence coverage 
impressively showed that, indeed, all possible phosphosites were found to be 
phosphorylated in vivo. In other words, next to all potential phosphosites within the 
consensus repeats, S and T residues found in different positions within non-
consensus repeats were all phosphorylated as well. Another interesting observation 
was that all repeats were also detected in their unphosphorylated state, with the 
exception of repeat 52, the most distal to its core subunit (Rpb1). This result 
suggests with the possible exception of repeat 52, that no constant phosphorylation 
state is maintained within distinct CTD repeats and highlights the importance of 
phosphorylation/de-phosphorylation cycles for the Pol II progression through 
transcription.   
Comparative studies of different organisms revealed the development of divergent 
sequences following the most distal CTD repeat (Allison et al., 1988). The 
mammalian most distal CTD repeat consists of a total of 17 amino acids, containing 
two potential casein kinase II (CKII) sites, and is essential for mediating the binding 
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and phosphorylation of the CTD by the Abl1/c-Abl and Abl2/Arg tyrosine kinases 
(Pinna et al., 1990; Baskaran et al., 1997 and 1999). The consensus sequence for 
CKII phosphorylation is (S/T)XX(D/E) and found once in the non-consensus repeat 
37 and twice in the most distal repeat of the Pol II CTD (Pinna et al., 1990; Chapman 
et al., 2004). Accordingly, it has been shown that CKII phosphorylates CTD (Dahmus 
et al., 1981), but not a stretch of consensus repeats (Bregman et al., 2000). 
Interestingly, stoichiometric analysis suggested that only one of these sites is being 
phosphorylated in vivo, most likely the outermost C-terminal serine (serine 13) of the 
CTD most distal repeat, as it was concluded due to the preference of CKII for sites 
surrounded by acidic residues (Kuenzel et al., 1987; Payne et al., 1989). Bensaude 
and co-workers established polyclonal antibodies that specifically recognized the 
CKII-phosphorylated or non-phosphorylated most distal CTD repeat 52, respectively. 
The CKII-phospho-specific antibody positively reacted with all forms of the largest 
subunit of Pol II under all conditions, whereas no reactivity was observed with the 
non-phospho specific antibody (Chapman et al., 2004). These results suggested that 
the most distal CTD repeat 52 is permanently phosphorylated by CKII in vivo and 
that CKII phosphorylation of this repeat takes place soon after translation of Rpb1, 
since a non-CKII-phosphorylated form could not be found in vivo (Chapman et al., 
2004). Mass spec data of CTD mutants produced in this thesis, confirmed the 
detection of a permanent phosphorylated most distal repeat of the CTD of Pol II in 
vivo. However, whereas previous mutation studies suggested that the serine in 
position 13 and not serine in position 9 within the last repeat is constitutively 
phosphorylated (Chapman et al., 2004), the new obtained mass spec data showed 
both residues to be phosphorylated in vivo. Interestingly either serine 9 or serine 13 
were found to be phosphorylated at a time and no double phosphorylated form of  
repeat 52 could be observed via MS analysis. 
 
 
 
 
 
 
 
Discussion 
 
 
 
70
3.4 Phosphorylation frequencies within CTD-peptides 
 
To date, the profound question on whether individual CTD repeats are independently 
phosphorylated, remains yet unanswered. Regarding the similarity of sequence 
among most of the CTD repeats, it has been doubted that kinases and 
phosphatases are capable of distinguishing these repeats sufficiently in order to 
modify adjacent heptad repeats individually. However, obtained mass spec data 
generated during this work demonstrated that neighbouring heptad repeats 
originating from the same CTD exhibit different phosphorylation patterns, while 
unphosphorylated and phosphorylated repeats have been detected as well. 
When analysing phosphorylation frequencies of different peptides of CTD fragments 
it turned out that the coexistence of four phosphosites displayed the upper detection 
limit in the MS analysis. In contrast, in MS analysis of yeast CTD mutants only mono- 
and di-phosphorylated CTD peptides have been detected so far (data not shown). 
The yeast data suggested that the complexity of a so-called CTD code in yeast might 
be simpler, containing less phosphorylation combinations among different CTD 
residues and lower phosphorylation frequencies along the overall length of CTD 
compared to a CTD code existing in higher eukaryotic organisms like mammals. 
Interestingly, the MS data presented here show that the same highest 
phosphorylation frequency could be found in mono-, di- and tri-heptads, where no 
more than four phosphosites were scored at the same time, suggesting that there 
could be a limit to the extent of phosphorylation within a certain sequence length. 
One reason for that could be that too many phosphosites located in close proximity 
to each other would lead to unfavoured structural changes due to strong charge 
repulsions between the negative charged phosphate groups. Moreover, it would be 
expected that longer CTD peptides, e.g. tetra- or penta-CTD heptads, would be 
found to carry more than four phosphosites explained by the longer distances 
between the individual phosphorylation residues. However, no highly phosphorylated 
tetra- or penta-CTD peptides could be detected, although there is an apparent weak 
data outcome of longer peptides in the MS analysis. Accordingly, CTD peptides 
containing two or three heptad repeats provided by far the highest amount of 
obtained MS information.  
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3.5 Establishment of CTD mutants 
 
Two different sets of CTD mutants were established during this work. In the first 
round, four different CTD mutants were designed (M-6K; M-3K5R; M-8K; M-4K2R; 
see also Appendix) and the obtained fragmented CTD peptides after protein 
digestion ranged from mono- to hexa-peptides. In designing the CTD mutants it was 
important to find a balance on the one hand, not making too many mutations within 
the CTD sequence, in order to avoid risking cell viability, while, on the other hand, 
obtaining CTD peptides after trypsin digestion that did not exceed a certain length 
which could lead to weak MS output.  Accordingly, CTD mutant M-8K, for instance, 
carried most mutations (13 mutations) leading to the highest number of fragmented 
peptides (18) ranging from mono- to penta-heptads. However, since it turned out that 
only di- and tri- heptads led to high MS data output, mapping of phosphosites did not 
cover the whole CTD length of the CTD mutants established by this first approach. 
Consequently, in a second round, five new mutants with even more mutations were 
designed, in order to retrieve shorter CTD peptides along the whole CTD sequence 
after protein digestion. Three out of five CTD mutants of round 2 were fragmented in 
only di-and tri-heptads after trypsinization and high numbers of phosphorylation sites 
could be mapped along the whole CTD. Importantly, although these mutants were 
frequently mutated within their CTD sequences, they all displayed full viability under 
normal cell culture conditions.  
 
3.6  Minimal functional unit of the CTD 
 
One reason for the high plasticity of the mammalian CTD of Pol II could originate 
from the genetic studies performed by Stiller and Greenleaf regarding the minimal 
functional unit of CTD in yeast. Results from yeast CTD mutants revealed that the 
minimal functional unit of CTD requires three consecutive serine residues in a 2-5-2 
configuration, as well as paired tyrosines spaced 7 amino acids apart (Y1-Y8). 
Accordingly, the functional unit in yeast is embedded within di-heptads. Based on 
these findings in yeast, mutations that were introduced in the CTD mutants used in 
this work are not interfering with the minimal functional unit of the CTD. More 
specifically, the minimal distances between single mutations lay within di-heptads 
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along the whole CTD sequence of all newly established CTD mutants. In order to 
confirm that the same requirements of a minimal functional unit within the CTD is 
needed in both yeast and mammals, our lab is working towards this end. The project 
aims to establish two CTD mutants that display the minimal functional unit by either 
deleting residues 12-14 or by replacing residues 12-14 with alanine in every second 
CTD repeat in accordance to the genetic studies previously performed in yeast.  
When comparing dominant phosphorylation patterns within the defined functional 
units of the CTD, one interesting observation was that newly identified 
phosphorylated residues, like Y1-P and S7-P, arose after the transition from highly 
abundant di-phosphorylated signatures to highly tri-phosphorylated signatures. 
Therefore, some phosphosites might be redundant in a low phospho-frequent 
background, but turn into dominant phosphosites when the overall phosphorylation 
frequency along a certain length of the CTD has increased. Accordingly, 
phosphorylation of distinct residues within the CTD might be triggered or enhanced 
by surrounding phosphosites of adjacent CTD residues. In the short functional unit 
(YSPTSPSYSP) the most dominant 2P-combination was also observed in 3 out of 
the 4 most abundant 3P-combinations suggesting an additive ‘switching’ mechanism 
between the different phosphorylation states within the CTD. However, in the longer 
version of the defined functional unit comprising of 14 residues, none of the five most 
abundant 2P-combinations could be found within the three most frequent 3P-
signatures. These findings suggest that next to an additive pathway a two direction 
‘switching’ mechanism including a dephosphorylation step followed by 
phosphorylation of new CTD residues might exist as well. Certainly, more data are 
required to decipher distinct mechanisms for switching between different 
phosphorylation states within defined CTD sequences, since the total count numbers 
of higher phosphorylated CTD peptides were much lower compared to the numbers 
obtained for mono- and di-phosphorylated CTD repeats. 
 
3.7  Phosphorylation signatures within the consensus   
        heptad repeat 
 
Posttranslational modifications could have evolved in order to offer diversity to the 
otherwise evolutionary highly conserved CTD sequence/structure. The existence, 
Discussion 
 
 
 
73
frequency and distinct combinations of phosphorylation sites across specific CTD 
lengths could offer valuable insights into unravelling possible different functional 
states of Pol II. In this MS analysis, all possible 1P-, 2P- and 3P-combinations within 
the consensus heptad sequence Y1S2P3T4S5P6S7 could be found, suggesting the 
occurrence of highly dynamic phosphorylation and dephosphorylation processes of 
CTD residues in vivo. At the 1P-level all 5 possible phosphosites were mapped in 
comparably high amounts, providing the idea that all potential phosphosites play 
equally important roles in contributing to a ‘so called’ CTD code. Towards this end, it 
would be interesting to investigate if T4-P and S7-P residues could also be part of 
distinct binding motifs that serve in specific protein-CTD binding interactions. So far 
only CTD peptides containing S2 and S5 phosphosites have been mainly used in the 
assembly of crystal structures of specific CTD-protein interactions. At the 2P- and 
3P-levels all possible phoshorylation combinations were found, implying that there 
are no phosphosites excluding each other and that the CTD uses its full repertoire of 
possible phosphorylation signatures within consensus repeats at different 
phosphorylation levels in vivo. Importantly, total count numbers of detected 1P-, 2P- 
and 3P-signatures showed that the 1P-CTD peptides were the dominant 
phosphorylation form within the CTD. The predominant existence of 1P-signatures 
could imply that mono-phosphorylated heptad repeats resemble the main scaffold of 
phosphorylated CTD and the addition of further phosphorylation groups, leading to 
2P-or 3P-CTD repeats, are more likely transient stages in response to certain stimuli 
within the cell fulfilling transient tasks, like binding to specific factors at a certain 
stage during the transcription cycle. 
 
 
3.8 Dominant phosphorylation signatures within CTD       
      repeats 
 
On big goal of this study was to identify dominant phosphorylation patterns within 
CTD repeats along the whole CTD domain. The proximal part consists mainly of 
consensus repeats and phosphorylation signatures were analysed within mono- and 
di-consensus repeats, as well as within defined functional units that originated from 
genetic studies of the CTD performed in yeast. Additionally, non-consensus WT-CTD 
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repeats located in the distal part of the CTD were also included in the mapping of 
highly abundant phosphorylation signatures. Accordingly highly abundant 2P-
signatures and to a lesser extent dominant 3P-signatures could be found within the 
CTD. The obtained data of dominant CTD signatures within defined areas of the 
CTD could be used for subsequent CTD binding studies in order to identify highly 
specific novel protein-CTD interactions. In more detail, our lab is working on the 
establishment of a far western-approach, where biotin labeled synthetic CTD-
peptides containing specific phosphorylation patterns will be used as bait proteins for  
‘fishing’ interacting proteins originating from mammalian cell extracts. Subsequently, 
IP experiments will be performed followed by MS analysis to identify cellular factors 
that interact with the synthetic modified peptides. Consequently, non-consensus 
CTD peptides located in the distal part of the CTD will also be included in the binding 
assays. It has been speculated that proteins with core functions in the transcription 
cycle bind to consensus sequences within the proximal part of the CTD, whereas the 
distal part of the CTD, with its non-consensus repeats, most likely serves as a 
binding platform for protein factors activated upon cellular stress responses or might 
have tissue specific tasks. It would be of profound interest to determine whether 
such stress-related or tissue specific protein factors tend to bind to non-consensus 
CTD peptides containing dominant phosphorylation signatures using a pull-down 
binding approach. 
 
 
3.9  Phosphorylation profiles are location dependent 
 
When comparing identical CTD sequences, like mono-consensus heptads 
originating from different repeats along the CTD, a high variability of the abundance 
of distinct phosphorylation signatures has been documented. These data suggest 
that CTD repeats positioned at different locations within the CTD are preferentially 
differently phosphorylated. Accordingly, it could, therefore, be hypothesized that both 
CTD-kinases and phosphatases might recognize, or are specifically recruited by 
additional protein factors, to distinct areas along the CTD upon which they exert their 
catalytic activity. Interestingly, this hypothesis could be further supported by 
differences observed in the phosphorylation patterns between CTD repeats located 
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in great distances to each other, as well as between adjacent CTD repeats. These 
distinct phosphorylation profiles of individual CTD repeats might be linked to the 
recruitment of specific CTD-interacting protein factors. It appears that the more 
complex the binding motif of a CTD-binding factor is, the more restricted its binding 
area within the CTD is. In line with this, the binding motif of mammalian capping 
enzyme Mce1 contains four phosphosites and was found at only one position along 
the whole CTD, whereas CID-binding motifs of several CTD-interacting factors 
requiring only one or two CTD phosphosites could be mapped within several CTD 
repeats located at different areas along the CTD. A noteworthy study showed that 
mammalian cells containing only 31 CTD repeats were capable of transcription, 
splicing and polyadenylation, but exhibited defects in the transport of the matured 
mRNAs, suggesting that the missing CTD repeats are responsible for the binding of 
protein factors responsible for this specific function (Custodio et al., 2007). These 
data implied that the requirement of a certain length of CTD is dependent from the 
respective protein factor the CTD is interacting with. Accordingly, in mammalian 
cells, about 20 repeats were necessary for correct splicing and cleavage of the 3’ 
end, whereas 16 repeats were sufficient for Pol II to support its own expression (de 
la Mata and Kornblihtt, 2006; Rosonina and Blencowe, 2004; Chapman et al., 2007). 
Consequently, a certain length of CTD might be the prerequisite for serving as an 
optimal binding platform for CTD-kinases, as well as for CTD- or phospho-CTD-
associated factors. In line with this, the core protein complexes that have evolved to 
interact with canonical essential units define the minimal CTD length whereas 
additional CTD repeats more distal to the core CTD region might serve as binding 
sites for proteins with accessory functions that are not essential to cell viability. 
Consequently, genetic studies in yeast have shown that cells containing shortened 
CTDs revealed higher temperature sensitivity, implying that additional CTD repeats 
are necessary for optimal survival under stress conditions (West and Corden, 1995). 
The highly conserved CTD length, e.g. 52 repeats in human and mouse, might be 
determined by the highest possible number of CTD-interacting factors that can bind 
the CTD at the same time. The native length of CTD provides an optimal binding 
platform for core factors mainly bound to its proximal part, as well as for additional 
protein complexes that might play an important role in cell growth, differentiation or in 
cellular responses upon stress signals and which preferentially interact with the distal 
part of the protein. Accordingly, changes in the sequence or length of the CTD could 
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influence single CTD-protein interactions as well as the overall composition of CTD-
associated proteins along the CTD. 
 
3.10 New insights into the CTD code 
 
One key finding in this work was the predominant occurrence of mono-
phosphorylated CTD repeats. In more detail, the portion of 1P-populations among all 
detected phosphoforms (1P, 2P 3P and 4P) within mono- and di-consensus repeats 
was 94,2% and 83,1%, respectively. Consequently, 1P-CTD repeats most probably 
reflect the main scaffold upon which higher phosphorylated forms are built up in a 
more temporary fashion. Especially, the switch between 1P- and 2P-levels seems to 
appear quite often whereas 3P- and 4P-combinations were found in only very low 
amounts (Figure 30A). Accordingly, at the 1P- and 2P-levels of mono- and di-
consensus heptads, all possible phosphorylation patterns could be found reflecting 
how dynamic and diverse CTD phosphorylations are in vivo. CTD residues Y1, S2, 
T4, S5 and S7 were found to be phosphorylated in similar amounts in a 1P-
background suggesting that all phosphosites within a CTD repeat fulfil important 
tasks in vivo. On the contrary, at the 2P-level, both low and high abundant 
phosphorylation patterns were detected and subsequently predominant 2P-
signatures could be mapped. Interestingly, the majority of the dominant 2P-
combinations contained two out of the three phosphosites S2P, T4P and S5P. At the 
3P-level, only a few more abundant phosphorylation signatures were found 
displaying much lower detection counts compared to the most abundant 2P-
signatures. Interestingly, when analysing the more abundant 3P-combinations, new 
phosphosites like Y1P and S7P were implemented that played only a minor role in 
high abundant 2P-signatures. 4P-combinations within mono- and di-consensus 
heptads were only found in substoichiometric amounts (0,005% in mono-heptads 
and 0,1% in di-heptads) and no predominant 4P-signatures could be assigned. 
Another important finding in this work was that different predominant 2P-signatures 
were detected within consensus repeats located at different regions within the CTD. 
Since these repeats have identical sequences these results suggest that CTD 
phosphorylation is location dependent. In other words, the CTD is divided into many 
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sub-compartments revealing different phosphorylation patterns defined by their 
position within the CTD (Figure 30B). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30 Key findings of this work. A) Different phosphorylation levels (1P/red, 
2P/blue, 3P/green and 4P/purple) of di-consensus heptad YSPTSPSYSPTSPS are shown. 
Portion of different phosphorylation forms are indicated (1P: 83,1%, 2P: 14,8%, 3P: 2,0%, 
4P: 0,1%). Detected and possible phosphorylation combinations within each 
phosphorylation state are shown (1P: 10/10, 2P: 45/45, 3P: 83/120, 4P: 16/210). 
Abundance of different phosphorylation (P-) signature profiles within the four possible 
phosphorylation levels are displayed and described. B) Different 2P-signature profiles 
obtained from consensus repeats located within different regions along the CTD (CTD 
repeat 9, 16, 28, 29, 30) are shown. 
  
A 
B 
YSPTSPS 
5 9 16 28 29 30
2P 2P 2P 2P 2P 
Dominant 2P-signatures are location dependent 
52
1P
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83,1% 
14,8% 
2,0% 
0,1% 
1P: 10/10 
2P: 45/45 
3P: 83/120 
4P: 16/210 
Di-consensus heptad P-level/abundance Detected/possible P-signatures 
Y1P, S2P, T4P, S5P and 
S7P in similar amounts 
Dominant signatures in 2P 
containing mainly S2P, T4P 
and S5P phosphosites 
Few more abundant signatures 
in 3P containing Y1P, S7P or 
non-consensus phosphosites 
like T7P  
No abundant signatures in 4P 
due to low count of 4P  
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3.11  Outlook 
 
This work provides new insights into phosphorylation signatures of Pol II CTD in 
vivo. For the first time CTD phosphosites could be mapped along the whole CTD 
molecule. In this study CTD peptides have been extracted from a total Pol II pool 
originating from cells cultured under normal cell conditions. In a future attempt, it will 
be interesting to compare CTD patterns that are linked to different cell states during 
cell cycle. Additionally, investigation of possible dynamic changes in phosphorylation 
patterns along the CTD upon cellular stress induction might contribute to a more 
detailed understanding of how a specific CTD code is defined upon a certain 
‘demand’. Furthermore, the MS approach established in this work could also be used 
for the mapping of CTD phosphosites in other mammalian cell culture cells other 
than Raji cells. Accordingly, insights into the CTD code of different tissue-specific 
cells, e.g. in mouse, might further expand the repertoire of distinct phosphorylation 
signatures within the CTD.  
ChIP data revealed that different CTD phosphosites reach their peaks at different 
regions along actively transcribed genes suggesting that distinct phosphorylation 
patterns of CTD are related to specific transcription states. One big challenge for the 
future will be to extract Pol II located at specific sites denoting actively transcribed 
genes and subsequently map phosphosites of CTDs that are linked to transcription 
initiation, transcription elongation or transcription termination. However, one aspect 
wherein a great deal of improvement is still desired is the volume of sample needed 
since approximately 300 million cells are required for efficiently mapping hundreds of 
phosphosites by MS analysis.  
Another noteworthy aspect of future research is the lack of information on the 
stoichiometry of phosphorylation of distinct CTD peptides. There are several 
established MS-based approaches available for analysing the stoichiometry of 
phosphorylation. In an isotope-free approach the big challenge is to calculate the 
‘flyability’ ratio for each of the phosphopeptide versions with respect to that of their 
unphosphorylated counterpart. The flyability ratio can be analysed by using the 
corresponding set of synthetic peptides (Steen et al., 2005). In a different approach, 
the use of a known amount of stable isotope-labeled standard peptides to quantify 
the abundance of different versions of the phosphopeptide might be the most 
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accurate existing method for measuring stoichiometry of phosphorylation (Mayya et 
al., 2006a; Mayya et al., 2006b). However, the cost of synthesizing thousands of 
stable isotope-labeled standard peptides that have been purified and quantified 
accurately is a substantial limitation in performing such experiments. 
One important point which is currently under investigation is how different 
neighbouring amino acid residues influence nearby phosphosites within the CTD. In 
this approach, identical sequences located within the same CTD repeats of different 
CTD mutants that differ in adjacent CTD residues will be analysed. Moreover, it is 
important to show that consensus repeats located at the same position in different 
mutants display similar 2P-signatures profiles and thereby strengthening the idea of 
a location dependency of CTD phosphorylation obtained by comparing consensus 
heptads along the CTD in this work. Additionally, the key finding in this work, that 
mono-phosphorylated CTD peptides are the predominant phosphorylation form in 
vivo, has to be confirmed by the analysis of synthetic peptides containing one to four 
phosphosites thereby excluding a technical bias towards low phosphorylated CTD 
peptides.  
Furthermore, separated data sets linked to the different Pol II forms which were 
detected by SDS-PAGE will be created. In this way useful information on possible 
dominant Pol II forms could be acquired. Last but not least, high abundant 
phosphorylation signatures will be used for pull down experiments ‘fishing’ for novel 
specific CTD-protein interactions by implementing synthetic peptides carrying the 
corresponding phosphosites. 
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4. Material and Methods 
 
4.1 Materials 
 
4.1.1 Chemicals 
 
1,4-Dithiothreitol (DTT)   Carl Roth GmbH&CoKG, Karlsruhe 
1 kb DNA ladder    Invitrogen, Karlsruhe 
3-(N-Morpholino)-propanesulfonic Acid  
(MOPS)     Sigma-Aldrich Chemie, GmbH, Deisenhofen 
Agarose     Invitrogen, Karlsruhe 
Albumin Fraktion V (BSA)   Carl Roth GmbH&CoKG, Karlsruhe 
α−Amanitin     Roche Molecular Biochemicals, Mannheim 
Bromophenol Blue (BPB)   Sigma-Aldrich Chemie GmbH, Deisenhofen 
Dimethyl Sulfoxide (DMSO)  Sigma-Aldrich Chemie GmbH, Deisenhofen 
Ethanol (EtOH), absolute   Merck, Darmstadt 
Ethidium Bromide (EtBr)   Fluka Chemie GmbH, Buchs 
Ethylendiaminetetraacetic Acid (EDTA) Carl Roth GmbH&CoKG, Karlsruhe 
Fetal Bovine Serum (FBS)   PAA Laboratories, Pasching, Österreich 
Formaldehyde (37 %)   Carl Roth GmbH&CoKG, Karlsruhe 
Glycerol 86%    Carl Roth GmbH&CoKG, Karlsruhe 
Glycine     Carl Roth GmbH&CoKG, Karlsruhe 
Isopropanol, absolute   Carl Roth, Karlsruhe 
L-Glutamine 200mM (100x)  Gibco BRL Life Technologies, Eggenstein 
Methanol (MeOH), absolute  Merck KGaA, Darmstadt 
Neomycin (G148)    Promega Corp., Wisconsin, USA 
Orange G     Sigma-Aldrich Chemie GmbH, Deisenhofen 
Peniciline/Streptomycin 10.000 U/ml Gibco BRL Life Technologies, Eggenstein 
Phenylmethanesulfonyl Fluoride   ICN Biomedicals Inc., Fountain Pkwy, USA 
(PMSF) 
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Polyacrylamide 30% (PAA)  Carl Roth GmbH&CoKG, Karlsruhe 
Powdered Milk, blotting grade  Carl Roth GmbH&CoKG, Karlsruhe 
Prestained Protein Ladder Plus  Fermentas, St. Leon-Rot 
RPMI Medium 1640    Gibco BRL Life Technologies, Eggenstein 
Sodium Dodecyl Sulfate (SDS)  Carl Roth, Karlsruhe 
Tetramethylethylenediamine (TEMED) Carl Roth GmbH&CoKG, Karlsruhe 
Tetracycline     Promega Corp., Wisconsin, USA 
Tris(hydroxymethyl)aminomethane Merck KGaA, Darmstadt 
(TRIS) 
Triton X-100     Sigma-Aldrich Chemie GmbH, Steinheim 
Tryphan Blue    Invitrogen, Karlsruhe 
Tween-20     Sigma-Aldrich Chemie GmbH, Deisenhofen 
 
4.1.2 Consumables and kits  
 
Agar plates     Greiner GmbH, Frickenhausen   
Cover Slides     Menzel, Braunschweig 
Cyrovials 1.5 ml    Nunc GmbH, Wiesbaden 
DNA Mini/Maxi kits    Qiagen GmbH, Hilden 
Electroporation cuvettes   Peqlab, Erlangen 
Gel Blotting Paper GB003   Schleicher & Schuell, Deutschland 
Hybond N+ Nylon Membrane  GE Healthcare, München 
Laboratory Glassware   Duran Productions GmbH & Co. KG, Mainz 
Nitrile Gloves    Kimberly-Clark, Koblenz 
Parafilm     Carl Roth GmbH&CoKG, Karlsruhe 
Pasteur Pipettes    Hirschmann Laborgeräte, Eberstadt 
Phosphataseinhibitor cocktail  Roche Diagnostics, Penzberg 
Pipette Tips ART 10, 20, 200, 1000) MolecularBio-Products, San Diego 
Plastic ware for cell culture  Greiner Bio-One,Frickenhausen 
Proteaseinhibitor cocktail   Roche Diagnostics, Penzberg 
Protein A-Sepharose beads  GE Healthcare, München 
Protein G-Sepharose beads  GE Healthcare, München 
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Reaction Tubes 1.5 ml, 2 ml  Eppendorf, Hamburg 
Reaction Tubes 15 ml, 50 ml  Becton Dickinson Biosiences, Heidelberg 
Scalpel     Braun, Tuttlingen 
Sterile filters     Milipore GmbH, Eschborn 
 
4.1.3 Technical Instruments 
 
-80°C freezer    Colora Messtechnik GmbH, Lorch 
-20°C freezer    Siemens, München 
Bacteria incubator    Heraeus Sepatech GmbH, Osterode 
Bacteria shaker (Series 25)  New Brunswick ScientificCo., NJ, USA 
Biofuge 13     Heraeus Sepatech GmbH, Osterode 
Bio-Rad PowerPac 300   Bio-Rad Laboratories GmbH, München 
Blotting chamber    Bio-Rad Laboratories GmbH, München 
Branson Sonifier 250   Heinemann Ultraschall- und Labortechnik 
Electrophoresis equipment  Bio-Rad Laboratories GmbH, München 
Electroporator (eukaryotic cells)  Bio-Rad Laboratories GmbH, München 
Eppendorf Centrifuge 5417R  Eppendorf, Hamburg 
Eppendorf Thermomixer 5436  Eppendorf-Netheler-Hinz GmbH, Hamburg 
Fridge KU 171    Liebherr, Biberach 
Fuchs-Rosentahl chamber  GLW Gesellschaft für Laborbedarf GmbH 
Gilson Pipettes 2,10, 20, 200,1000 Gilson, Bad Camberg 
Hypercassette    Amersham Pharmacia Biotech, Freiburg 
Inkubator Heraeus 6000   Heraeus Sepatech GmbbH, Osterode 
Laminar Flow Hood    BDK Luft-und Reinraumtechnik GmbH 
Magnet stirer M23    GLW, Würzburg 
Megafuge 2.0    Heraeus Sepatech GmbH, Osterode 
Microwave     Panasonic, Hamburg 
Multi-calimatic pH-meter   Knick GmbH & Co. KG, Berlin 
Nanodrop 1000    Thermo Scientific, Braunschweig 
Odyssey Infrared Imaging System Odyssey LI-COR 
PipetMan P     Gilson, Bad Camberg 
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Rollermixer SRT 2    Dunn GmbH, Augsburg 
SDS-PAGE gel tank   Amersham Pharmacia Biotech, Freiburg 
ST305 Electrophoresis Power Supply Gibco BRL Life Technologies, Eggenstein 
Telaval 31 Lichtmikroskop   Carl Zeiss Jena GmbH, Göttingen 
UV lamp VL-4. LC    PeqLab Biotechnologie GmbH, Erlangen 
Vortexer Vortex Genie 2   Bender & Hobein GmbH, Ismaning 
Waterbath     Thermo Fisher Scientific, Karlsruhe 
 
4.1.4 Buffer and Solutions 
 
0,7% Agarose-TAE-Gel for DNA   2,1 g Agarose 
       300 ml 1x TAE 
       boil in microwave 
       cool to 65°C 
       EtBr (375 ng/µl) 
 
10 x DNA Loading Dye    20 g Sucrose 
       100 mg Orange G 
       ad 50 ml H2O   
  
PBS       137 mM NaCl 
       2,7 mM KCl 
       4,3 mM Na2HPO4*6H2O 
       1,4 mM KH2PO4 
 
Lämmli-Buffer (2x)     2% SDS 
       100 mM DTT 
       10 mM EDTA 
       10% Glycerol 
       60 mM Tris/HCl pH 6,8 
       0,01% BPB 
       1 mM PMSF 
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Milk powder solution    5% powdered milk in 1 x TBST 
 
NP40-Lysisbuffer     50 mM Tris-Cl, pH 8,0 
       1% NP40 
       150 mM NaCl 
       Phosphataseinhibitor (1:200) 
       Proteaseinhibitor (1:200) 
 
IP-Washingbuffer     50 mM Tris-Cl, pH 8,0 
       150 mM NaCl 
 
TiO2-Loading Buffer    80% Acetonitrile 
       5% TFA 
       1 M Glycolic acid 
 
TiO2-Washing Buffer 1    80% Acetonitrile 
       1% TFA 
 
TiO2-Washing Buffer 2    10% Acetonitrile 
       0,2% TFA 
 
TiO2-Elution Buffer     40 µl Ammonium solution (28%)  
       in 960 µl H2O, pH 11,3   
       
2xTris/SDS pH 8,8     22,68 g Tris/Base 
       2,5 ml SDS 20%  
       add 250 ml H2O 
       pH 8,8 (with HCL) 
 
2xTris/SDS pH 6,8     7,56 g Tris/Base 
       2,5 ml SDS 20% 
       add 250 ml H2O 
       pH 6,8 (with HCL) 
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Running-gel (6,5%)     8,6 ml PAA 30% 
       20 ml 2xTris/SDS pH 8,8 
       11 ml H2O 
       334 µl APS 
       20 µl TEMED 
 
Stacking-gel (3%)     1,5 ml PAA 30% 
       7,5 ml 2xTris/SDS pH 6,8 
       5,9 ml H2O 
       90 µl APS 
       20 µl TEMED 
 
SDS-PAGE-running buffer (10x)   60,4 g Tris/Base 
       288 g Glycin 
       5 ml SDS 20% 
       add 2 l H2O 
 
Western-transfer buffer (10x)   60,4 g Tris/Base 
       288 g Glycin 
       5 ml SDS 20% 
       200 ml Methanol 
       add 2 l H2O 
 
Western-blocking-reagent    10% (v/v) TBS 
       0,1% (v/v) Tween 20 
       5% (w/v) Magermilchpulver  
 
PBS/T ween      99,9% (v/v) PBS 
       0,1% (v/v) Tween 20 
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4.1.5 Antibodies 
 
Primary antibodies: 
Pol3.3: 
Monoclonal antibody (mouse) that recognizes a conserved epitope of the large 
subunit of Pol II (Rpb1) outside of the CTD.  
(originally produced from E.K. Bautz, Universität Heidelberg. Received as a 
supernatant solution from E. Kremmer, Helmholtz Zentrum, München) 
 
8WG16: 
Monoclonal antibody (mouse) that recognizes the unphosphorylated CTD of the 
large subunit of Pol II (Rpb1).  
(Received as a supernatant solution from E. Kremmer, Helmholtz Zentrum, 
München) 
 
1C7: 
Monoclonal antibody (rat) that recognizes the unphosphorylated CTD of the large 
subunit of Pol II (Rpb1).  
(Received as a supernatant solution from E. Kremmer, Helmholtz Zentrum, 
München) 
 
3F10 (HA): 
Monoclonal antibody (rat) that recognizes an epitope contained in the 
haemagglutinin polypeptide of the human influenza virus (Roche Diagnostics, 
GmbH, Mannheim) 
 
α-Tyr-1-P, α-Ser-2-P, α-Ser-5-P, α-Ser-7-P, and α-Thr-4-P: 
Monoclonal antibodies (rat) that recognize the phosphorylated form of their 
respective amino acids within the CTD of the large subunit of Pol II (Rpb1). 
(Received as a supernatant solution from E. Kremmer, Helmholtz Zentrum, 
München) 
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Secondary antibodies: 
 
Alexa Fluor 680 Goat α-Rat IgG (H+L)   Molecular Probes 
IR Dye 800 CW α-Rat IgG (H+L)    Rockland Inc, Rockland 
Alexa Fluor 680 Goat α-Mouse IgG (H+L)  Molecular Probes 
IR Dye 800 CW α-Mouse IgG (H+L)   Rockland Inc, Rockland 
 
4.2 Materials for cloning 
 
4.2.1 Oligonucleotides 
Newly synthesized CTD sequences: 
All mutated CTD sequences as well as the wildtype-CTD sequence were 
synthesized by GeneArt Regensburg. 
 
Primers for CTD sequencing in the final expression vector LS*mock: 
 
wt fwd: 5’CTCCTGCTGACGCACCTGTTCT3’ 
 
CTD fwd: 5’CCTTTGTCTTTTCCTATAGGTGGTGC3’ 
 
CTD rev: 5’GTCAGACAACCTCGGTGGCCTGTGTG3’ 
 
4.2.2 Plasmids used during this work 
 
RX2-287 vector (subcloning vector): 
Vector containing last exon (CTD) of the α-amanitin resistant Pol II Rpb1 gene. 
 
RX4-267 (LS*Mock - expression vector): 
A tetracycline-regulated expression vector containing the α-amanitin-resistant and 
HA-tagged mouse Rpb1 gene. 
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4.2.3 Cloning strategy 
 
All synthesized CTD must be flanked by an AvrII restriction site upstream to the CTD 
sequence and by a NotI restriction site downstream to the CTD sequence.  
Synthesized CTDs must not contain AvrII, NotI, AgeI, BspEI, NgoMIV, NheI, SpeI 
and ClaI restriction sites within the sequence. 
First the newly synthesized CTD cassette will be cloned into the subcloning vector 
RX2-287 vector using the restriction sites AvrII and NotI. RX2-287 will be cut with 
BspEI and NotI and cloned into the AgeI/NotI site of RX4-267 (Figure 31).  
 
 
 
 
   
 
 
 
 
 
 
Figure 31 Cloning strategy. Schematic view of the two step cloning procedure 
using two different vectors and different restriction sites. In red letters: recognition sites 
of AvrII (left) and NotI (right). AvrII recognition site encodes proline and arginine (P and 
R). NotI recognition site encodes two alanines (A). These two sites flank the CTD open 
reading frame. Restriction sites in red circles are used for the first cloning step into the 
subcloning vector (RX 287) and restriction sites in green circles are used for the 
second cloning step into the final expression vector (RX4 267). All cloning steps and 
vectors used in this work have been established by Chapman et al. 
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4.2.4 Bacteria 
 
DH10B: E.coli strain purchased from Invitrogen GmbH, Karlsruhe. Used for the 
cloning of all plasmid DNA. 
4.3 Human cell lines 
 
4.3.1 Basic cell lines 
Raji: 
Cell type: human Burkitt lymphoma  
DSMZ no.: ACC 319  
Origin: established from the left maxilla of a 12-year-old African boy with Burkitt 
lymphoma in 1963; first continuous human hematopoietic cell line; classified as risk 
category 1 according to the German Central Commission for Biological Safety 
(ZKBS)  
References: Pulvertaft, Lancet: 238-240 (1964), PubMed ID 14086209 
 
 (1965), PubMed ID 4284655 
  
 
4.3.2 Stably transfected cell lines 
Name  Plasmid  Cell line    Resistance 
WT rec  LS*mock  Raji   neomycine 
M-6K   --   --   -- 
M-3K5R  --   --   -- 
M-8K   --   --   -- 
M-4K2R  --   --   -- 
M-13K2R  --   --   -- 
M-9K4R  --   --   -- 
M-12K2R  --   --   -- 
M-8K4R  --   --   -- 
M-9K2R  --   --   -- 
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4.4 Methods 
 
4.4.1 Bacterial cell culture 
 
4.4.1.1 The maintenance and preparation of bacterial plasmids 
 
Bacteria were cultured either on LB-agar plates in a bacterial incubator, or in liquid 
LB medium in a thermoshuttler at 37°C overnight. Liquid cultures were produced 
through infection of 200-400 ml LB medium with a single bacterial colony picked from 
an agar plate. Transformed bacteria were selected for the antibiotic resistance of the 
transformed plasmid through the addition of antibiotic (Ampicillin, Kanamycin or 
Spectionomycin) to growth media: liquid culture medium, 100 µg/ml; agar plates, 
50µg/ml. 
 
LB-medium:    20 mM MgSO4; 10 mM KCL; 1% Bacto-Tryptone; 0,5% Bactoyeast   
    extract; 0,5% NaCl 
LB-agar: 20 mM MgSO4; 10 mM KCL; 1% Bacto-Tryptone; 0,5% Bactoyeast 
extract; 0,5% NaCl; 1,2% Bacto-agar 
 
4.4.1.2 Preparation of competent bacteria 
 
To increase the efficiency of plasmid DNA uptake (transformation), bacteria were 
treated with solutions of di-valent cations. An LB plate was first inoculated with a 
probe from a bacterial stock and grown overnight at 37°C. A single colony was then 
used to inoculate 2.5 ml of LB medium, which was then incubated overnight in a 
loose-capped vessel, with shaking. The following day, the entire overnight culture 
was used to inoculate 250 ml of LB medium containing 20 mM MgSO4. Bacteria 
were grown in a 1 dm3 flask, with shaking, at 37°C until the absorbance at 600 nm 
(A600) reached 0,4-0,6 (approx. 5-6 h). 
Bacteria were pelleted at 4,500 x g, 5’ at 4°C. Medium was discarded and the 
bacteria re-suspended in 0,4 volume (of the original culture volume) of ice-cold 
TFB1. Bacteria were incubated a further 5’ on ice before centrifugation (as above), 
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and re-suspension in 1/25 of the original culture volume of ice-cold TFB2 and 
incubated a further 15-60’ on ice. Aliquots of 50-100 µl bacteria were snap-frozen in 
liquid nitrogen and removed to storage at -80°C. 
NOTE: All vessels and pipettes should be pre-chilled. 
 
TFB1:  30 mM Potassium acetate; 10 mM CaCl2; 50 mM MnCl2; 100 mM RbCl;   
  15% glycerol. Adjust to pH 5,8 with 1 M acetic acid; sterile filter  
                      (0,2 µm)    
TFB2:  10 mM MOPS pH 6,5; 75 mM CaCl2; 10mM RbCl; 15% glycerol.  
  Adjust to pH 6,5 with 1 M KOH; sterile filter (0,2 µm) 
 
 
4.4.1.3 Transformation of bacteria 
 
For standard sub-cloning and production of large amounts of cloned DNA, the 
recombination-deficient Escherichia Coli strain, DH10B was used. For 
transformation, 1 ng to 0,1 µg of plasmid DNA or 10 µl of ligation mixture was added 
to 50-100 µl of competent bacteria suspension and incubated on ice for 30’.  Cells 
were then subjected to heat shock at 42°C for 30’’ before returning to ice for 2’. 200-
400 µl (4 volumes) of LB recovery medium was added to the cells and incubated at 
37°C for 1h for cells to express resistance genes conferred by the plasmid. 
Finally, 50-200 µl of suspension was plated onto LB-agar plates containing 
ampicillin, kanamycin or spectinomycin and grown at 37°C for 16-18 h. 
 
4.4.1.4 Miniprep of plasmid DNA 
 
Single colonies obtained from transformation of bacteria following ligation reactions 
were used to inoculate 2 ml LB, and grown overnight. Using the alkaline lysis method 
(Birnboim, 1983), plasmid DNA was isolated from a bacteria culture. This method 
relies on the fact that high molecular weight linear chromosomal DNA will be 
denatured when cells are lysed at pH 12-12,6, whereas low molecular weight 
supercoiled plasmid DNA remains unaffected. Neutralisation of pH in the presence of 
high salt concentrations subsequently precipitates chromosomal DNA, which can be 
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separated from the mix. The following protocol was routinely used: 2 ml of LB media 
containing appropriate antibiotic was inoculated with a single colony of transformed 
bacteria in a 20 ml loose-capped tube. The culture was incubated overnight at 37°C 
with vigorous shaking. 1,5 ml of culture was then decanted into a microfuge tube and 
centrifugated at maximum speed for 1’ in a microfuge. Medium was removed from 
the pellet and re-suspended in 150 µl of alkaline lysis solution 1 by vigorous pipetting 
up and down, ensuring complete dispersal of bacterial cells. 150 µl of alkaline lysis 
solution 2 was added, and mixed gently by inverting 5 times before incubation at 
room temperature for 5’. To precipitate, 150 µl of pre-chilled alkaline lysis solution 3 
was added, and then mixed by inverting, before incubation on ice for 20’. After 
centrifugation at maximum speed for 10’, the resulting supernatant was transferred 
to a fresh microfuge tube and mixed with 450 µl isopropanol (1:1) to precipitate 
plasmid DNA, and centrifuged at maximum speed for 10’. The pellet was then 
washed once with 5 ml of 70% ethanol and centrifuged at maximum speed for 5’. 
Supernatant was thoroughly removed and pellets re-suspended either in 200 µl H2O 
or in 100 µl TE buffer. 
For screening of these crude preparations with restriction enzymes, master mixes of 
enzymes and appropriate restriction enzyme buffers (New England Biolab/Promega) 
containing RNase A were prepared, such that 10 µl of mix could be added to 10 µl of 
miniprep to give 0,5-3 units of enzyme (depending on efficiency), 1x restriction 
enzyme buffer and 20 µg/ml RNase A. Digests were incubated at appropriate 
temperatures for at least 2 h before separation on agarose gels. 
 
Solution 1: 50 mM Tris-Cl; pH 8; 10 mM EDTA 
Solution 2: 0,2 M NaOH; 1% SDS 
Solution 3: 3M potassium acetate; 2M glacial acetic acid 
 
4.4.1.5 Maxiprep of plasmid DNA 
 
Large quantities of plasmids were purified using Qiagen Maxiprep protocols based 
on a modified alkaline lysis procedure. Plasmid DNA is recovered by running the 
bacterial lysate through an anion exchange column under appropriate low-salt and 
pH conditions. Following washing, the DNA can be eluted by a high-salt buffer.  
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A single colony was picked from a freshly streaked selection plate and incubated in 
200-400 ml of selective LB medium overnight at 37°C on an orbital shaker. Cells 
were harvested by centrifugation at 6000 x g for 15’ at 4°C. Supernatant was 
discarded and pellets were re-suspended in 10 ml of chilled alkaline lysis solution 1 
containing 100 µg/ml RNAase A.  10 ml of alkaline lysis solution 2 was added to the 
suspension and mixed gently by inverting. Cells were lysed for 5 min at room 
temperature before stopping the reaction by addition of 10 ml alkaline lysis solution 3 
and mixed again by inverting. Mixtures were incubated on ice for 20’ to aid 
precipitation of cell debris, genomic DNA and SDS. The sample was then centrifuged 
at 20.000 x g for 30’ at 4°C. The supernatant was then passed through a filter paper 
to remove any residual precipitate and applied to a Qiagen column equilibrated with 
10 ml of equilibration buffer and washed twice with 30 ml wash buffer. The bound 
plasmid was eluted in 15 ml elution buffer and precipitated by adding 10.5 ml (0,7 
volumes) of room temperature isopropanol, followed by centrifugation at 20.000 x g 
for 30’ at 4°C. Pellets were re-suspended in 300 µl TE or H2O and transferred to a 
microfuge tube. 
 
Equilibration buffer:  50mM MOPS, pH 7; 750 mM NaCl; 15% ethanol 
Wash buffer:   50mM MOPS, pH 7; 1 M NaCl; 15% ethanol  
Elution buffer:  50mM Tris-Cl, pH 8,5; 1,25 M NaCl; 15% ethanol 
 
 
 
4.4.2 Eukaryotic cell culture 
 
4.4.2.1 Human cell culture methods 
 
Raji is a human, EBV positive Burkitt lymphoma cell line that is cultivated at 37°C in 
a 5% CO2-containing atmosphere in cell culture bottles under sterile conditions. The 
suspension cells were splitted in a 1:3 ratio with fresh media every three days, 
receiving a cell density of about 250000 cells/ml. 
 
Media for cell culture: RPMI-Medium with following additives: 10% FCS,  
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100 U Penicillin/ml, 100 µg Streptomycin/ml und 2 mM L-
Glutamine.  
Medium for the transfected cells additionally contained:   
1 mg G418/ml. 
 
α-amanitin (stock solution: 1mg/ml in H2O) was added in a final concentration of 2 
μg/ml to inhibit the endogenous Pol II. Protein extracts for western analysis were 
prepared 24 - 48 h after treatment with α-amanitin. 
 
 
4.4.2.2 Determination of the living cell number 
 
The living cell number was calculated using a Fuchs-Rosenthal-Zählkammer.  
40 μl of cell suspension was mixed with 0,5% Trypanblau-solution (w/v in PBS) 
containing the same volume. Dead cells absorb the stain over their membranes and 
can be distinguished from the colourless, living cells. The calculation of the living cell 
number results from the counting of four big squares using the formula: c (cells/ml) = 
average value of the cells per big square x 104. 
 
4.4.2.3 Unfreezing of cells 
To revive stocks from storage, cryotubes were thawed at room temperature for 3’ 
before transfer to 15 ml fresh RPMI medium. Cells and medium was mixed through 
inversion several times, before re-centrifugation (300 x g, 4’), and re-suspension in 
10 ml fresh culture medium containing 20% FCS. 
 
4.4.2.4 Refreezing of cells 
Cells were split 1:1 with fresh medium one day before storage. Cells were pelleted 
(300 x g, 4’), and medium discarded, before resuspension in storage medium and 
transfer of 1 ml aliquots to 1,5 ml cryotubes. The tubes were wrapped with paper 
avoiding shock freezing and first stored overnight at - 80°C before transfer to storage 
facilities in liquid nitrogen. 
 
Storage medium: 10% RPMI 1640; 10% DMSO; 80% FCS 
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4.4.2.5 Stable transfection of B-cells 
 
For the production of stable cell lines, plasmid vectors were introduced into cell lines, 
and a selection performed utilizing an antibiotic resistance gene expressed by the 
introduced vector. For best results, cells should be split 1:1 one day prior to 
transfection. 2 x 107 cells are required per transfection. Cells were collected by 
centrifugation (300 x g, 4’), and re-suspended at a density of 2 x 107 cells / 500 µl in 
PBS. Cells were transferred to a 4 mm electroporation cuvette, and gently mixed with 
10 µg of plasmid DNA through knocking against the wall of the cuvette. The 
cell/plasmid DNA mixture was incubated at room temperature for 20’ before starting 
the electroporation. Electroporation was performed using a voltage of 250 V and 
capacitance charge of 950 µF. Both pulse buttons were pushed simultaneously till 
the noise signal appeared and then immediately 1 ml FCS was added to the cuvette 
and mixed with the transfected cells through pipetting up and down. Transfected 
probes were incubated for 5’ at room temperature before transfer to a flask 
containing 5 ml fresh medium. It is important to leave the white smear (toxic) 
consisting of dead cell material behind. 
Two days following transfection, the appropriate selection reagent for the vectors 
used was applied to the cell culture medium. Selection typically requires 2 – 4 weeks 
to recover a viability of 95%. This technique produces a polyclonal cell line. 
 
Neomycin (G418): Stock: 100 mg/ml in PBS; Working concentration 1mg/ml 
 
 
4.4.3 Molecular techniques for cloning 
 
4.4.3.1 Digestion of DNA using restriction endonucleases 
 
Restriction enzymes were used as described by the manufacturer. For the analysis 
of plasmid ‘mini-prep’ DNA, multiple digests were performed in a compatible buffer. 
For subsequent gel extraction 5 µg of DNA was digested. 
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4.4.3.2 Ligation of DNA fragments 
 
Equimolar amounts of DNA fragments (100 – 200 ng) were mixed together and 
heated to 45°C for 5’, before transfer to ice. Ligase buffer and T4 DNA ligase were 
added, as recommended by the manufacturer, and incubated overnight at 16°C in 
the cold room. The entire ligation mixture was used for transformation. 
 
 
4.4.3.3 DNA agarose-gel electrophoresis 
 
For a 0.7 % DNA agarose-gel, 2,1 g agarose was boiled in 300 ml 1 x TAE buffer.  
3 µl/100 ml ethidium bromide (EtBr, stock: 10 mg/µl) was added after cooling of the 
gel to 65°C. DNA was mixed with 10 x DNA loading dye and loaded on the gel. The 
gel was run with a 1 kb DNA ladder in 1 x TAE buffer (80 V, 3 hours). A gel photo 
was taken under UV light. 
 
4.4.3.4 DNA-gel extraction for cloning 
 
Purification of a mixture of different-sized DNA was achieved via separation over a 1 
x TAE 0,7% agarose gel, containing ethidium bromide (0,5 µg/ml). A band of interest 
was removed from the gel using a scalpel, melted at 65°C and further processed by 
using the QIAquick gel extraction Kit. This kit provides spin column, buffers and 
collection tubes for silica-membrane-based purification of DNA fragments from gels. 
DNA ranging from 70 bp to 10 kb is purified using a simple and fast bind-wash-elute 
procedure and an elution volume of 30-50 µl. An integrated pH indicator allows easy 
determination of the optimal pH for DNA binding to the spin column. The procedure 
can be fully automated on the QIAcube. The final DNA concentration was measured 
by using the nanodrop system. 
For gel extraction of DNA bigger than 10 kb the QIAEX II gel extraction kit was used. 
This method provides a suspension of silica particles to which DNA fragments bind in 
the presence of chaotropic salts. QIAEX II suspension is added to solubilized 
agarose gel slices and binds DNA. The particles are collected by a brief 
centrifugation, washed, and DNA up to 50 kb is eluted in Tris buffer or water. 
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4.4.4 Methods for the analysis of protein 
 
4.4.4.1 Cell lysis 
 
For subsequent western analysis Raji cells were transferred to 15 ml falcons and 
centrifuged at 300 x g for 4’. The supernatant was removed and the cell pellet was 
washed with PBS. After a second centrifugation step (300 x g, 4’) 100 - 300 μl 2x 
Lämmli-buffer was added and the viscous lysate was repeatedly drawn through a 
narrow pipette tip to shear genomic DNA, before denaturing by boiling at 95°C for 5’. 
After briefly cooling on ice, samples were centrifuged (15000 x g, 4’) to clear 
insoluble contaminants. Finally the lysates were either directly loaded on to the gel or 
stored at –20°C. 
For subsequent immunoprecipitation, Raji cells were harvested by centrifugation 
(300 x g, 4’), washed twice with cold PBS, re-centrifuged and re-suspended in ice-
cold NP40 lysis buffer (100 μl lysis buffer/1,5 x 106 cells). Cells were mixed by 
sporadic vortexing while incubation on ice for at least 30’ before sonication (duration 
time 1’; output 7; duty cycle 70%) and subsequent incubation for another 20’ on ice. 
Cells were mixed before pelleting of the nuclei (472 x g, 15’, 4°C). The supernatant 
was carefully removed for following immunoprecipitation, or storage at -20°C. 
 
2 x Lämmli buffer: 2% SDS; 100 mM DTT; 10 mM EDTA; 10% Glycerol; 60 mM 
Tris/HCl pH 6,8; 0,01% Bromphenol Blue; 1 mM PMSF 
 
NP40 lysis buffer: 50 mM Tris-Cl, pH 8,0; 1% NP40; 150 mM NaCl 
  
        
4.4.4.2 Immunoprecipitation 
 
First, 4 ml of antibody solution (20-40 μg/ml) was incubated with 60 μl of Protein A 
sepharose beads (stored in 20% ethanol) for 3 – 4 hours in the cold room on a rotary 
shaker. After two washing steps with PBS 10 ml of lysates (100 μl lysis buffer/1,5 x 
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106 cells) was added to the antibody-beads mixture and incubated in the cold room 
on a rotary shaker overnight. After incubation time, the probes were centrifuged (300 
x g, 4’), the supernatant was removed and the specific protein-antibody-beads 
mixture was transferred to 1,5 ml eppendorf tubes. The samples were washed three 
times with washing buffer and finally resuspended in 30 μl Lysis buffer and 30 μl 2 x 
Lämmli buffer (final volume: 60μl). The probes were boiled at 95°C for 8’ under high 
shaking to separate the proteins from the protein-A beads. After centrifugation 
(15000 x g, 4’) the whole supernatant was loaded on to the SDS-PAGE.    
      
        
4.4.4.3 SDS-PAGE and transfer 
 
Lysate samples were loaded and separated on a denaturating SDS-polyacrylamide 
gel with a 6.5 % running gel and a 4 % stacking gel in 1 x SDS running buffer (SDS-
PAGE, 30 mA for 3 hours). 3.5 µl of a pre-stained protein ladder was used as a 
running marker. The gel was transferred to a nitrocellulose membrane by semi-dry 
blotting in 1 x transfer buffer (450 mA, 1.5 hours). The membrane was blocked in 
milk powder solution (1 hour at RT) and incubated with specific primary antibodies, 
diluted in antibody stock solution, on a roller mixer at 4°C over night. Primary 
antibodies were removed and membranes were washed three times with 1 x TBST 
for 5’. Membranes were then either incubated with horseradish peroxidase (HRP)-
conjugated secondary antibodies when the enhanced chemiluminescence (ECL) kit 
was used for signal detection or  incubated with fluorescent-tagged secondary 
antibodies when the the Odyssey-Licor-Scanner system was chosen for detection. 
Secondary antibodies were diluted in milk powder solution and hybridized to 
membranes for 1.5 hours at RT. Membranes were washed three times with 1 x TBST 
for 5’ and briefly poured in H2O. When using the ECL-detection method, reagents 
were mixed (1:1) and incubated with membranes for 2’. Membranes were transferred 
to a detection cassette, a film was exposed and signals were detected with a 
developing machine.  
Due to the use of fluorescent-coupled antibodies instead of peroxidase-linked 
antibodies, it is possible to check one and the same lysate with two different 
antibodies as long as they originate from different organisms (e.g. rat and mouse) 
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and are recognized by the appropriate secondary antibodies emitting different 
wavelenghts (680nm and 800nm). Since the membranes can be examined through 
the different channels either individually or simultaneously, both quantitative and 
qualitative conclusions can be made. In addition, varieties in the intensity of different, 
defined areas on the membrane can be visualized and therefore it is possible to 
make statements about e.g. the phosphorylation scale of Pol II (within the same 
channel) or about the amount of binding motifs of different antibodies comparing 
both channels. 
Finally, it is very important to test the different antibodies used in this system for 
possible cross-reactions that can occur between them and would falsify the results 
obtained with the Odyssey system.  
 
4.4.4.4 Coomassie staining 
For Coomassie staining of SDS-PAGE-gels the EZBlue™ Gel Staining Reagent from 
Sigma was used. EZBlue™ Coomassie Brilliant Blue G-250 colloidal protein stain 
improves protein electrophoresis results while significantly reducing staining time. As 
a colloidal stain, it reacts only with proteins, not the gel itself. Background staining is 
reduced, so protein bands can be visualized very fast. EZBlue is extremely sensitive, 
detecting as little as 5 ng of protein. 
Following electrophoresis the gel was placed in a tray and washed three times with 
water for 5’ each with agitation. 40 ml EZBlue was added and the gel was incubated 
for 1 hour under shaking. Coomassie stain was removed and the gel was rinsed with 
water several times up to 1 hour to intensify protein bands. Gel was stored in water 
in the fridge covered by parafilm. 
 
4.4.4.5 Protein in-gel digestion with trypsin 
 
In-gel digestion comprises the four main steps destaining, reduction and alkylation 
(R&A) of the cysteines in the protein, proteolytic cleavage of the protein and 
extraction of the generated peptides. 
After excision of the protein band of interest from the Coomassie stained gel, it was 
cut into three equal pieces and placed in a 96-well plate covered with water. For 
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destaining, the gel pieces were incubated with ammonium bicarbonate (ABC) and 
acetonitrile (ACN) in a 1:1 ratio three times for 20’ at 37°C under shaking. After 
washing with ABC and subsequent dehydration of the gel pieces with ACN, 
dithiothreitol (DTT) was added and the probes were incubated for 1 hour at RT. The 
reduction reaction was stopped by adding iodoacetamide (IAA) and the gel pieces 
were incubated 30’ at RT in darkness that led to the irreversible alkylation of the SH 
groups and the cysteines were transformed to the stable S-
carboxyamidomethylcysteine (CAM). The gel pieces were dehydrated by repeated 
treatment with ACN and after removing of all the supernatant the probes were dried 
by applying vacuum for 5’. For digestion of the proteins, the enzyme trypsin was 
used and diluted to approximately 10 ng/µl using 20mM ABC. Trypsin solution was 
added covering the gel pieces. The gel pieces were incubated at 4°C for 30’ taking 
up the trypsin solution. Supernatant was removed, 100 µl 20mM ABC were added 
and the probes were incubated at 37°C under shaking overnight. Next day, peptides 
were extracted by incubation with 50% ACN/ 0.25% TFA twice for 10’ followed by 
two subsequent incubation steps with 100% ACN for 10’ each. The supernatants 
containing the extracted peptides were transferred to a cool 1.5 ml tube on ice. 
 
 
4.4.4.6 Purification of phosphorylated peptides using titanium dioxid (TiO2) 
 
Solution containing the extracted peptides was evaporated to approximately 5 µl 
dryness and then incubated in 100 µl loading buffer for 1 hour. 10 µl of TiO2 beads 
slurry solution (slurry concentration: 0,03 mg/µl beads in 100% ACN) were added 
and the tubes were placed on the shaker (high shaking) at RT for 10’. TiO2 beads 
bound to the phosphopeptides were pelleted by centrifugation (table centrifuge < 1’) 
and supernatant (unbound fraction) was transferred to a new 1,5 ml tube and stored 
at -20°C. Beads were washed with 50 µl loading buffer, mixed for 15’’ by pipetting up 
and down and centrifuged (table centrifuge < 1’). After removing the supernatant 2 
additional washing steps were performed (washing buffer 1 + washing buffer 2). After 
the final washing step, the supernatant was completely removed without removing 
the beads and the lid of the tube was left open in the fume hood for at least 10’ to 
allow drying. For eluting the phosphopeptides, 50 µl elution buffer was added, mixed 
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well and the solution was left shaking for 10’ to allow an efficient elution. Probes 
were centrifuged for 1’ (table centrifuge) and the supernatant was transferred to a 
new 1,5 ml tube without any beads. Eluate containing the purified phosphopeptides 
was evaporated to 5-10 µl dryness. 30 µl 0,1% formic acid (FA) was added and the 
probes were stored at -20°C. 
 
 
4.4.4.7 Liquid chromatography– tandem mass spectrometry (LC-MS/MS) 
 
For LC-MS/MS purposes, ~ 28- 30 µl of purified phosphopeptides were injected in an 
Ultimate 3000 HPLC system (LC Packings) and desalted on-line in a C18 micro 
column (300 µm i.d. x 5mm cm, PepMap100 C18 5 µm, 100 Å from LC Packings). 
Desalted sample was then separated in a C18 analytical column (75 µm i.d. x 10 cm, 
packed in-house with Reprosil Pur C18 AQ 2.4 µm from Doctor Maisch) with a 60 
min gradient from 5 to 30% and 10 minutes from 30 to 95% acetonitrile in 0.1% 
formic acid. The effluent from the HPLC was directly electrosprayed into a LTQ 
Orbitrap XL mass spectrometer. The MS instrument was operated in data dependent 
mode to automatically switch between full scan MS and MS/MS acquisition. Survey 
full scan MS spectra (from m/z 300 – 2000) were acquired in the Orbitrap with 
resolution R=60,000 at m/z 400 (after accumulation to a ‘target value’ of 500,000 in 
the linear ion trap). The three most intense peptide ions with charge state higher 
than 1 were sequentially isolated to a target value of 10,000, fragmented in the linear 
ion trap by collision induced dissociation (CID). The pseudoMS3 (pdMS3) or 
multistage activation (MSA) was selected to automatically select and further 
fragment the fragment ion originating from the loss of one or two phosphate groups 
from the parent ion. For all measurements with the Orbitrap detector, 3 lock-mass 
ions from ambient air (m/z=371.10123, 445.12002, 519.13882) were used for 
internal calibration as described (Olsen 2005). Typical mass spectrometric conditions 
were: spray voltage, 1.5 kV; no sheath and auxiliary gas flow; heated capillary 
temperature, 200ºC; normalized collision energy 35% for CID in LTQ. The ion 
selection threshold was 10,000 counts for MS2. An activation q = 0.25 and activation 
time of 30 ms were used. Mass spectrometry data was analyzed using Proteome 
Discoverer 1.3 (MS tol, 10ppm; MS/MS tol, 0.8Da, Variable modifications, Oxidation 
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(M) and Phosphorylation (S,T,Y); Fixed modifications, Carbamidomethyl (C); FDR 
Peptide, 0,01) using a DB including the sequences of the wild type and the mutated 
RNA polymerase II. 
 
 
4.4.4.8 Data analysis software program 
SEQUEST is a tandem mass spectrometry database search program originally 
developed in 1993 in the Yates lab at the University of Washington. It correlates 
tandem mass spectra of peptides against peptide sequences from a sequence 
database. Classical SEQUEST applies a two-stage scoring method for each search. 
The first stage applies the preliminary score to filter through all candidate peptides in 
the sequence database. The best scoring candidate peptides are then re-scored 
using the cross correlation algorithm. The sensitivity of the cross correlation 
algorithm is enhanced by the correction factor that is applied in its calculation (copied 
from http://proteomicsresource.washington.edu/sequest.php). 
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6. Appendix 
 
A  
Rpb1 CTD mutants with corresponding CTD peptide fragmentation 
pattern 
 
 
>gi|6677795|ref|NP_033115.1| DNA-directed RNA polymerase II 
subunit RPB1 [Mus musculus]M-6K 
 
MHGGGPPSGDSACPLRTIKRVQFGVLSPDELKRMSVTEGGIKYPETTEGGRPKLGGLMDPRQGVIERT
GRCQTCAGNMTECPGHFGHIELAKPVFHVGFLVKTMKVLRCVCFFCSKLLVDSNNPKIKDILAKSKGQ
PKKRLTHVYDLCKGKNICEGGEEMDNKFGVEQPEGDEDLTKEKGHGGCGRYQPRIRRSGLELYAEWKH
VNEDSQEKKILLSPERVHEIFKRISDEECFVLGMEPRYARPEWMIVTVLPVPPLSVRPAVVMQGSARN
QDDLTHKLADIVKINNQLRRNEQNGAAAHVIAEDVKLLQFHVATMVDNELPGLPRAMQKSGRPLKSLK
QRLKGKEGRVRGNLMGKRVDFSARTVITPDPNLSIDQVGVPRSIAANMTFAEIVTPFNIDRLQELVRR
GNSQYPGAKYIIRDNGDRIDLRFHPKPSDLHLQTGYKVERHMCDGDIVIFNRQPTLHKMSMMGHRVRI
LPWSTFRLNLSVTTPYNADFDGDEMNLHLPQSLETRAEIQELAMVPRMIVTPQSNRPVMGIVQDTLTA
VRKFTKRDVFLERGEVMNLLMFLSTWDGKVPQPAILKPRPLWTGKQIFSLIIPGHINCIRTHSTHPDD
EDSGPYKHISPGDTKVVVENGELIMGILCKKSLGTSAGSLVHISYLEMGHDITRLFYSNIQTVINNWL
LIEGHTIGIGDSIADSKTYQDIQNTIKKAKQDVIEVIEKAHNNELEPTPGNTLRQTFENQVNRILNDA
RDKTGSSAQKSLSEYNNFKSMVVSGAKGSKINISQVIAVVGQQNVEGKRIPFGFKHRTLPHFIKDDYG
PESRGFVENSYLAGLTPTEFFFHAMGGREGLIDTAVKTAETGYIQRRLIKSMESVMVKYDATVRNSIN
QVVQLRYGEDGLAGESVEFQNLATLKPSNKAFEKKFRFDYTNERALRRTLQEDLVKDVLSNAHIQNEL
EREFERMREDREVLRVIFPTGDSKVVLPCNLLRMIWNAQKIFHINPRLPSDLHPIKVVEGVKELSKKL
VIVNGDDPLSRQAQENATLLFNIHLRSTLCSRRMAEEFRLSGEAFDWLLGEIESKFNQAIAHPGEMVG
ALAAQSLGEPATQMTLNTFHYAGVSAKNVTLGVPRLKELINISKKPKTPSLTVFLLGQSARDAERAKD
ILCRLEHTTLRKVTANTAIYYDPNPQSTVVAEDQEWVNVYYEMPDFDVARISPWLLRVELDRKHMTDR
KLTMEQIAEKINAGFGDDLNCIFNDDNAEKLVLRIRIMNSDENKMQEEEEVVDKMDDDVFLRCIESNM
LTDMTLQGIEQISKVYMHLPQTDNKKKIIITEDGEFKALQEWILETDGVSLMRVLSEKDVDPVRTTSN
DIVEIFTVLGIEAVRKALERELYHVISFDGSYVNYRHLALLCDTMTCRGHLMAITRHGVNRQDTGPLM
KCSFEETVDVLMEAAAHGESDPMKGVSENIMLGQLAPAGTGCFDLLLDAEKCKYGMEIPTNIPGLGAA
GRSGMTPGAAGFSPSAASDASGFSPGYSPAWSPTPGSPGSPGPSSPYIPSPGGAMSPR 
YSPTSPAYEPR 
SPGGYTPQSPSYSPTSPSYSPTSPK 
YSPTSPNYSPTSPSYSPTSPSYSPTSPSYSPTSPK 
YSPTSPSYSPTSPSYSPTSPSYSPASPSYSPTSPK 
YSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPK 
YSPTSPSYSPTSPNYSPTSPNYTPTSPSYSPTSPK 
YSPTSPNYTPTSPNYSPTSPSYSPTSPSYSPTSPSYSPSSPK 
YTPQSPTYTPSSPSYSPSSPSYSPTSPK 
YTPTSPSYSPSSPEYTPASPK 
YSPTSPK 
YTPTSPK 
YSPTSPTYSPTTPK 
YSPTSPTYSPTSPVYTPTSPK 
YSPTSPTYSPTSPK 
YSPTSPTYTPASPK 
GSTYSPTSPGYSPTSPTYSLTSPAISPDDSDEEN 
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>gi|6677795|ref|NP_033115.1| DNA-directed RNA polymerase II 
subunit RPB1 [Mus musculus]M-3K5R 
 
MHGGGPPSGDSACPLRTIKRVQFGVLSPDELKRMSVTEGGIKYPETTEGGRPKLGGLMDPRQGVIERT
GRCQTCAGNMTECPGHFGHIELAKPVFHVGFLVKTMKVLRCVCFFCSKLLVDSNNPKIKDILAKSKGQ
PKKRLTHVYDLCKGKNICEGGEEMDNKFGVEQPEGDEDLTKEKGHGGCGRYQPRIRRSGLELYAEWKH
VNEDSQEKKILLSPERVHEIFKRISDEECFVLGMEPRYARPEWMIVTVLPVPPLSVRPAVVMQGSARN
QDDLTHKLADIVKINNQLRRNEQNGAAAHVIAEDVKLLQFHVATMVDNELPGLPRAMQKSGRPLKSLK
QRLKGKEGRVRGNLMGKRVDFSARTVITPDPNLSIDQVGVPRSIAANMTFAEIVTPFNIDRLQELVRR
GNSQYPGAKYIIRDNGDRIDLRFHPKPSDLHLQTGYKVERHMCDGDIVIFNRQPTLHKMSMMGHRVRI
LPWSTFRLNLSVTTPYNADFDGDEMNLHLPQSLETRAEIQELAMVPRMIVTPQSNRPVMGIVQDTLTA
VRKFTKRDVFLERGEVMNLLMFLSTWDGKVPQPAILKPRPLWTGKQIFSLIIPGHINCIRTHSTHPDD
EDSGPYKHISPGDTKVVVENGELIMGILCKKSLGTSAGSLVHISYLEMGHDITRLFYSNIQTVINNWL
LIEGHTIGIGDSIADSKTYQDIQNTIKKAKQDVIEVIEKAHNNELEPTPGNTLRQTFENQVNRILNDA
RDKTGSSAQKSLSEYNNFKSMVVSGAKGSKINISQVIAVVGQQNVEGKRIPFGFKHRTLPHFIKDDYG
PESRGFVENSYLAGLTPTEFFFHAMGGREGLIDTAVKTAETGYIQRRLIKSMESVMVKYDATVRNSIN
QVVQLRYGEDGLAGESVEFQNLATLKPSNKAFEKKFRFDYTNERALRRTLQEDLVKDVLSNAHIQNEL
EREFERMREDREVLRVIFPTGDSKVVLPCNLLRMIWNAQKIFHINPRLPSDLHPIKVVEGVKELSKKL
VIVNGDDPLSRQAQENATLLFNIHLRSTLCSRRMAEEFRLSGEAFDWLLGEIESKFNQAIAHPGEMVG
ALAAQSLGEPATQMTLNTFHYAGVSAKNVTLGVPRLKELINISKKPKTPSLTVFLLGQSARDAERAKD
ILCRLEHTTLRKVTANTAIYYDPNPQSTVVAEDQEWVNVYYEMPDFDVARISPWLLRVELDRKHMTDR
KLTMEQIAEKINAGFGDDLNCIFNDDNAEKLVLRIRIMNSDENKMQEEEEVVDKMDDDVFLRCIESNM
LTDMTLQGIEQISKVYMHLPQTDNKKKIIITEDGEFKALQEWILETDGVSLMRVLSEKDVDPVRTTSN
DIVEIFTVLGIEAVRKALERELYHVISFDGSYVNYRHLALLCDTMTCRGHLMAITRHGVNRQDTGPLM
KCSFEETVDVLMEAAAHGESDPMKGVSENIMLGQLAPAGTGCFDLLLDAEKCKYGMEIPTNIPGLGAA
GRSGMTPGAAGFSPSAASDASGFSPGYSPAWSPTPGSPGSPGPSSPYIPSPGGAMSPR 
YSPTSPAYEPR 
SPGGYTPQSPSYSPTSPR 
YSPTSPSYSPTSPNYSPTSPSYSPTSPSYSPTSPK 
YSPTSPSYSPTSPSYTPTSPSYSPTSPSYSPTSPR 
YSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPK 
YSPTSPSYSPTSPSYSPTSPNYSPTSPNYTPTSPR 
YSPTSPSYSPTSPNYTPTSPNYSPTSPK 
YSPTSPSYSPTSPSYSPSSPR 
YTPQSPTYTPSSPSYSPSSPSYSPTSPK 
YTPTSPSYSPSSPEYTPASPK 
YSPTSPR 
YSPTSPK 
YSPTSPTYSPTTPK 
YSPTSPTYSPTSPVYTPTSPK 
YSPTSPTYSPTSPR 
YSPTSPTYSPTSPK 
GSTYSPTSPGYSPTSPTYSLTSPAISPDDSDEEN 
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>gi|6677795|ref|NP_033115.1| DNA-directed RNA polymerase II 
subunit RPB1 [Mus musculus]M-8K 
 
MHGGGPPSGDSACPLRTIKRVQFGVLSPDELKRMSVTEGGIKYPETTEGGRPKLGGLMDPRQGVIERT
GRCQTCAGNMTECPGHFGHIELAKPVFHVGFLVKTMKVLRCVCFFCSKLLVDSNNPKIKDILAKSKGQ
PKKRLTHVYDLCKGKNICEGGEEMDNKFGVEQPEGDEDLTKEKGHGGCGRYQPRIRRSGLELYAEWKH
VNEDSQEKKILLSPERVHEIFKRISDEECFVLGMEPRYARPEWMIVTVLPVPPLSVRPAVVMQGSARN
QDDLTHKLADIVKINNQLRRNEQNGAAAHVIAEDVKLLQFHVATMVDNELPGLPRAMQKSGRPLKSLK
QRLKGKEGRVRGNLMGKRVDFSARTVITPDPNLSIDQVGVPRSIAANMTFAEIVTPFNIDRLQELVRR
GNSQYPGAKYIIRDNGDRIDLRFHPKPSDLHLQTGYKVERHMCDGDIVIFNRQPTLHKMSMMGHRVRI
LPWSTFRLNLSVTTPYNADFDGDEMNLHLPQSLETRAEIQELAMVPRMIVTPQSNRPVMGIVQDTLTA
VRKFTKRDVFLERGEVMNLLMFLSTWDGKVPQPAILKPRPLWTGKQIFSLIIPGHINCIRTHSTHPDD
EDSGPYKHISPGDTKVVVENGELIMGILCKKSLGTSAGSLVHISYLEMGHDITRLFYSNIQTVINNWL
LIEGHTIGIGDSIADSKTYQDIQNTIKKAKQDVIEVIEKAHNNELEPTPGNTLRQTFENQVNRILNDA
RDKTGSSAQKSLSEYNNFKSMVVSGAKGSKINISQVIAVVGQQNVEGKRIPFGFKHRTLPHFIKDDYG
PESRGFVENSYLAGLTPTEFFFHAMGGREGLIDTAVKTAETGYIQRRLIKSMESVMVKYDATVRNSIN
QVVQLRYGEDGLAGESVEFQNLATLKPSNKAFEKKFRFDYTNERALRRTLQEDLVKDVLSNAHIQNEL
EREFERMREDREVLRVIFPTGDSKVVLPCNLLRMIWNAQKIFHINPRLPSDLHPIKVVEGVKELSKKL
VIVNGDDPLSRQAQENATLLFNIHLRSTLCSRRMAEEFRLSGEAFDWLLGEIESKFNQAIAHPGEMVG
ALAAQSLGEPATQMTLNTFHYAGVSAKNVTLGVPRLKELINISKKPKTPSLTVFLLGQSARDAERAKD
ILCRLEHTTLRKVTANTAIYYDPNPQSTVVAEDQEWVNVYYEMPDFDVARISPWLLRVELDRKHMTDR
KLTMEQIAEKINAGFGDDLNCIFNDDNAEKLVLRIRIMNSDENKMQEEEEVVDKMDDDVFLRCIESNM
LTDMTLQGIEQISKVYMHLPQTDNKKKIIITEDGEFKALQEWILETDGVSLMRVLSEKDVDPVRTTSN
DIVEIFTVLGIEAVRKALERELYHVISFDGSYVNYRHLALLCDTMTCRGHLMAITRHGVNRQDTGPLM
KCSFEETVDVLMEAAAHGESDPMKGVSENIMLGQLAPAGTGCFDLLLDAEKCKYGMEIPTNIPGLGAA
GRSGMTPGAAGFSPSAASDASGFSPGYSPAWSPTPGSPGSPGPSSPYIPSPGGAMSPR 
YSPTSPAYEPR 
SPGGYTPQSPSYSPTSPK 
YSPTSPSYSPTSPNYSPTSPSYSPTSPK 
AYSPTSPSYSPTSPSYTPTSPSYSPTSPK 
YSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPK 
YSPTSPSYSPTSPSYSPTSPK 
YSPTSPSYSPTSPNYSPTSPNYTPTSPK 
AYSPTSPSYSPTSPNYTPTSPNYSPTSPK 
YSPTSPSYSPTSPSYSPSSPK 
YTPQSPTYTPSSPSYSPSSPSYSPTSPK 
YTPTSPSYSPSSPEYTPASPK 
AYSPTSPK 
YSPTSPK 
YSPTSPTYSPTTPK 
YSPTSPTYSPTSPVYTPTSPK 
AYSPTSPTYSPTSPK 
YSPTSPTYSPTSPK 
GSTYSPTSPGYSPTSPTYSLTSPAISPDDSDEEN 
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>gi|6677795|ref|NP_033115.1| DNA-directed RNA polymerase II 
subunit RPB1 [Mus musculus]M-4K2R 
 
MHGGGPPSGDSACPLRTIKRVQFGVLSPDELKRMSVTEGGIKYPETTEGGRPKLGGLMDPRQGVIERT
GRCQTCAGNMTECPGHFGHIELAKPVFHVGFLVKTMKVLRCVCFFCSKLLVDSNNPKIKDILAKSKGQ
PKKRLTHVYDLCKGKNICEGGEEMDNKFGVEQPEGDEDLTKEKGHGGCGRYQPRIRRSGLELYAEWKH
VNEDSQEKKILLSPERVHEIFKRISDEECFVLGMEPRYARPEWMIVTVLPVPPLSVRPAVVMQGSARN
QDDLTHKLADIVKINNQLRRNEQNGAAAHVIAEDVKLLQFHVATMVDNELPGLPRAMQKSGRPLKSLK
QRLKGKEGRVRGNLMGKRVDFSARTVITPDPNLSIDQVGVPRSIAANMTFAEIVTPFNIDRLQELVRR
GNSQYPGAKYIIRDNGDRIDLRFHPKPSDLHLQTGYKVERHMCDGDIVIFNRQPTLHKMSMMGHRVRI
LPWSTFRLNLSVTTPYNADFDGDEMNLHLPQSLETRAEIQELAMVPRMIVTPQSNRPVMGIVQDTLTA
VRKFTKRDVFLERGEVMNLLMFLSTWDGKVPQPAILKPRPLWTGKQIFSLIIPGHINCIRTHSTHPDD
EDSGPYKHISPGDTKVVVENGELIMGILCKKSLGTSAGSLVHISYLEMGHDITRLFYSNIQTVINNWL
LIEGHTIGIGDSIADSKTYQDIQNTIKKAKQDVIEVIEKAHNNELEPTPGNTLRQTFENQVNRILNDA
RDKTGSSAQKSLSEYNNFKSMVVSGAKGSKINISQVIAVVGQQNVEGKRIPFGFKHRTLPHFIKDDYG
PESRGFVENSYLAGLTPTEFFFHAMGGREGLIDTAVKTAETGYIQRRLIKSMESVMVKYDATVRNSIN
QVVQLRYGEDGLAGESVEFQNLATLKPSNKAFEKKFRFDYTNERALRRTLQEDLVKDVLSNAHIQNEL
EREFERMREDREVLRVIFPTGDSKVVLPCNLLRMIWNAQKIFHINPRLPSDLHPIKVVEGVKELSKKL
VIVNGDDPLSRQAQENATLLFNIHLRSTLCSRRMAEEFRLSGEAFDWLLGEIESKFNQAIAHPGEMVG
ALAAQSLGEPATQMTLNTFHYAGVSAKNVTLGVPRLKELINISKKPKTPSLTVFLLGQSARDAERAKD
ILCRLEHTTLRKVTANTAIYYDPNPQSTVVAEDQEWVNVYYEMPDFDVARISPWLLRVELDRKHMTDR
KLTMEQIAEKINAGFGDDLNCIFNDDNAEKLVLRIRIMNSDENKMQEEEEVVDKMDDDVFLRCIESNM
LTDMTLQGIEQISKVYMHLPQTDNKKKIIITEDGEFKALQEWILETDGVSLMRVLSEKDVDPVRTTSN
DIVEIFTVLGIEAVRKALERELYHVISFDGSYVNYRHLALLCDTMTCRGHLMAITRHGVNRQDTGPLM
KCSFEETVDVLMEAAAHGESDPMKGVSENIMLGQLAPAGTGCFDLLLDAEKCKYGMEIPTNIPGLGAA
GRSGMTPGAAGFSPSAASDASGFSPGYSPAWSPTPGSPGSPGPSSPYIPSPGGAMSPR 
YSPTSPAYEPR 
SPGGYTPQSPSYSPTSPSYSPTSPSYSPTSPNYSPTSPK 
YSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPK 
YSPTSPSYSPSSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPK 
YSPTSPSYSPTSPSYSPTSPNYSPTSPNYTPTSPSYSPTSPK 
YSPTSPNYTPTSPNYSPTSPSYSPTSPSYSPTSPSYSPSSPR 
YTPQSPTYTPSSPSYSPSSPSYSPTSPK 
YTPTSPSYSPSSPEYTPASPK 
YSPTSPR 
YSPTSPK 
YSPTSPTYSPTTPK 
YSPTSPTYSPTSPVYTPTSPK 
YSPTSPTYSPTSPR 
YSPTSPTYSPTSPK 
GSTYSPTSPGYSPTSPTYSLTSPAISPDDSDEEN 
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>gi|6677795|ref|NP_033115.1| DNA-directed RNA polymerase II 
subunit RPB1 [Mus musculus]M-13K2R 
 
MHGGGPPSGDSACPLRTIKRVQFGVLSPDELKRMSVTEGGIKYPETTEGGRPKLGGLMDPRQGVIERT
GRCQTCAGNMTECPGHFGHIELAKPVFHVGFLVKTMKVLRCVCFFCSKLLVDSNNPKIKDILAKSKGQ
PKKRLTHVYDLCKGKNICEGGEEMDNKFGVEQPEGDEDLTKEKGHGGCGRYQPRIRRSGLELYAEWKH
VNEDSQEKKILLSPERVHEIFKRISDEECFVLGMEPRYARPEWMIVTVLPVPPLSVRPAVVMQGSARN
QDDLTHKLADIVKINNQLRRNEQNGAAAHVIAEDVKLLQFHVATMVDNELPGLPRAMQKSGRPLKSLK
QRLKGKEGRVRGNLMGKRVDFSARTVITPDPNLSIDQVGVPRSIAANMTFAEIVTPFNIDRLQELVRR
GNSQYPGAKYIIRDNGDRIDLRFHPKPSDLHLQTGYKVERHMCDGDIVIFNRQPTLHKMSMMGHRVRI
LPWSTFRLNLSVTTPYNADFDGDEMNLHLPQSLETRAEIQELAMVPRMIVTPQSNRPVMGIVQDTLTA
VRKFTKRDVFLERGEVMNLLMFLSTWDGKVPQPAILKPRPLWTGKQIFSLIIPGHINCIRTHSTHPDD
EDSGPYKHISPGDTKVVVENGELIMGILCKKSLGTSAGSLVHISYLEMGHDITRLFYSNIQTVINNWL
LIEGHTIGIGDSIADSKTYQDIQNTIKKAKQDVIEVIEKAHNNELEPTPGNTLRQTFENQVNRILNDA
RDKTGSSAQKSLSEYNNFKSMVVSGAKGSKINISQVIAVVGQQNVEGKRIPFGFKHRTLPHFIKDDYG
PESRGFVENSYLAGLTPTEFFFHAMGGREGLIDTAVKTAETGYIQRRLIKSMESVMVKYDATVRNSIN
QVVQLRYGEDGLAGESVEFQNLATLKPSNKAFEKKFRFDYTNERALRRTLQEDLVKDVLSNAHIQNEL
EREFERMREDREVLRVIFPTGDSKVVLPCNLLRMIWNAQKIFHINPRLPSDLHPIKVVEGVKELSKKL
VIVNGDDPLSRQAQENATLLFNIHLRSTLCSRRMAEEFRLSGEAFDWLLGEIESKFNQAIAHPGEMVG
ALAAQSLGEPATQMTLNTFHYAGVSAKNVTLGVPRLKELINISKKPKTPSLTVFLLGQSARDAERAKD
ILCRLEHTTLRKVTANTAIYYDPNPQSTVVAEDQEWVNVYYEMPDFDVARISPWLLRVELDRKHMTDR
KLTMEQIAEKINAGFGDDLNCIFNDDNAEKLVLRIRIMNSDENKMQEEEEVVDKMDDDVFLRCIESNM
LTDMTLQGIEQISKVYMHLPQTDNKKKIIITEDGEFKALQEWILETDGVSLMRVLSEKDVDPVRTTSN
DIVEIFTVLGIEAVRKALERELYHVISFDGSYVNYRHLALLCDTMTCRGHLMAITRHGVNRQDTGPLM
KCSFEETVDVLMEAAAHGESDPMKGVSENIMLGQLAPAGTGCFDLLLDAEKCKYGMEIPTNIPGLGAA
GRSGMTPGAAGFSPSAASDASGFSPGYSPAWSPTPGSPGSPGPSSPYIPSPGGAMSPR 
YSPTSPAYEPR 
SPGGYTPQSPSYSPTSPR 
AYSPTSPSYSPTSPK 
YSPTSPSYSPTSPK 
VYSPTSPSYSPTSPK 
LYSPTSPSYSPTSPK 
AAYSPTSPSYSPTSPK 
AVYSPTSPSYSPTSPK 
ALYSPTSPSYSPTSPK 
VVYSPTSPSYSPTSPK 
LLYSPTSPSYSPTSPK 
LYSPTSPNYTPTSPK 
LVYSPTSPSYSPTSPK 
YTPTSPNYSPTSPK 
YSPTSPSYSPTSPSYSPSSPR 
YTPQSPTYTPSSPK 
YSPSSPSYSPTSPK 
YTPTSPSYSPSSPEYTPASPK 
AALYSPTSPSYSPTSPK 
YSPTSPTYSPTTPK 
YSPTSPTYSPTSPVYTPTSPK 
AYSPTSPTYSPTSPK 
YSPTSPTYSPTSPK 
GSTYSPTSPGYSPTSPR 
YSLTSPAISPDDSDEEN 
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>gi|6677795|ref|NP_033115.1| DNA-directed RNA polymerase II 
subunit RPB1 [Mus musculus]M-9K4R 
 
MHGGGPPSGDSACPLRTIKRVQFGVLSPDELKRMSVTEGGIKYPETTEGGRPKLGGLMDPRQGVIERT
GRCQTCAGNMTECPGHFGHIELAKPVFHVGFLVKTMKVLRCVCFFCSKLLVDSNNPKIKDILAKSKGQ
PKKRLTHVYDLCKGKNICEGGEEMDNKFGVEQPEGDEDLTKEKGHGGCGRYQPRIRRSGLELYAEWKH
VNEDSQEKKILLSPERVHEIFKRISDEECFVLGMEPRYARPEWMIVTVLPVPPLSVRPAVVMQGSARN
QDDLTHKLADIVKINNQLRRNEQNGAAAHVIAEDVKLLQFHVATMVDNELPGLPRAMQKSGRPLKSLK
QRLKGKEGRVRGNLMGKRVDFSARTVITPDPNLSIDQVGVPRSIAANMTFAEIVTPFNIDRLQELVRR
GNSQYPGAKYIIRDNGDRIDLRFHPKPSDLHLQTGYKVERHMCDGDIVIFNRQPTLHKMSMMGHRVRI
LPWSTFRLNLSVTTPYNADFDGDEMNLHLPQSLETRAEIQELAMVPRMIVTPQSNRPVMGIVQDTLTA
VRKFTKRDVFLERGEVMNLLMFLSTWDGKVPQPAILKPRPLWTGKQIFSLIIPGHINCIRTHSTHPDD
EDSGPYKHISPGDTKVVVENGELIMGILCKKSLGTSAGSLVHISYLEMGHDITRLFYSNIQTVINNWL
LIEGHTIGIGDSIADSKTYQDIQNTIKKAKQDVIEVIEKAHNNELEPTPGNTLRQTFENQVNRILNDA
RDKTGSSAQKSLSEYNNFKSMVVSGAKGSKINISQVIAVVGQQNVEGKRIPFGFKHRTLPHFIKDDYG
PESRGFVENSYLAGLTPTEFFFHAMGGREGLIDTAVKTAETGYIQRRLIKSMESVMVKYDATVRNSIN
QVVQLRYGEDGLAGESVEFQNLATLKPSNKAFEKKFRFDYTNERALRRTLQEDLVKDVLSNAHIQNEL
EREFERMREDREVLRVIFPTGDSKVVLPCNLLRMIWNAQKIFHINPRLPSDLHPIKVVEGVKELSKKL
VIVNGDDPLSRQAQENATLLFNIHLRSTLCSRRMAEEFRLSGEAFDWLLGEIESKFNQAIAHPGEMVG
ALAAQSLGEPATQMTLNTFHYAGVSAKNVTLGVPRLKELINISKKPKTPSLTVFLLGQSARDAERAKD
ILCRLEHTTLRKVTANTAIYYDPNPQSTVVAEDQEWVNVYYEMPDFDVARISPWLLRVELDRKHMTDR
KLTMEQIAEKINAGFGDDLNCIFNDDNAEKLVLRIRIMNSDENKMQEEEEVVDKMDDDVFLRCIESNM
LTDMTLQGIEQISKVYMHLPQTDNKKKIIITEDGEFKALQEWILETDGVSLMRVLSEKDVDPVRTTSN
DIVEIFTVLGIEAVRKALERELYHVISFDGSYVNYRHLALLCDTMTCRGHLMAITRHGVNRQDTGPLM
KCSFEETVDVLMEAAAHGESDPMKGVSENIMLGQLAPAGTGCFDLLLDAEKCKYGMEIPTNIPGLGAA
GRSGMTPGAAGFSPSAASDASGFSPGYSPAWSPTPGSPGSPGPSSPYIPSPGGAMSPR 
YSPTSPAYEPR 
SPGGYTPQSPSYSPTSPR 
YSPTSPSYSPTSPNYSPTSPK 
YSPTSPSYSPTSPSYSPTSPK 
YSPTSPSYSPTSPSYSPASPK 
YSPTSPSYSPTSPSYSPSSPK 
YSPTSPSYSPTSPSYSPLSPK 
AYSPTSPSYSPTSPSYSPLSPR 
YSPTSPNYTPTSPSYSPTSPK 
YSPTSPNYTPTSPNYSPTSPK 
YAPTSPSYSPASPSYAPSSPR 
YTPQSPTYTPSSPK 
YSPSSPSYSPTSPK 
YTPTSPSYSPSSPEYTPTSPK 
YSPTSPSYSPTSPK 
YSPTSPTYSPTTPK 
YSPTSPTYTPTSPVYTPTSPR 
YSPTSPTYSPTSPK 
YSPTSPTYSPTSPR 
GSTYSPTSPGYSPTSPK 
YSLTSPAISPDDSDEEN 
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>gi|6677795|ref|NP_033115.1| DNA-directed RNA polymerase II 
subunit RPB1 [Mus musculus]M-12K2R 
 
MHGGGPPSGDSACPLRTIKRVQFGVLSPDELKRMSVTEGGIKYPETTEGGRPKLGGLMDPRQGVIERT
GRCQTCAGNMTECPGHFGHIELAKPVFHVGFLVKTMKVLRCVCFFCSKLLVDSNNPKIKDILAKSKGQ
PKKRLTHVYDLCKGKNICEGGEEMDNKFGVEQPEGDEDLTKEKGHGGCGRYQPRIRRSGLELYAEWKH
VNEDSQEKKILLSPERVHEIFKRISDEECFVLGMEPRYARPEWMIVTVLPVPPLSVRPAVVMQGSARN
QDDLTHKLADIVKINNQLRRNEQNGAAAHVIAEDVKLLQFHVATMVDNELPGLPRAMQKSGRPLKSLK
QRLKGKEGRVRGNLMGKRVDFSARTVITPDPNLSIDQVGVPRSIAANMTFAEIVTPFNIDRLQELVRR
GNSQYPGAKYIIRDNGDRIDLRFHPKPSDLHLQTGYKVERHMCDGDIVIFNRQPTLHKMSMMGHRVRI
LPWSTFRLNLSVTTPYNADFDGDEMNLHLPQSLETRAEIQELAMVPRMIVTPQSNRPVMGIVQDTLTA
VRKFTKRDVFLERGEVMNLLMFLSTWDGKVPQPAILKPRPLWTGKQIFSLIIPGHINCIRTHSTHPDD
EDSGPYKHISPGDTKVVVENGELIMGILCKKSLGTSAGSLVHISYLEMGHDITRLFYSNIQTVINNWL
LIEGHTIGIGDSIADSKTYQDIQNTIKKAKQDVIEVIEKAHNNELEPTPGNTLRQTFENQVNRILNDA
RDKTGSSAQKSLSEYNNFKSMVVSGAKGSKINISQVIAVVGQQNVEGKRIPFGFKHRTLPHFIKDDYG
PESRGFVENSYLAGLTPTEFFFHAMGGREGLIDTAVKTAETGYIQRRLIKSMESVMVKYDATVRNSIN
QVVQLRYGEDGLAGESVEFQNLATLKPSNKAFEKKFRFDYTNERALRRTLQEDLVKDVLSNAHIQNEL
EREFERMREDREVLRVIFPTGDSKVVLPCNLLRMIWNAQKIFHINPRLPSDLHPIKVVEGVKELSKKL
VIVNGDDPLSRQAQENATLLFNIHLRSTLCSRRMAEEFRLSGEAFDWLLGEIESKFNQAIAHPGEMVG
ALAAQSLGEPATQMTLNTFHYAGVSAKNVTLGVPRLKELINISKKPKTPSLTVFLLGQSARDAERAKD
ILCRLEHTTLRKVTANTAIYYDPNPQSTVVAEDQEWVNVYYEMPDFDVARISPWLLRVELDRKHMTDR
KLTMEQIAEKINAGFGDDLNCIFNDDNAEKLVLRIRIMNSDENKMQEEEEVVDKMDDDVFLRCIESNM
LTDMTLQGIEQISKVYMHLPQTDNKKKIIITEDGEFKALQEWILETDGVSLMRVLSEKDVDPVRTTSN
DIVEIFTVLGIEAVRKALERELYHVISFDGSYVNYRHLALLCDTMTCRGHLMAITRHGVNRQDTGPLM
KCSFEETVDVLMEAAAHGESDPMKGVSENIMLGQLAPAGTGCFDLLLDAEKCKYGMEIPTNIPGLGAA
GRSGMTPGAAGFSPSAASDASGFSPGYSPAWSPTPGSPGSPGPSSPYIPSPGGAMSPR 
YSPTSPAYEPR 
SPGGYTPQSPSYSPTSPR 
YSPTSPSYSPTSPNYSPTSPK 
YSPTSPSYSPTSPSYSPTSPK 
AYSPTSPSYSPTSPK 
AYSPTSPSYSPTSPSYSPTSPK 
YSPTSPSYSPTSPK 
AAYSPTSPSYSPTSPSYSPTSPK 
AYSPTSPSYSPTSPNYSPTSPK 
YTPTSPSYSPTSPSYSPTSPK 
AYTPTSPNYSPTSPSYSPTSPK 
YSPTSPSYSPASPK 
YTPQSPTYTPSSPK 
YSPSSPSYSPTSPK 
YTPTSPSYSPSSPEYTPASPR 
AAYSPTSPSYSPTSPK 
YSPTSPTYSPTTPK 
YSPTSPTYSPTSPVYTPTSPK 
AYSPTSPTYSPTSPK 
YSPTSPTYSPTSPK 
GSTYSPTSPGYSPTSPK 
YSLTSPAISPDDSDEEN 
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>gi|6677795|ref|NP_033115.1| DNA-directed RNA polymerase II 
subunit RPB1 [Mus musculus]M-8K4R 
 
MHGGGPPSGDSACPLRTIKRVQFGVLSPDELKRMSVTEGGIKYPETTEGGRPKLGGLMDPRQGVIERT
GRCQTCAGNMTECPGHFGHIELAKPVFHVGFLVKTMKVLRCVCFFCSKLLVDSNNPKIKDILAKSKGQ
PKKRLTHVYDLCKGKNICEGGEEMDNKFGVEQPEGDEDLTKEKGHGGCGRYQPRIRRSGLELYAEWKH
VNEDSQEKKILLSPERVHEIFKRISDEECFVLGMEPRYARPEWMIVTVLPVPPLSVRPAVVMQGSARN
QDDLTHKLADIVKINNQLRRNEQNGAAAHVIAEDVKLLQFHVATMVDNELPGLPRAMQKSGRPLKSLK
QRLKGKEGRVRGNLMGKRVDFSARTVITPDPNLSIDQVGVPRSIAANMTFAEIVTPFNIDRLQELVRR
GNSQYPGAKYIIRDNGDRIDLRFHPKPSDLHLQTGYKVERHMCDGDIVIFNRQPTLHKMSMMGHRVRI
LPWSTFRLNLSVTTPYNADFDGDEMNLHLPQSLETRAEIQELAMVPRMIVTPQSNRPVMGIVQDTLTA
VRKFTKRDVFLERGEVMNLLMFLSTWDGKVPQPAILKPRPLWTGKQIFSLIIPGHINCIRTHSTHPDD
EDSGPYKHISPGDTKVVVENGELIMGILCKKSLGTSAGSLVHISYLEMGHDITRLFYSNIQTVINNWL
LIEGHTIGIGDSIADSKTYQDIQNTIKKAKQDVIEVIEKAHNNELEPTPGNTLRQTFENQVNRILNDA
RDKTGSSAQKSLSEYNNFKSMVVSGAKGSKINISQVIAVVGQQNVEGKRIPFGFKHRTLPHFIKDDYG
PESRGFVENSYLAGLTPTEFFFHAMGGREGLIDTAVKTAETGYIQRRLIKSMESVMVKYDATVRNSIN
QVVQLRYGEDGLAGESVEFQNLATLKPSNKAFEKKFRFDYTNERALRRTLQEDLVKDVLSNAHIQNEL
EREFERMREDREVLRVIFPTGDSKVVLPCNLLRMIWNAQKIFHINPRLPSDLHPIKVVEGVKELSKKL
VIVNGDDPLSRQAQENATLLFNIHLRSTLCSRRMAEEFRLSGEAFDWLLGEIESKFNQAIAHPGEMVG
ALAAQSLGEPATQMTLNTFHYAGVSAKNVTLGVPRLKELINISKKPKTPSLTVFLLGQSARDAERAKD
ILCRLEHTTLRKVTANTAIYYDPNPQSTVVAEDQEWVNVYYEMPDFDVARISPWLLRVELDRKHMTDR
KLTMEQIAEKINAGFGDDLNCIFNDDNAEKLVLRIRIMNSDENKMQEEEEVVDKMDDDVFLRCIESNM
LTDMTLQGIEQISKVYMHLPQTDNKKKIIITEDGEFKALQEWILETDGVSLMRVLSEKDVDPVRTTSN
DIVEIFTVLGIEAVRKALERELYHVISFDGSYVNYRHLALLCDTMTCRGHLMAITRHGVNRQDTGPLM
KCSFEETVDVLMEAAAHGESDPMKGVSENIMLGQLAPAGTGCFDLLLDAEKCKYGMEIPTNIPGLGAA
GRSGMTPGAAGFSPSAASDASGFSPGYSPAWSPTPGSPGSPGPSSPYIPSPGGAMSPR 
YSPTSPAYEPR 
SPGGYTPQSPSYSPTSPK 
YSPTSPSYSPTSPNYSPTSPK 
YSPTSPSYSPTSPK 
YSPTSPSYSPTSPSYSPTSPK 
YSPTSPSYSPTSPSYSPASPK 
YSPTSPSYSPTSPSYSPSSPK 
AYSPTSPSYSPTSPSYSPLSPR 
YSPTSPNYSPTSPNYTPTSPK 
YSPTSPSYSPTSPNYTPTSPNYSPTSPK 
YSPTSPSYSPTSPSYSPSSPR 
YTPQSPTYTPSSPSYSPSSPSYSPTSPK 
YTPTSPSYSPSSPEYTPASPR 
YSPTSPK 
YSPTSPR 
YSPTSPTYSPTTPK 
YSPTSPTYSPTSPVYTPTSPK 
YSPTSPTYSPTSPR 
YSPTSPTYSPTSPK 
GSTYSPTSPGYSPTSPTYSLTSPAISPDDSDEEN 
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>gi|6677795|ref|NP_033115.1| DNA-directed RNA polymerase II 
subunit RPB1 [Mus musculus]M-9K2R 
 
MHGGGPPSGDSACPLRTIKRVQFGVLSPDELKRMSVTEGGIKYPETTEGGRPKLGGLMDPRQGVIERT
GRCQTCAGNMTECPGHFGHIELAKPVFHVGFLVKTMKVLRCVCFFCSKLLVDSNNPKIKDILAKSKGQ
PKKRLTHVYDLCKGKNICEGGEEMDNKFGVEQPEGDEDLTKEKGHGGCGRYQPRIRRSGLELYAEWKH
VNEDSQEKKILLSPERVHEIFKRISDEECFVLGMEPRYARPEWMIVTVLPVPPLSVRPAVVMQGSARN
QDDLTHKLADIVKINNQLRRNEQNGAAAHVIAEDVKLLQFHVATMVDNELPGLPRAMQKSGRPLKSLK
QRLKGKEGRVRGNLMGKRVDFSARTVITPDPNLSIDQVGVPRSIAANMTFAEIVTPFNIDRLQELVRR
GNSQYPGAKYIIRDNGDRIDLRFHPKPSDLHLQTGYKVERHMCDGDIVIFNRQPTLHKMSMMGHRVRI
LPWSTFRLNLSVTTPYNADFDGDEMNLHLPQSLETRAEIQELAMVPRMIVTPQSNRPVMGIVQDTLTA
VRKFTKRDVFLERGEVMNLLMFLSTWDGKVPQPAILKPRPLWTGKQIFSLIIPGHINCIRTHSTHPDD
EDSGPYKHISPGDTKVVVENGELIMGILCKKSLGTSAGSLVHISYLEMGHDITRLFYSNIQTVINNWL
LIEGHTIGIGDSIADSKTYQDIQNTIKKAKQDVIEVIEKAHNNELEPTPGNTLRQTFENQVNRILNDA
RDKTGSSAQKSLSEYNNFKSMVVSGAKGSKINISQVIAVVGQQNVEGKRIPFGFKHRTLPHFIKDDYG
PESRGFVENSYLAGLTPTEFFFHAMGGREGLIDTAVKTAETGYIQRRLIKSMESVMVKYDATVRNSIN
QVVQLRYGEDGLAGESVEFQNLATLKPSNKAFEKKFRFDYTNERALRRTLQEDLVKDVLSNAHIQNEL
EREFERMREDREVLRVIFPTGDSKVVLPCNLLRMIWNAQKIFHINPRLPSDLHPIKVVEGVKELSKKL
VIVNGDDPLSRQAQENATLLFNIHLRSTLCSRRMAEEFRLSGEAFDWLLGEIESKFNQAIAHPGEMVG
ALAAQSLGEPATQMTLNTFHYAGVSAKNVTLGVPRLKELINISKKPKTPSLTVFLLGQSARDAERAKD
ILCRLEHTTLRKVTANTAIYYDPNPQSTVVAEDQEWVNVYYEMPDFDVARISPWLLRVELDRKHMTDR
KLTMEQIAEKINAGFGDDLNCIFNDDNAEKLVLRIRIMNSDENKMQEEEEVVDKMDDDVFLRCIESNM
LTDMTLQGIEQISKVYMHLPQTDNKKKIIITEDGEFKALQEWILETDGVSLMRVLSEKDVDPVRTTSN
DIVEIFTVLGIEAVRKALERELYHVISFDGSYVNYRHLALLCDTMTCRGHLMAITRHGVNRQDTGPLM
KCSFEETVDVLMEAAAHGESDPMKGVSENIMLGQLAPAGTGCFDLLLDAEKCKYGMEIPTNIPGLGAA
GRSGMTPGAAGFSPSAASDASGFSPGYSPAWSPTPGSPGSPGPSSPYIPSPGGAMSPR 
YSPTSPAYEPR 
SPGGYTPQSPSYSPTSPK 
YSPTSPSYSPTSPNYSPTSPSYSPTSPK 
YSPTSPSYSPTSPSYSPTSPK 
YSPTSPSYSPTSPSYSPASPK 
YSPTSPSYSPTSPSYSPTSPSYSPTSPK 
YSPTSPSYSPTSPSYSPASPSYSPTSPK 
AYSPTSPNYTPTSPSYSPTSPK 
YSPTSPNYTPTSPNYSPTSPK 
YSPTSPSYSPTSPSYSPSSPR 
YTPQSPTYTPSSPK 
YSPSSPSYSPTSPK 
YTPTSPSYSPSSPEYTPASPK 
YSPTSPR 
YSPTSPK 
YSPTSPTYSPTTPK 
YSPTSPTYSPTSPVYTPTSPK 
YSPTSPTYSPTSPR 
YSPTSPTYSPTSPK 
GSTYSPTSPGYSPTSPTYSLTSPAISPDDSDEEN 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
 
125
B   Curriculum vitae 
 
     Roland Schüller 
     Born 30th of November, 1982 in Salzburg, Austria 
 
 
 
School Education 
 
1989 -1993    Volksschule Bad Vigaun, Salzburg 
 
1993 - 2001    A-levels 2.0 
     Bundesrealgymnasium Hallein, Salzburg 
 
2002 - 2008    Diploma 1.3 
     Faculty for Biology 
     Ludwig Maximilian University (LMU) of Munich, 
     Germany 
  
 
 
Research Experience 
2009 - 2013    Doctoral Thesis  
     Institute for Clinical Molecular Biology and Tumor 
     Genetics 
     Department of Molecular Epigenetics 
     Helmholtz Zentrum (HMGU), Germany  
     „Insights into the RNA Polymerase II CTD code” 
     Prof. Dr. Dirk Eick 
 
 
C   Publications   
 
  Sims RJ 3rd,  Rojas LA,  Beck D,  Bonasio R, 
Schüller R,  Drury WJ 3rd,  Eick D,  Reinberg D. 
(2011) The C-terminal domain of RNA polymerase 
II is modified by site-specific methylation 
 Science. 2011, 332, 99-103.  
 
 
 
 
 
 
 
 
Appendix 
 
 
126
D   Acknowledgements 
 
In the final section I would like to thank all the people who supported me and 
believed in me during my time as a PhD student. 
 
Prof. Dr. Dirk Eick for his supervision, for always keeping me on the right way 
during this project, and for his inspiration and dedication towards science.  
 
My colleagues, Martin Heidemann, Corinna Hintermair, Kirsten Voss, Bastian 
Muehl, Kaspar Burger, Markus Kellner, Michaela Rohrmoser, Nilay Shah, Tim 
Decker and Anita Gruber-Eber for good team work, for great lab atmosphere and 
for becoming friends. 
 
Dr. Ignasi Forne, Dr. Tobias Straub, and Andrew Flatley for successful 
collaboration and fruitful discussion during this project. 
 
Dr. Rob Chapman for introducing me into this project, and for all the tools he 
bequeathed me.  
 
Dr. Marcus Conrad and his group, Ugur Hirlak, Harald Polzer, Diana Schmid, 
Verena Weth, Nadine Sandhoefer, Hanna Janke and many more, for all the great 
time spending together in the Helmholtz Zentrum. 
 
 
My family who is the best family one can have. 
 
 
My love, Yolanda, who makes me the most happiest man alive. 
 
 
 
